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Preface 
This thesis is based on two feeding studies in mice conducted September through December 2009, and 
August through November 2010, at the Department of Systems Biology, Technical University of Denmark, 
Kgs. Lyngby, Denmark, and an immune cell study. An immune cell study was conducted with samples from 
a human intervention study conducted at Department of human nutrition, University of Copenhagen, 
Frederiksberg, Denmark, and samples from volunteers at the Department of Systems Biology, Technical 
University of Denmark, Kgs. Lyngby, Denmark. Immune cell studies were conducted January through June 
2010, and January through April 2011, respectively. Furthermore, results, from two human interventions 
conducted at Department of human nutrition, University of Copenhagen, Frederiksberg, Denmark, is 
included, conducted September through October 2009, and January through June 2010, respectively. 
During my PhD my time has primarily been spend at department of systems biology, were I have been 
provided with hands on experience in conducting experiments. Being in charge of conducting larger studies 
was new to me, and had great educational value to me as well as I have gained experience within analysis 
methods that were new to me. 
The project was a sub-project under a cooperative project called “Green feed”, in which the effects by 
intake of dairy fat with altered FA-composition due to feeding various amounts of green plant material to 
cattle, on metabolic health was studied. “Green Feed” was part of a scientific network called “Tailored 
milk”. The project was funded by The Danish Council for strategic Research, Danish Cattle, and The Danish 
Dairy Research Board. The butter used for experiments was experimentally produced butter from Søren K. 
Jensen, Foulum AU, butter from ARLA Foods, Denmark, and TINE sa, Norway. High oleic sunflower oil was 
kindly provided from AarhusKarlshamn AB. 
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The studies 
Five different studies are covered in this thesis; manuscripts/articles are enclosed as appendixes: 
A. “A hyper caloric diet based on monounsaturated fatty acids has more detrimental effects on 
metabolic parameters than diets based on butter or linoleic acid” 
 
Objective: To compare effects on metabolic parameters, from high fat diets based on butter from 
either high- or low yield production forms, to high fat diets based on oleic acid or linoleic acid, in 
obese mice. 
 
B. “Effects of the natural PPARα and RXR agonist phytanic acid on glucose homeostasis and hepatic 
lipid status in obese C57bl/6j mice” 
 
Objective: To investigate the effects of PA in high fat diets based on in part butter and in part grape 
seed oil rich in linoleic acid, on parameters related to glucose metabolism and hepatic lipid 
metabolism. 
 
C. “Implications of dairy-fat and the dairy fat component phytanic acid on T-cell cytokine shifting in 
activated CD3+ T-cells from a double blinded 12 week-randomized butter intervention” 
 
Objective: To investigate whether butter intake and/or PA are able to alter the CD3+ T-cell 
polarization towards a Th2 response. 
 
D. “Effect of dairy fat on plasma phytanic acid in healthy volunteers - A randomized controlled study” 
Objective: To investigate if cow feeding regimes affects concentration of plasma phytanic acid and 
risk markers of the metabolic syndrome in human 
 
E. “Effects of milk derived from mountain-pasture grazing cows on risk markers of the metabolic 
syndrome compared to conventional Danish milk”  
 
Objective: To investigate the effect of milk delivered from mountain-pasture grazing cows (green 
diet) on risk markers of the metabolic syndrome and type-2 diabetes with the effect of control diet, 
including conventional Danish milk. The study should reveal the importance of phytanic acid 
content for these effects. 
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The overall plan by conducting these five studies were to do a broad investigation of the effects from intake 
of dairy fat, and the influence of feeding and production form of the dairy fat. Furthermore we wanted to 
examine whether dairy intake is able to alter the phytanic acid concentrations found in humans and mice, 
and if this would affect metabolic parameters.  
By this set up we were also able to test hypothesized effects of phytanic acid (PA) on T-cell polarization. As 
we used mice as a model organism, we were among others also able to do studies on isolated effects from 
PA intake, as this was not possible by human interventions. An advantage from this larger set up of studies, 
is that we could use the same butters in both mice and human studies, as the grazing butter used in study A 
and E is the same, and the butter from conventional fed cattle is the same used in study A and D, as well as 
for the PA dose response in study B. Furthermore the subjects from the butter intervention of study C, is a 
subpopulation from study E.  
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Summary 
The still growing obesity epidemic is a major risk for our society, as it is associated with the development of 
the so called metabolic syndrome, which is a clinical diagnosis correlated to development of metabolic 
disorders. Lack of physical activity, excess energy intake, and nutritional factors e.g. fatty acid composition 
of the diet, are important factors with regard to development of metabolic syndrome.   
There is a controversy between the fact that several studies has shown that intake of saturated fatty acids 
are strongly correlated to the development of metabolic related diseases, such as cardiovascular diseases 
and type 2 diabetes, and against the fact that other studies has shown that intake of dairy fat, which has 
high saturated fatty acid content, correlates negatively with risk factors. Hence, it has even been suggested 
that dairy fat might have beneficial impacts in relation to metabolic disorders. Dairy fat is the most complex 
type of fat occurring in the nature, with more than 400 identified fatty acids. Several of these fatty acids 
that occur in low amounts have been suggested to have beneficial properties with regard to metabolic 
disorders. The concentrations of certain of these minor fatty acids are raised in dairy fat along with the 
amount of green plant material intake of the cattle. Phytanic acid is one of these minor fatty acids, due to 
agonist activities for nuclear receptors with central roles in among others the lipid and glucose metabolism. 
To determine the effects of both dairy fat in general and phytanic acid on metabolic parameters, we 
performed several studies.   First, we investigated effects on hepatic lipid metabolism, glucose homeostasis, 
and circulating metabolic markers, of high fat diets based on butter from high- or low-yield production, a 
diet based on high oleic acid sunflower oil, and a diet based on grape-seed oil with high amount of linoleic 
acid, in diet induced obese mice. Second, we investigated phytanic acid effects on similar parameters in 
obese mice, both as dose response in butter based diets, and in grape-seed oil based diets with and 
without addition of phytanic acid. Third, we investigated butter and phytanic acid effects on human T-cell 
polarization, both by in vitro incubation with phytanic acid, and by a 12 weeks intervention with intake of 
butter. Finally, we performed two human interventions, first one with intake of butter and cheese, and the 
second with intake of butter. In these studies we investigated whether it is possible to alter the human 
plasma concentration of phytanic acid due to dairy fat intake, and if butter from different feeding regimes, 
and production forms has different effects on metabolic parameters upon intake.   
Fat type intervention in mice 
Obesity was induced in mice, by addition of sucrose to the drinking water, and giving high fat diets, based 
on butter from either grazing or conventional fed cattle, high oleic acid (monounsaturated fatty acid) 
sunflower oil, or finally from grape-seed oil with high content of the n-6 poly unsaturated fatty acid linoleic 
acid, along with having a lean reference group. Oral glucose tolerance test was performed after 10 weeks 
intervention, and animals sacrificed two days later. Parameters relevant to glucose metabolism, and 
hepatic lipid metabolism e.g. lipid deposition, were measured, just as RT-qPCR were used to measure 
expression of genes relevant for lipid metabolism in the liver. Plasma lipids, adipokines, and a marker of 
inflammation were also measured. We found that the hyper caloric diet based on oleic acid had the most 
detrimental effects on metabolic parameters, of the tested fats, as it led to increased hepatic lipid 
deposition, and reduced glucose tolerance. The butter based diets had more unfavorable effects on 
concentration of blood lipids, observed as raised triacylglycerol and total cholesterol. Compared to the 
literature the results with regard to oleic acid are controversial, as the common advice is to substitute SFA 
by MUFA in the diet.  
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Phytanic acid effects in mice 
Production of phytanic acid by organic synthesis, allowed us to investigate isolated effects of phytanic acid 
intake. Obesity were induced in similar manner as in the fat type intervention described above, with 
different amounts of phytanic acid ethyl-esters added to either butter or grape-seed oil based diets, to 
investigate the effects from phytanic acid intake, on parameters similar to those in the fat type 
intervention. We saw that PA intake have aggravating effect on glucose homeostasis in dosages of 1.0 % of 
total fat. We did se limited up regulation of PPARα and ACOX1 due to 1.0 % phytanic acid in butter. As we 
are the first to perform interventions with physiological realistic amounts of phytanic acid, which have been 
proposed to have protective effects due to its agonist activities for central nuclear receptors, our results 
most definitely, add to the knowledge of the field. 
 
Butter and phytanic acid effects in humans, and on T-cell polarization  
Two human dairy fat interventions was conducted, with healthy subjects divided into groups and given 
dairy fat (as butter and cheese) from cattle under different feeding regimes, resulting in among others 
difference in phytanic acid content. From the first intervention, we found that it is possible to alter the 
human plasma phytanic acid concentration due to four weeks dairy fat intervention. From the second 
intervention we found that butter from grazing cattle, which among others have increased phytanic acid 
content, increase plasma LDL cholesterol and insulin, compared to conventional butter. From a 
subpopulation of the second intervention, T-cells were isolated from blood before and after the 
intervention, to analyze the effect on T-cell polarization. Furthermore we performed an in vitro incubation 
of T-cells, from eight donors, with phytanic- and palmitic acid, to investigate if phytanic acid affects T-cell 
polarization as hypothesized. Phytanic acid was not found to change the T-cell polarization, neither in the 
incubation study nor due to the difference in concentrations in the butter intervention. We saw up 
regulation in mRNA expression of both IL-4 and IFN-γ due to the butter intervention, when the groups were 
regarded as one. This was more pronounced for IL-4 than IFN-γ, and we observed increase in the ratio IL-4: 
IFN-γ due to the intervention. This is pointing towards a general effect towards Th2 polarization of human 
T-cells due to increased intake of butter. These results add to the understanding of potential phytanic acid 
and butter effects, on the immune system as similar studies have not been performed on T-cells before. 
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Resume (dansk) 
Den stadigt voksende fedme epidemi er en betydningsfuld risiko for vores samfund, da fedme er associeret 
til udvikling af såkaldt metabolisk syndrom, der er en klinisk diagnose korreleret til udvikling af metaboliske 
lidelser. Mangel på fysisk aktivitet, overskydende energi indtag, og ernæringsmæssige faktorer som 
eksempelvis kostens fedtsyre sammensætning, er vigtige faktorer med hensyn til udvikling af metabolisk 
syndrom. 
Der er et kontrovers mellem kendsgerningen at adskillige studier har vist at indtag af mættede fedtsyrer er 
stærkt korreleret til udviklingen af metabolisk relaterede sygdomme, såsom hjertekarsygdomme og type 2 
diabetes, og den kendsgerning at andre studier har vist, at indtag af mælkefedt, som har et højt indhold af 
mættet fedt, korrelerer negativt med risiko faktorer. Således har det endda været foreslået, at mælkefedt 
måske har gavnlig indflydelse i relation til metaboliske lidelser.   Mælkefedt er den mest komplekse 
naturligt forekommende fedttype, med mere end 400 identificerede fedtsyrer. Flere af disse fedtsyrer der 
forekommer i små mængder har været foreslået at have gavnlige egenskaber med hensyn til metaboliske 
forstyrrelser. Koncentrationerne af visse af disse mindre forekommende fedtsyrer er forhøjet i takt med 
mængden af grønt plantemateriale som kvæget indtager. Phytansyre er en af disse fedtsyrer, eftersom den 
har agonist aktivitet for kernereceptorer der har centrale roller i blandt andet lipid og glukose 
metabolismen. 
For at fastlægge effekterne af både mælkefedt generelt og phytansyre på metaboliske parametre, har vi 
udført en række studier. Først, har vi undersøgt effekter på leverens lipid metabolisme, glucose 
homeostase og cirkulerende metaboliske markører, af diæter med højt fedtindhold, givet til diæt induceret 
fede mus. Vi har sammenlignet diæter baseret på smør fra henholdsvis højt- og lavt-ydende 
produktionsform, en diæt baseret på solsikkeolie med højt indhold af oliesyre, samt en diæt baseret på 
vindruekerneolie med højt indhold af linolsyre. Dernæst, undersøgte vi phytansyre effekter på tilsvarende 
parametre i fede mus, både som et dosisrespons tilsat en smør baseret diæt, og i en vindruekerneolie 
baseret diæt med og uden tilsat phytansyre. Derudover, undersøgte vi smør og phytansyre effekt på 
polarisering af humane T-celler, både som in vitro inkubering med phytansyre, og ved en 12-ugers smør 
intervention. Endeligt, har vi udført to humane interventioner. Den første med indtag af smør og ost, og 
den anden kun med indtag af smør. I disse studier undersøgte vi hvorvidt det er muligt at påvirke 
plasmakoncentrationen af phytansyre i mennesker gennem indtag af mælkefedt, samt om smør fra 
forskellige fodringsstrategier og produktionsform har forskellig indflydelse på metaboliske parametre ved 
indtag. 
Fedttype intervention i mus 
Fedme blev induceret i mus, ved tilsætning af sukrose til drikkevand, og ved at give diæter med højt 
fedtindhold, baseret på smør fra enten græssende eller konventionelt fodret kvæg, solsikkeolie med højt 
oliesyre (monoumættet fedtsyre) indhold, eller vindruekerneolie med højt indhold af den n-6 fler-
umættede linolsyre. Sideløbende havde vi en mager reference gruppe. Oral glukose tolerance test blev 
udført efter 10 ugers intervention, og dyrene blev aflivet to dage senere. Relevante parametre for glucose 
metabolisme og leverens fedt metabolisme, eksempelvis lipid ophobning, blev målt, ligesom der blev målt 
ekspressionsniveauer, for gener der er relevante for leverens fedtsyre metabolisme, ved RT-qPCR. Desuden 
blev plasma lipider, adipokiner, og en inflammatorisk markør målt. Vi fandt at høj energi diæten baseret på 
oliesyre havde de mest skadelige virkninger på metaboliske parametre, af de fedttyper, idet den førte til 
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forøget lipid ophobning i leveren samt reduceret glukose tolerance. De smørbaserede diæter havde mere 
ufavorable effekter på koncentration af blodlipider, observeret som forhøjet triglycerid og total-kolesterol. 
Sammenlignet med litteraturen, er resultaterne omhandlende oliesyre kontroversielle, da den gængse 
anbefaling er at erstatte mættet fedt med mono-umættet.  
Phytansyre effekter i mus 
Produktion af phytansyre ved organisk syntese, tillod os at undersøge isolerede effekter af phytansyre 
indtag. Fedme blev induceret på samme måde som i fedttype interventionen beskrevet ovenfor, med 
forskellige mængder af phytansyre-ethylester tilsat til enten smør eller vindruekerne olie baserede diæter, 
for at udforske effekterne af phytansyreindtag, på lignende parametre som i fedttype interventionen. Vi 
fandt, at phytansyreindtag har forværrende effekt på glukose homeostase mængde af 1,0 % af total fedt. Vi 
så desuden begrænset opregulering af PPARα og ACOX1, som følge af 1,0 % phytansyre i smør. Da vi er de 
første til, at udføre interventioner med fysiologisk realistiske mængder af phytansyre, som har været 
foreslået at have beskyttende effekter som følge af dens agonist aktivitet for centrale kerne receptorer, 
bidrager resultaterne bestemt til viden på området. 
Smør og phytansyre effekt i mennesker og på T-celle polarisering 
To humaninterventioner blev udført med raske deltagere, inddelt i grupper, blev givet mælkefedt (i form af 
smør og ost) fra kvæg underlagt forskellige fodringsstrategier, resulterende i blandt andet forskel i 
phytansyre indhold.  Ved den første intervention, fandt vi ud af at det er muligt at ændre den humane 
plasma koncentration af phytansyre gennem fire ugers mælkefedt intervention. I det andet 
interventionsstudie fandt vi at smør fra græssende kvæg, som blandt andet har højere phytansyre indhold, 
forøger plasma kolesterol og har negativ effekt på insulinfølsomhed, sammenlignet med konventionelt 
smør. Fra en subpopulation i den anden intervention, isolerede vi T-celler før og efter interventionen, for at 
undersøge effekter på T-celle polarisering ved smørindtaget. Ydermere udførte vi en in vitro inkubering af 
T-celler, fra otte donorer, med phytansyre og palmitinsyre, for at undersøge om phytansyre påvirker T-celle 
polarisering som foreslået. Vi fandt ikke at phytansyre ændrer T-celle polarisering, hverken i 
inkuberingsstudiet eller gennem koncentrationsforskelle i smørinterventionen. Vi så upregulering i mRNA 
udtryk af både IL-4 og IFN-γ som følge af smør indtag, når resultaterne for de to grupper blev lagt sammen. 
Dette var mere udtalt for IL-4 end for IFN-γ, og vi observerede stigning i forholdet IL-4: IFN-γ som følge af 
interventionen. Dette peger i retning af en generel effekt i retning af Th2 polarisering af humane T-celler 
som følge af øget smørindtag. Disse resultater bidrager til forståelsen af potentielle phytansyre og smør 
effekter på immunsystemet, eftersom lignende studier ikke tidligere er udført på T-celler.  
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Abbreviations 
ACOX Peroxisomal acyl-coenzyme A oxidase 
AKT Protein kinase B (also abbreviated PKB) 
ALA α-linolenic acid 
AMCAR α-methylacyl-CoA racemase 
AP Activator protein 
BAT Brown adipose tissue 
BCL B-cell lymphoma protein 
BMI Body mass index 
CAT Catalase 
CCR Chemokine (C-C motif) receptor  
CD Cluster of differentiation 
CETP Cholesteryl ester transfer protein 
ChREBP Carbohydrate responsive element binding protein 
CLA Conjugated linoleic acid 
CPT1b Carnitine palmitoyltranferase-1b 
CVD Cardiovascular disease 
DAG Diacylglyceride 
DBD DNA binding domain 
DHA Docosa-hexanoic acid 
DNA Deoxyribonucleic acid 
DNL De-novo lipid synthesis 
EPA Eicosapentanoic acid 
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinases (also known as MAPK) 
FA Fatty acid 
FAS Fatty acid synthase 
Fasn Gene encoding FAS 
FFA Free fatty acid, also known as non-esterified fatty acid (NEFA) 
G6Pase Glucose-6-phosphatase 
GATA Erythroid transcription factor (also known as GATA-binding factor) 
GCP Glycerol-phosphocholine 
GI Gastro intestinal 
GLUT4 Glucose transporter 
GSO Grape seed oil 
HDL High density lipoprotein 
HFD High fat diet 
HOMA-IR Homeostatic model assessment–insulin resistance 
ICAM Intercellular adhesion molecule 
IFN Interferon 
IKK Inhibitor κB kinase 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
IR Insulin receptor 
IRS Insulin receptor substrate 
IV Intravenous 
JNK c-Jun N-terminal kinase 
LA linoleic acid 
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LBD Ligand binding domain 
LDL Low density lipoprotein 
LXR Liver X receptor 
m% Mass % 
M1 Macrophage subtype 1 (classical activated macrophage) 
M2 Macrophage subtype 2 (alternatively activated macrophage) 
MAG Monoacylglyceride 
MAPK Mitogen activated Protein kinase (also known as ERK) 
MCP Monocyte specific chemokine 
MI Myocardial infarction 
MIP  Macrophage inflammatory protein 
MS Metabolic syndrome (also known as syndrome X) 
MUFA Mono unsaturated fatty acid 
NAFL Non-alcoholic fatty liver 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NEFA Non-esterified fatty acid, also known as free fatty acid (FFA) 
NF Nuclear factor 
NFAT Nuclear factor of activated T-cells 
NFκB Nuclear factor κ-light-chain-enhancer of activated B cells 
Nlrp3 NOD-like receptor family, pryin domain containing 3 (gene coding for NALP3) 
OGTT Oral glucose tolerance test 
PA Phytanic acid 
PDK Phosphoinositide dependent kinase 
PhyH Phytanoyl-CoA hydroxylase 
PI3K  Phosphatidylinositol-3-kinase 
PIP3 Phosphatidylinositol-3-phosphat 
PK Protein kinase 
PL Phospholipids 
PP2A Protein-phosphatase-2A 
PPAR Peroxisome proliferator-activated receptor 
PPRE PPAR response element 
PUFA Poly unsaturated fatty acid 
RAS RAt Sarcoma (RAS subfamily of GTPases) 
RT-qPCR Reverse transcriptase quantitative polymerase chain reaction 
RXR Retinoid X receptor 
SFA Saturated fatty acid 
SM Sphingomyelin 
SOD Superoxide dismutase 
SREBP Sterol regulatory element binding protein 
TAG Triacylglyceride 
tFA Trans fatty acid 
Th T -helper (cell) 
TNF Tumor necrosis factor 
Treg Regulatory T-cell 
tVA Trans-vaccenic acid 
UCP Uncoupling protein 
UPR Unfolded protein response 
VCAM Vascular cell adhesion protein 
VEGF Vascular endothelial growth factor 
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VLDL Very low density lipoprotein 
WAT White adipose tissue 
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Motivation 
The ongoing obesity epidemic and dramatic increase in obesity related diseases has created growing 
interest in prevention of obesity development.  Along with lack of physical activity, changes in nutrition are 
a very important parameter in the development of obesity, as dietary components have been shown to 
affect parameters used to diagnose metabolic syndrome (MS). MS is a cluster of metabolic disorders 
correlated to the development of type 2 diabetes and cardiovascular disease (CVD). The belief is therefore 
that identification of nutrients that comprise preventive effect due to the development of MS could have a 
positive effect with regard to reduction of disease incidences. 
Lipids and thereby fatty acids (FA) is an extremely important factor in this context. The common nutritional 
recommendations has, during the last decades, focused on reduction of saturated fatty acids (SFA) and 
trans-fatty acids (tFA), and thereby reduction of dairy fat intake, as these has been shown correlate with 
risk of CVD. However, a number of studies have now indicated that intake of dairy fat might not be as 
harmful as earlier thought, or even that intake of dairy fat might have beneficial impacts in with regard to 
prevention of development of metabolic disorders. Dairy fat is extremely complex, and contains many 
different FAs in minor concentrations. Some of these minor fatty acids might have very interesting potential 
with regard to prevention of metabolic disorders. One of these is phytanic acid (PA) which has agonist 
activity for nuclear receptors, with important functions in among others the lipid metabolism, and is 
therefore important in the context of metabolic disorders. 
In this study we investigate the effects of energy dense diets, with high content of butter which we 
compare to diet high in either oleic acid, the most common mono-unsaturated fatty acid (MUFA) in the 
diet, and a diet high in linoleic acid, an n-6 poly-unsaturated fatty acid (PUFA), from grape seed oil, in obese 
mice. The focus has been on hepatic lipid metabolism and glucose metabolism. Furthermore we compare 
effects on metabolic disorders, from  butter from either low- or high yield production forms, as the fatty 
acid composition in dairy fat varies due to among others feeding regimen. This is investigated both in 
studies with obese mice and in human interventional studies. We also investigate whether PA in 
physiological realistic concentrations has impact on such parameters, and whether intake of PA is able 
affect polarization of T-cells. 
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Introduction 
Obesity 
The world has during the last decades experienced an ongoing increase in the incidents of obesity in such a 
dramatic manner that it is defined as an obesity epidemic. This obesity epidemic is the most likely cause of 
the rising in incidences of insulin resistance, and obesity seems to be the strongest determinant of MS 
(Ogden et al., 2006; Cornier et al., 2008).  
White adipose tissue is believed to have limited storage capacity of fat. When this capacity has been filled 
up further lipid load will lead to ectopic fat deposition in liver, muscles etc and lead to lipotoxicity in the 
tissues (Virtue & Vidal-Puig, 2008). Through secretion of adipokines, adipocytes communicate with other 
tissues and influences important processes such as energy balance, insulin sensitivity and glucose 
metabolism, inflammation, lipid metabolism, blood pressure, haemastasis and angiogenesis (Wood et al., 
2009).  Adipocytes secretes cytokines and the large overfilled adipocytes secretes more pro-inflammatory 
cytokines than anti-inflammatory cytokines compared to small adipocytes, and furthermore also secrete 
more chemoatractants associated with macrophage infiltration (Skurk et al., 2007; Virtue & Vidal-Puig, 
2008). It has been shown that the macrophages in lean mice express many genes characteristic for 
alternatively activated macrophages, also called M2, and macrophages in DIO mice decreased expression of 
those genes while increasing expression of proinflammatory genes such as TNFα and iNOS, which are 
characteristic for classical acitivated macrophages, M1. In the same study it is suggested that the M2-
polarized macrophages might protect against TNFα induced insulin resistance (Lumeng et al., 2007). Th1 
cytokines has been shown to promote M1 macrophages, while Th2 promote M2 polarization of T-cells 
(Bouhlel et al., 2009). The combination of inflammation and lipotoxicity is believed to disturb the proper 
metabolism of all major organs and tissues. This might be the reason why MS is associated not only with 
diabetes type II and CVD, but also liver disease (such as NAFLD), kidney disease, and reproductive disorders 
among others (Cornier et al., 2008). The type of WAT is also a very important factor, as different adipose 
tissue depots have distinct gene expression profiles (Zhang et al., 2007). Visceral adipose tissue in humans 
is strongly associated with increased metabolic risk, whereas subcutaneous adipose tissue is not associated 
with metabolic disorders and might even have protective effects (Snijder et al., 2003).  
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Metabolic syndrome 
Metabolic syndrome (MS), also called syndrome X, is a cluster of metabolic disorders that increase the risk 
of developing cardiovascular disease (CVD) and diabetes mellitus. These risk factors occurs together more 
often than alone (Alberti et al., 2009). The risk factors that make up the MS are raised blood pressure, 
dyslipedimia (raised TAG and lowered HDL cholesterol), raised fasting glucose, and central obesity.  
 
Table 1 Criteria for clinical diagnosis of the metabolic syndrome (Alberti et al., 2009). 
Measure Categorial cut points 
Elevated waist circumference Population- and country-specific definitions1 
Elevated triglycerides ≥150 mg/dL (1.7 mM) 
Reduced HDL cholesterol Males:      < 40 mg/dL (1.0mM) 
Females:  < 50 mg/dL (1.3 mM) 
Elevated blood pressure Systolic ≥130 and/or diastolic ≥ 85 mm Hg 
Elevated fasting glucose ≥100 mg/dL 
1. There are no common categorical cut point values for waist circumference, as there are large differences in 
the related cardiovascular risk between ethnic groups and sexes (Danish cut-off values 94 cm for men and 
80cm for women (www.hjertedoktor.dk, 2011)). 
 
In Denmark the prevalence of MS is around 20 %, which corresponds to the world wide prevalence. The 
prevalence is a little higher for men than for women in Denmark, which though not are a general tendency 
worldwide. The prevalence between sexes differs a lot between countries, which can be due to differences 
in several factors such as work-related activities and cultural views on body fat (Cornier et al., 2008). 
 
Cardiovascular diseases (CVD)/atherosclerosis 
Atherosclerosis is one of the most common causes of death in industrialized western societies, and CVD 
caused 9.9 % of all deaths in Denmark in 2009, only exceeded by the sum of all cancer types 
(www.danmarksstatistik.dk, 2011) The treatment against atherosclerosis has evolved as our understanding 
of the disease and the underlying causes evolved, and that is the primary reason why it is no longer the 
number one cause of death in e.g Denmark. CVD is now regarded as an inflammatory disease, involving 
both the immune system and the lipid metabolism (Lowenstein & Matsushita, 2004). CVD risk factors is 
connected to development of type 2 diabetes (D'Agostino et al., 2004), as well as lipid metabolism is 
associated to development of CVD (Neve et al., 2000). 
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Lipid metabolism and Dyslipidemia 
The lipid metabolism is very central in the development of metabolic disorders, and especially when it is 
dysregulated, leading to dyslipedimia. Many lipids and lipid metabolites from different lipid classes, 
function as signal transducers by inhibiting or inducing metabolic processes, as in e.g. the insulin cascade, 
which is described below, and are thereby involved in development of metabolic disorders. 
 The liver plays a central role in fatty acid balance of the body, by chylomicron clearance, remnants, uptake 
of endogenous NEFA from circulation, and lipid neo synthesis from glucose (Adiels et al., 2008; Musso et 
al., 2009), and lipid export in VLDL particles. Increased lipid supply, as observed within obesity, leads to 
increased TAG-rich VLDL-particle production. By use of stable isotope methodology, Donnelly et al. has 
shown that in patients suffering from non-alcoholic-fatty-liver disease (NAFLD), 59 % of TAG in the liver 
comes from circulating NEFA, 26 % from de novo lipogenesis (DNL) and 15 % from the diet. They also 
showed that in these patients DNL was the same postpranidial as in fasting state (Donnelly et al., 2005). By 
the actions of cholesteryl ester transfer protein (CETP) and hepatic lipase, TAG from VLDL-particles is 
transferred to HDL- and LDL-particles. TAG-rich lipoproteins are preferred substrates of hepatic lipase, and 
therefore TAG is removed from HDL and LDL. This results in formation of small dense LDL and small dense 
HDL. Small dense HDL is catabolized and removed from circulation, which results in reduced HDL 
concentrations, and small dense LDL is more atherogenic than larger subpopulations of LDL (Adiels et al., 
2008; Musso et al., 2009). 
Non-alcoholic fatty liver disease (NAFLD) has been suggested to be a main factor driving the development 
of MS, and is defined as: Liver fat content >5-10 % by weight in the absence of excess alcohol consumption 
or any other liver disease. (Vanni et al., 2010). NAFLD covers variable degrees from simple and benign 
steatosis, to nonalcoholic steatohepatitis (NASH), and Cirrhosis.  NASH is defined by the presence of 
hepatocyte injury, inflammation and/or fibrosis which can lead to cirrhosis, liver failure and hepatocyt 
carcinoma. Therefore inflammatory markers, such as TNFα, are also important factors to take into account 
with regard to excess hepatic lipid accumulation. When the liver gets fatty due to NAFLD, the ability of 
insulin to inhibit hepatic glucose production is impaired. This leads to a slight increase in concentration of 
plasma glucose and stimulation of insulin secretion. Therefore Vanni et al. suggests that hyperinsulinemia is 
likely to be the consequence rather than the cause of NAFLD, since exogenous insulin therapy for seven 
months significantly decreases liver fat content (Juurinen et al., 2007; Vanni et al., 2010). Dyslipidemia is an 
independent risk factor for type 2 diabetes, and Rhee et al. has identified a TAG signature of insulin 
resistance, which they propose is able to improve diabetes prediction in humans (Rhee et al., 2011). 
 
Insulin resistance 
The pleitropic molecule insulin has many different effects and are involved in many processes, e.g.: amino 
acid uptake, protein synthesis, adipose tissue TAG lipolysis, lipoprotein lipase activity, very low density 
lipoprotein (VLDL) TAG secretion, muscle and liver glycogen synthesis, endogenous glucose production, and 
most commonly known muscle and adipose tissue glucose uptake(Cornier et al., 2008). The many actions of 
insulin is mediated through a single receptor tyrosine kinase, called insulin receptor (Kido et al., 2001). 
Insulin resistance, and the opposite insulin sensitive, is generally defined due to the response to oral or 
intravenous (IV)glucose or insulin stimulus (Pacini, 2006). Insulin resistance is closely coupled to obesity, 
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and as mentioned above also to dyslipidemia (Rhee et al., 2011). Though, increased intracellular lipid 
concentrations in muscle cells, can together with external inflammatory stimuli interfere with the insulin 
signaling and glucose uptake. Insulin sensitivity is inversely correlated with intramyocellular TAG 
concentration; it is probably not TAG itself that is directly responsible, as it is more likely that TAG is just a 
marker for FFA and other lipid metabolites such as the sphingolipid ceramide and diacylglyceride (DAG). 
Both ceramide and DAG has been shown to activate protein kinases or –phosphatases that impair the 
signal from insulin receptor, with following increased insulin resistance (Chavez et al., 2003; Corcoran et al., 
2007). Furthermore ceramide has been suggested to be involved in the activation of the Nlrp3 
inflammasome during  induced inflammatory development, which also seems to play a role in early stages 
of high fat diet (HFD)-induced insulin resistance (Vandanmagsar et al., 2011). 
 
 
Figure 1 Insulin signalling cascade, and inhibition by Diacylglycerol (DAG) and Ceramide. IR: Insulin 
receptor, GLUT4: Glucose transporter 4, IRS1: Insulin receptor substrate 1, PI3K: 
Phosphatidylinositol-3-kinase, PIP3: Phosphatidylinositol-3-phosphat, PDK: Phosphoinositide 
dependent kinase, PK: Protein Kinase, PP2A: Protein-phosphatase-2a, RAS: , Mek: , MAPK: 
Mitogen-activated protein kinase.  
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Insulin resistance can also be induced by endoplasmic  reticulum (ER) stress, as it leads to activation of IKK 
by NFκB activators (Yuan et al., 2001; Fleischman et al., 2008) and c-Jun N-terminal kinase (JNK), and 
thereby alternative phosphorylation of members of the insulin signaling cascade (Gregor et al., 2009). ER 
stress is also called unfolded protein response (UPR) and occurs when the amount of un- or malfolded 
protein exceeds the capacity of ER to ensure proper folding, leading to the UPR, including activation of JNK. 
As treatment with chemical chaperones prevents insulin resistance in obese mice, this pathway is thought 
to be an important contributor to development of insulin resistance (Harding & Ron, 2002; Schenk et al., 
2008). ER stress is believed to induce insulin resistance in liver, adipose tissue and skeletal muscle (Gregor 
et al., 2009).  
Adipokines is another important factor in the development of insulin resistance (Rabe et al., 2008). 
Especially adiponectin seems to be an important factor with regard to insulin resistance. The level of 
adiponectin is normally lowered with obesity and insulin resistance, which is unlike most other 
adipokines(Hotta et al., 2001), and decreased expression of adiponectin correlates with insulin resistance 
(Yamauchi et al., 2001). Administration of adiponectin leads to decreased TAG levels in muscle and liver in 
obese mice, due to expression of e.g. CD36, ACOX, and UCP2 (Yamauchi et al., 2001). Other adipokines 
involved in insulin resistance are e.g. leptin, resistin, TNFα, IL-6, and IL-10 etc (Rabe et al., 2008; Ropelle et 
al., 2010). Several of these adipokines are involved in the regulation of each other, e.g. adiponectin suppres 
TNFα and IL-6, while they suppress adiponectin and stimulate other adipokines such as leptin and resistin 
(Rabe et al., 2008).  
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Nuclear receptors  
The term nuclear receptor superfamily covers a diverse array of transcription factors, from which three 
specific receptors will be further described, as they mediate important functions within the scope of 
current thesis. Both Retinoid-X-Receptor (RXR), liver-x-receptor (LXR), and the three different isoforms of 
peroxisome proliferator-activated receptors (PPAR) (α, γ, and δ) are transcription factors and members of 
the so called nuclear receptor super family, including nuclear hormone receptors and orphan nuclear 
receptors (Olefsky, 2001).   
 
Common for all the nuclear receptors are that they function through so-called response elements, which 
are recognition/binding sites for the given at receptor dimer at the DNA strand, e.g. PPARs conduct their 
actions as transcription factors upon agonist activation, by binding to a PPAR response element (PPRE) on 
the DNA strand. All nuclear receptors therefore also have common structural features, including a DNA 
binding domain (DBD) which are responsible for the recognition and binding to the response elements, and 
a ligand binding domain (LBD) (Desvergne & Wahli, 1999; Olefsky, 2001; Desvergne, 2007).  
 
Retinoid-X-Receptor 
Retinoid-X-receptor (RXR) was originally discovered as a receptor involved in the retinoid signaling 
pathway, and there are three different isoforms, α, β, and γ. RXR is most known for its role as partner for a 
number of other nuclear receptors (e.g. PPARs and LXR), which conducts their functions as heterodimers 
with RXR (Shulman & Mangelsdorf, 2005). Though, RXR also act as a dimeric orphan receptor forming 
homodimers (Nagao & Yanagita, 2008). RXRα is abundantly expressed in liver, kidney, spleen, placenta, 
epidermis and a variety of visceral tissues, RXRβ is expressed ubiquitously, and RXRγ is mainly expressed in 
muscle and brain(Mangelsdorf et al., 1992; Szanto et al., 2004). RXR specific ligands has been indicated to 
have glucose-lowering and insulin sensitizing effects, and a RXRα agonist has been reported to have anti 
atherosclerotic effect in apoE mice (Nagao & Yanagita, 2008). Some of the most important effects from 
RXR, whit in the scope of this thesis, is conducted together with PPARs, and is described below. RXR also 
plays interesting roles in the immune system, as RXRα has been shown to be essential for an appropriate 
Th2-response, and RXRα knockout mice show a Th1-bias in vivo (Du et al., 2005; Stephensen et al., 2007). 
IFN-γ is in vitro inhibited by RXR-specific agonists as well as by 9-cis retinoic acid (Dawson et al., 2008), 
though it is not clear whether this is mediated through RXR or retinoic acid receptor (RAR).  
 
Peroxisome Proliferator-Activated receptors 
As mentioned there is three different isoforms of PPARs, namely α, δ, and γ. PPARs are extremely 
important factors in e.g. the fatty acid metabolism in the liver, where PPARα operates in the catabolism of 
fatty acids, and PPARγ influences the storage of fatty acids in the adipose tissue, but has also controlling 
roles in inflammation (Kersten et al., 2000; Varga et al., 2011). PPARs are related to the modulation of 
environmental and dietary stimuli, and all three types are involved in the regulation of lipid metabolism, 
but they have distinctive roles, as well as they isoforms vary in tissue distributions and functions. Their 
cellular and systemic roles extend far beyond the control of hepatic peroxisome proliferation in rodents 
after which they were initially named, which among others has been reviewed in 2010 by Yessoufou and 
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Wahli (Yessoufou & Wahli, 2010). In the early 1990s PPARα was the first genetic sensor for fats that was 
identified (Evans et al., 2004), and the PPARs are the main receptors acted upon by lipids (Guri et al., 2006). 
Following ligand binding, PPARS heterodimize with RXR, inducing the detachment of co-repressors, 
recruitment of co-activators, some of which with acetylation activity, and subsequent binding to PPAR 
response element (PPRE) on DNA that initiates the transcription of responsive genes (Guri et al., 2006; 
Nagao & Yanagita, 2008). 
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Table 2 Metabolic functions of PPARs. Compilation of the known main metabolic functions of PPARα, 
PPARδ, and PPARγ in the liver, muscle, white adipose tissue, brown adipose tissue, and pancreas. Redrawn 
from (Yessoufou & Wahli, 2010), information on brown adipose tissue from (Kang et al., 2005; Komatsu et 
al., 2010). 
Tissue PPARα PPARδ PPARγ 
 
Liver Increases fatty acid uptake 
Increases fatty acid oxidation 
Increases HDL apolipoproteins 
Decreases VLDL production 
Decreases acute-phase 
reactants 
Decreases inflammation 
 
Decreases glucose production 
via increase of pentose 
phosphate shunt 
Increases lipogenesis 
Increases insulin sensitivity 
Muscle PPARα overexpression shifts 
substrate utilization from 
glucose to fatty acids 
Increased fatty acid uptake 
Increased fatty acid oxidation 
Increased triglyceride lipolysis 
Increased glucoseintolerance/ 
insulin resistance 
Decreased glucose utilization 
 
PPARδ (major isotype) 
Increased expression during 
starvation 
Increased fatty acid oxidation 
Increased fatty acid transport 
Increased thermogenesis 
Increases endurance capacity 
Increases insulin sensitivity 
White adipose 
tissue 
Increases lipolysis during 
starvation 
Increased fatty acid oxidation 
Increased fatty acid transport 
Increased thermogenesis 
 
Increases adipocyte 
differentiation 
Increases adipocyte survival 
Increases lipogenesis 
Increases insulin sensitivity 
Increases adipokine secretion 
 
Brown 
adipose tissue 
Increases fatty acid oxidation 
during cold exposure 
 Involved in the differentiation 
of preadipocytes into brown 
adipocytes  
 
Pancreas Decreases β-cell lipotoxity 
Increases glucose-stimulated 
insulin secretion 
Increses fatty acid oxidation 
 
Decreases insulin secretion in 
rodents 
 
 PPARα agonists he systemic effects in humans: Decreased triglycerides, increased HDL cholesterol, 
decreased hyperlipidimia and LDL, steady glycemia. 
 
PPARγ agonists are used as insulin sensitizing drugs. PPARγ ligand resistance syndrome (PLRS) –
phenotypic characteristics of PLRS subjects are: Partial lipodystrothy, dyslipidemia, type 2 diabetes, 
insulin resistance, hypertension, hepatic steatosis, polycystic ovary syndrome. 
 
No PPARδ agosnists are on the market. 
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PPARα 
PPARα are highly expressed in the liver, brown adipose tissue (BAT), heart, skeletal muscle, and kidney, 
which are organs with high rates of FA catabolism. In other organs PPARα are expressed at lower levels. In 
the liver PPARα plays an extremely important role in the promotion of fatty acid oxidation and is especially 
active during fasting (Kersten et al., 2000; Yessoufou & Wahli, 2010), but it is also involved in FA uptake 
through membranes, FA activation, intracellular FA trafficking, and TAG storage and lipolysis 
(Rakhshandehroo et al., 2010).  A very central enzyme in hepatic lipid oxidation, which is under 
transcriptional control from PPARα, is acylCoenzymeA oxidase 1 (ACOX1), as it is the first enzyme in the β 
oxidation of straight chain FAs. 
PPARα in the liver are activated by FAs from peripheral tissue and the diet, as well as FA derivatives from 
diet and glycerol-phosphocholine (GCP) resulting from high sucrose intake. PPARα deficiency is associated 
with hepatic steatosis, decreased levels of plasma glucose and ketone bodies and elevated plasma NEFA 
and hypothermia, which are due to decreased expression of PPARα target genes involved in hepatic lipid 
metabolism (Leone et al., 1999; Rakhshandehroo et al., 2010).  
PPARα has a broad range of both artificial and natural ligands. The artificial ligands of PPARα include 
hypolipidemic drugs, such as Wy-14643, clofibrate, plasticizers, and insecticides. A broad array of 
unsaturated fatty acids, long chain fatty acids, and branched chain fatty acids (e.g. phytanic- and pristanic-
acid), are natural ligands for PPARα (Gloerich et al., 2005; Rakhshandehroo et al., 2010). Various artificial 
PPARα agonists commonly known as fibrates, has gained great success as oral agents against 
hypertriglyceridemia (Kota et al., 2005; Berger et al., 2005). 
Beside the effects in the lipid metabolism, specific agonists to both PPAR- and PPAR-modulate the 
Th1/Th2-balance in the Th2 direction, since both types  attenuates the IFN- secretion from CD4+ T-cells 
after CD3 crosslinking, while  PPAR- agonists also  increases the production of IL-4 from murine and 
human lymphocytes (Marx et al., 2002; Lovett-Racke et al., 2004). In one study that shows increase in IL-4 
due to treatment with specific PPARα agonists, one specific potent PPARα ligand (GW7,647) does not seem 
to augment IL-4 (Cunard et al., 2002). Furthermore, PPAR- -/- - mice, show an impaired induction of 
regulatory T-cells (Treg) (Dubrac et al., 2011) , indicating that PPAR- activation also are involved in 
differentiation of regulatory T-cells. The PPARα agonist Fenofibrate has also been shown to repress IL-17 
and IFN-γ via PPARα in IL-10 deficient mice, which is normally characterized by Th1 polarized inflammation 
(Lee et al., 2007). PPARα, as well as PPARγ, are also expressed in B cells, and PPARα activators decrease the 
amount of NFκB in both transformed T-cell and B-cell lines (Cunard et al., 2002; Jones et al., 2002). 
Treatment of macrophages with PPARα agonists has been showm to suppress IL-6 gene transcription by 
interfering with NFκB-driven promoter activation (Delerive et al., 1999). 
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Figure 2 Simplified scheme illustrating the production of ligands activating PPARα. Dietary fatty acids and 
fatty acid derivatives activate PPARα. On a high sucrose (no fat diet), the production of 16:0/18:1 GPC 
activates PPARα. Activation of PPARα results in the transcriptional regulation of numerous genes, the so-
called PPARα transcriptome, which contributes to maintaining the energy balance in part through the 
promotion of mitochondrial and peroxisomal beta-oxidation of fatty acids and many other metabolic 
pathways. FA: fatty acids; 16:0/18:1 GPC: 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine; TG: 
triglycerides; VLDL: very low density lipoprotein. (Redrawn from (Yessoufou & Wahli, 2010) with permission 
from EMH Swiss Medical Publishers Ltd). 
 
PPARγ 
PPARγ exists in two isoforms, PPARγ1 and PPARγ2, which is the result of differential promoter usage and 
splicing. PPARγ2 is expressed primarily in adipocytes, wheras PPARγ1 is also relatively abundant in 
macrophages, colon epithelia, and endothelium (Lehrke & Lazar, 2005). A third PPARγ (PPARγ3) which 
encodes the same protein as PPARγ1 also exists (Desvergne & Wahli, 1999). PPARγ is involved in many 
different processes such as insulin sensitivity, body mass, atherosclerosis and macrophage biology, 
inflammation, and cancer (Lehrke & Lazar, 2005), but the most pronounced effects is the promotion of lipid 
storage in adipose tissue, together with the pivotal role in adipocyte differentiation (Madsen et al., 2008; 
Yessoufou & Wahli, 2010). The key role in adipocyte development is controlled by PPARγ, though all three 
forms has been detected in adipose tissue (Madsen et al., 2008). PPARγ can be activated by many different 
FAs, but it seems that PUFAs are better activators than MUFAs and SFAs, and highest binding affinity is 
achieved with FAs with 16-20 C-atoms (Madsen et al., 2008).The group of PPARγ agonists called 
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thiazolidinediones, has been widely used as drugs for treatment of type 2 diabetes, which is often leads to 
increased weight gain due to the promotion of lipid storage in adipose tissue (Bloomgarden, 2011). Despite 
relatively low expression of PPARγ in liver, it is critical for the development of hepatic steatosis (Yu et al., 
2003; Patsouris et al., 2006), and has recently been shown to promote osteoclast differentiation and bone 
resorption when activated by the agonist rosiglitazone (Wahli, 2008). 
As mentioned in the section about PPARα, both PPARα and PPARγ specific agonists, has been shown to 
modulate the Th1/Th2-balance in the Th2 direction, since both types  attenuates the IFN- secretion from 
CD-4+ T-cells after CD-3 crosslinking (Marx et al., 2002). Furthermore PPARγ has been shown to promote 
human monocyte differentiation toward alternative macrophages (M2), which are normally promoted by 
Th2 cytokines, while Th1 cytokines promote the pro-inflammatory M1 macrophages. M2 macrophages are 
present in atherosclerotic lesions, where the expression of M2 markers correlates positively with 
expression of PPARγ (Bouhlel et al., 2009), which is in accordance with the promotion of differentiation of 
monocytes towards M2 by PPARγ. PPARα and PPARδ does not promote differentiation of monocytes 
towards M2 macrophages (Bouhlel et al., 2009). 
 
 
Figure 3 Anti-inflammatory effects of reroxisome proliferator-activated receptor (PPAR) ligands. ERK: Extracellular 
signal-regulated kinases (also known as MAPK), BCL: B cell lymphoma protein, MCP: Monocyte specific chemokine , 
CCR: Chemokine (C-C motif) receptor , MIP: Macrophage inflammatory protein, TNF: Tumor necrosis factor, IFN: 
Interferon , IL: Interleukin , E-selectin: , ICAM: Intercellular adhesion molecule, VCAM: Vascular cell adhesion protein, 
VEGF: Vascular endothelial growth factor, SOD: Superoxide dismutase , CAT:  Catalase, Akt: Protein kinase B (PKB) , 
TGF: transforming growth factor, NF: Nuclear factor, AP: activator protein, GATA: Erythroid transcription factor (GATA-
binding factor), NFAT: Nuclear factor of activated T-cells . Redrawn from (Yessoufou & Wahli, 2010) by permission 
from EMH Swiss Medical Publishers Ltd. 
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PPARδ 
PPARδ, also known as PPARβ, did for a long time PPARδ receive much less attention than the two other 
isotypes of PPAR, because of its ubiquitous expression and unavailability of selective ligands. However, 
genetic studies and development of synthetic PPARδ agonists have helped reveal its role as a powerful 
regulator of fatty acid catabolism and energy homeostasis, beside implication in processes such as 
keratinocyte proliferation and differentiation during wound healing (Evans et al., 2004; Yessoufou & Wahli, 
2010). It has also been shown to be is expressed in preadipocytes and may be induced during the initial 
stages of adipocyte differentiation (Amri et al., 1995; Madsen et al., 2008). The PPAR agonist GW501516 
has been shown to lower plasma triglyceride levels in obese monkeys while raising HDL levels (Oliver et al., 
2001), and PPARδ upregulates fatty acid oxidation and energy expenditure in skeletal muscles, to a far 
greater extent than does the lesser-expressed PPARα (Evans et al., 2004). It appears that FAs that are 
unable to undergo oxidation are effective activators of PPARδ, but other FAs are also able to activate 
PPARδ (Madsen et al., 2008). 
 
LXR 
Liver X receptors (LXR) are receptors that bind oxysterols, and there is two isoforms, α and β. LXRs form 
heterodimers with RXR. LXRα is expressed primarily in liver, adipose tissue, intestine, macrophages, and 
kidney, whereas LXRβ is ubiquitously expressed. LXRs are involved in transport of cholesterol from 
peripheral back to the liver and the hepatic cholesterol metabolism. Interestingly, with regard to the scope 
of this thesis LXR, and especially LXRα, increase the synthesis of FAs and TAGs due to up regulation of sterol 
regulatory binding protein 1C (SREBP-1c), which is regarded as the main regulator of FA synthesis (Repa et 
al., 2000; Shulman & Mangelsdorf, 2005; Desvergne, 2007). An interesting feature of PUFAs with regard to 
LXR, is that Srebp-1c has been shown to be suppressed by PUFAs, and in particular eicosapentanoic acid 
(EPA), due to inhibition of LXR binding to the LXR response elements (Yoshikawa et al., 2002). 
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Lipid intake and the risk of metabolic disease 
It is commonly known that lipid intake has great influence on the metabolic status and development of 
various metabolic diseases, but there are many different classes and aspects of lipids, and the effects from 
intake, and general functions, of lipids differs a lot. Most lipids in the diet are fatty acids in the form of TAG. 
A Very important factor with regard to fatty acids and lipid intake is the differences in degree of saturation 
and chain lengths of the individual fatty acids. Within unsaturated fatty acids there are many factors with 
importance with regard to health effects e.g. chain length, number of double bonds, cis/trans isomerism of 
double bond , chain branches, placement of the double bonds e.g. n-3, n-6, and n-9 unsaturated FAs. One 
of the most studied types of fatty acids is the long chained polyunsaturated fatty acids (LCPUFA) mainly 
found in fish. This is due to great potential for health promoting effects from intake, with regard to many 
different metabolic parameters (Leon et al., 2008; Eslick et al., 2009). 
Several studies has pointed out that intake of saturated fatty acids (SFA) has negative effects with regard to 
development of metabolic related diseases, such as cardiovascular disease (Hu et al., 1997; Steyn et al., 
2004) and type 2 diabetes (Steyn et al., 2004). Trans-unsaturated fatty (tFA) acid is another type of fatty 
acids that have been shown to elicit disadvantages effects with regard to health (Brouwer et al., 2010). As a 
consequence from the knowledge provided from these studies, the general recommendations have been to 
decrease intake of SFA and tFA (Vartiainen et al., 2010). The common nutritional recommendations for the 
Nordic countries from 2004, advice that the sum of SFA and tFA should be not higher than 10 E% of the 
total energy intake, and total fat intake not higher than 25-35 E%. Cis-MUFA should comprise 10-15 E%, and 
PUFAs 5-10 E% including 1 E% n-3 PUFAs (Nordic Council of Ministers, 2005). As animal fat generally 
contain high levels of SFA, and fat from ruminant animals also tFA, it has also been generally recommended 
to reduce intake of animal fat, including dairy fat.  
However, a number of studies have now indicated that intake of dairy fat might not be as  harmful as 
earlier believed (Gibson et al., 2009), or even that intake of dairy fat might have beneficial impacts in 
relation to cardiovascular and metabolic disorders (German et al., 2009), and the effects of reduction in SFA 
intake has been questioned (Astrup et al., 2011). The three latter references all question whether the 
common recommendations to avoid SFA have the intentional effect on among others CVD, and German et 
al. points on positive effects from dairy intake. The viewpoint from German et al. is supported by several 
studies showing negative correlations between validated biomarkers for milk-fat intake and cardiovascular 
and metabolic risk markers as well as incidence of the first myocardial infarction in case-control studies 
(Smedman et al., 1999; Warensjo et al., 2004; Biong et al., 2006; Hodge et al., 2007; Warensjo et al., 2009; 
Warensjo et al., 2010). Smedman et al. found inverse associations of milk product intake and metabolic risk 
markers e.g. BMI and fasting plasma glucose by 7 days dietary records for 72 men, and the studies by 
Warensjo et al. indicates positive effects on risk of developing CVD by dairy fat intake. Biong et al. suggest 
that intake of dairy fat or some component within dairy products, protect persons at risk against a first 
myocardial infarction (MI), and Hodge et al. shows that dietary saturated fat intake is inversely associated 
with diabetes risk. Thus, the metabolic effects of dairy fat intake seem to be positively modulated by other 
components than the major saturated fatty acids.  In 2007 (revised in 2009) The Danish Dairy Board 
published a report by Lars Ovesen, in which studies about intake of milk and dairy products, and risk of 
disease gone through. The report came up with conclusion on positive effect by intake of dairy products on 
among others type 2 diabetes (Ovesen, 2009), on the background of four prospective studies regarding 
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dairy intake and risk of type 2 diabetes (Choi et al., 2005; Liu et al., 2006; van Dam et al., 2006; Elwood et 
al., 2007). 
As in other nutritional fats, TAG is the far most dominating lipid class in milk fat, and constitutes more than 
95 % of the total lipid fraction. Diacylglycerides (DAG) constitute around 2%, Phospholipids (PL) 1% 
(including sphingomyelin), and the rest of the lipid fraction is covered by cholesterol, cholesteryl esters, 
free fatty acids (FA), monoacylglycerides (MAG) and trace amounts of hydrocarbons (Jensen, 1973; Jensen, 
2002). Milk fat is the most complex type of fat occurring in nature, with at present more than 400 different 
fatty acids (FA) identified, which gives an enormously amount of theoretical possible different TAGs, of 
which probably several thousands are present (Jensen, 2002). Several factors are associated with variations 
in the FA-composition of bovine milk. These factors could be divided into factors correlated to the animals, 
and factors correlated to the feed (Palmquist et al., 1993; Jensen, 2002), why there is often large seasonal 
variations in the FA composition. Normally only 12 different FAs each constitute more than 1% of the total 
fatty acid mass in milk, and the three most dominating FAs are the SFAs myristic-, palmitic-, and stearic 
acid. MUFAs are also accounting for a relatively large share of the FAs in milk fat, but PUFA are found in 
small amounts (Jensen, 2002), that are often regarded as inconsiderable.  
Several FAs are almost specifically found in dairy fat and some of them can therefore be used as markers 
for dairy fat intake, as done in several of the studies referred above. Pentadecanoic acid (15:0) and 
margaric acid (17:0), which cannot be synthesized in humans, have been regarded as valid biomarkers of 
dairy intake, though both of them are also found in lamb, beef, venison, and fatty fish (Baylin et al., 2002; 
Hodson et al., 2008; Iggman & Riserus, 2011). Tetradecanoic acid (14:0) level in adipose tissue has been 
considered a valid biomarker of long-term dairy intake, although it can also be synthesized endogenously 
(Warensjo et al., 2004; Iggman & Riserus, 2011). Trans-fatty acids (tFA) are another type of FAs that are 
quite exclusive for dairy fat, and deduce around 5 mass % of total fat. The amount varies over the season, 
and is found to higher in summer-butter than winter-butter (Jakobsen et al., 2006). 
Among the huge pool of minor fatty acids present in milk fat, there are several that might be able to abolish 
some of the unhealthy effects of SFA and tFA. Minor FAs that might have protective effects, either alone or 
synergistically, could be short-chain fatty acids (SCFA) (Legrand et al., 2010), conjugated linoleic acid (CLA) 
(Roche et al., 2001), Trans vaccenic acid, and phytanic acid (Hellgren, 2010). CLA has gained a lot of 
attention in the recent years, as in-vivo models in animals has shown that CLA has an ability to increase 
muscle mass and decrease adipose tissue mass, as well as repressing tumor growth, atherogenisis and 
diabetes (Tricon et al., 2005). CLA content in milk varies with feed, and intake of linoleic- and linolenic-acid, 
especially from grass, leads to increased amounts of CLA in milk (Dhiman et al., 2005). In Denmark the 
content has been shown to increase from 0.37 m% at winter to 0.57 m% (mean values) of total milk fat in 
summer (Jakobsen et al., 2006). 
A study by Legrand et al. indicates that the saturated short chain fatty acids (SCFA) in dairy fat, has the 
ability to decrease circulating cholesterol and increase the content of tissue n-3 PUFA in the rat (Legrand et 
al., 2010). Trans-palmitoleic acid has been proposed to have metabolic benefits and have protective 
function against diabetes (Mozaffarian et al., 2010). 
Phytanic acid 
The branched-chain fatty acid phytanic acid (PA, 3, 7, 11, 15-tetramethyl hexadecanoic acid) is an 
interesting component of dairy fat, since it, as well as its primary metabolite pristanic acid (2,6,10,14-
30 
 
tetramethylpentadecanoic acid), has strong agonistic activities on the nuclear receptors RXRα and PPARα 
(Kitareewan et al., 1996; Zomer et al., 2000; Heim et al., 2002). PA originates from chlorophyll, from which 
it is cleaved by ruminant microbiota, and therefore found in dairy- and meat products of ruminant origin. 
PA has been suggested to have preventive effects on the development of metabolic disorders, due to the 
agonistic activity on RXR (Lemotte et al., 1996; Kitareewan et al., 1996), and PPARα, maybe through its 
primary metabolite pristanic acid (Gloerich et al., 2005; Fluehmann et al., 2007). PA and its potential as a 
bioactive FA were reviewed in 2010 (Hellgren, 2010). Most of these suggestions on preventive effects of PA, 
builds on studies performed with its precursor phytol, see Figure 4 (Gloerich et al., 2005; Gloerich et al., 
2007), probably as is not nearly as expensive as PA. PA has been shown to activate transcription of 
uncoupling protein-1 (UCP1) and suggested to be a nutrient with potential as regulator of brown adipocyte 
differentiation and thermogenesis (Schluter et al., 2002a), and pristanic acid has been excluded as the 
mediator of these positive effects on brown adipocyte differentiation (Schluter et al., 2002b).  
 
 
Figure 4 Structures of chlorophyll (A), phytol (B), and Phytanic acid (C)  
 
Though PA, as well as phytol, are also associated with negative health effects. An increased level of 
phytanic acid in the body is toxic, so the fatty acid needs to be broken down (Gloerich et al., 2007). Most 
important is its implication in Refsums disease, which is a disease with over-accumulation of PA, leading to 
among others neurologic damage and cerebellar degeneration. The reason for the increased PA 
accumulation in Refsums disease lies in the metabolism of PA. Before PA can enter β-oxidation, it has to 
undergo one round of α-oxidation, to form pristanic acid. An important enzyme in this process is phytanoyl-
CoA hydroxylase (PhyH), and in general Refsums disease is caused by mutation in this enzyme (Verhoeven 
et al., 1998). Only stereoisomers with the 2-methyl group in S-configuration can be degraded by β-
oxidation. That makes α-methyl-CoA racemase (AMCAR), a very important enzyme in the oxidation process 
of PA, as it catalyses conversion of (2R)-methyl-branched-chain acyl-CoAs to the corresponding S-
stereoisomers (Verhoeven & Jakobs, 2001).  For further information on PA breakdown and metabolism of 
PA the articles (Verhoeven & Jakobs, 2001), as well as (van den Brink & Wanders, 2006), can be 
recommended. 
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Due to the agonistic activity towards RXR and PPARα, PA are also hypothesized to have effects in systemic 
inflammation, as other ligands for these nuclear receptors have been shown to impact the polarization of T-
cells. Both RXR and PPARα specific ligands have been shown to repress IFN-γ (fundamental Th1 marker)and 
IL-17 (essential marker of Th17 cells), to increase expression of IL-4  in T-cells, reflecting a Th2-polarization 
of the T-cell response (Cunard et al., 2002; Straus & Glass, 2007; Lee et al., 2007; Hwang et al., 2009). 
Additionally, PPARα activation seems to be involved in differentiation of Tregs (Dubrac et al., 2011). Th1 cells 
are generally believed to induce pro-inflammatory immune responses, as they improve activation of 
cytotoxic CD8+ T-cells by dendritic cells in lymph nodes, and moreover, activate macrophages in peripheral 
tissues in an antigen-dependent manner. CD8+ T-cells mediate cytolytic effects towards infected cells within 
all body sites. Th2 cells, on the other hand, are involved in the humoral immune system via its essential role 
in propagation of B-cells to become plasma cells (producing antibodies)(Munder et al., 1999; Spilianakis et 
al., 2005; Hwang et al., 2009). Th17 cells were initially described as a cellular T-cell subset implicated in 
autoimmunity, but are now thought to have their own distinct effector and regulatory functions, mainly 
mediating activation of neutrophils, controlling extracellular microbes through phagocytosis, hence being 
involved in balancing the number of microbes at mucosal tissue sites. However, Th17 cells can be highly 
proinflammatory and induce severe autoimmunity (Harrington et al., 2005; Bettelli et al., 2007). Treg´s are 
crucial for maintenance of immunological tolerance. Their main role is to shut down T-cell mediated 
immunity towards the end of an immune reaction(Mills, 2004; Du et al., 2005; Belkaid & Rouse, 2005). For 
functions of the cytokines relevant for the current studies, see Table 3. 
 
 
Table 3 Biological functions and roles of T-cell polarizing cytokines of relevance for the studies within this thesis. 
Cytokine T-cell producers Functions References 
 
IFN-γ Th1, 
CD8
+
, 
NKT,  
γδT-cells
 
Activates macrophages and natural killer (NK) cells. 
Role in delayed type hypersensitivity. 
Represses Th2 and Th17 differentiation. 
Promotes Th1 differentiation. 
Central for cell-mediated immunity 
 
(Kwok et al., 1993; 
Billiau, 1996; Smyth & 
Godfrey, 2000; Ansel 
et al., 2003; Auphan-
Anezin et al., 2003; 
Korn et al., 2009) 
 
IL-4 Th2,  
NKT,  
γδT-cells 
Promotes B cell proliferation, differentiation, and 
immunoglobulin isotype switching to IgE.  
Negative regulator of Th1. 
Promotes Th2 differentiation 
 
(Brown & Hural, 
1997; Smyth & 
Godfrey, 2000; Ansel 
et al., 2003)  
IL-10 Tregs  
Th1,  
Th2,  
Th17 
Anti-inflammatory.  
Regulates growth and/or differentiation of B cells, NK 
cells, CD8
+ 
T-cells and Th-cells. 
Negative regulator of Th1 by inhibition of IFN-γ. 
 
(Billiau, 1996; Smyth 
& Godfrey, 2000; 
Moore et al., 2001; 
Xu et al., 2009)  
IL-17 Th17,  
NKT,  
γδT-cells 
Antimicrobial and antifungal. 
Activates neutrophils 
Induces tissue inflammation.  
IL-17 does not act as a growth or differentiation factor for 
Th17. 
A reciprocal relationship between Tregs and Th17 exists. 
(Korn et al., 2009; 
Onishi & Gaffen, 
2010) 
 
32 
 
Nutritional sources of phytanic acid 
Humans and most other mammals are not able to convert chlorophyll into phytol, but the diverse 
microbiota in the rumen of ruminal animals is able to carry out this reaction. Hence, the human intake of 
phytol and PA originates form ruminal animal sources, such as dairy and meat products. There have not 
been many studies on phytol and PA contents in dairy products and even less in meat products. Though, 
due to the implication in Refsums disease some has been carried out. Most thoroughly is the study by 
Brown et al. from 1993, as they list the content of PA and phytol in many different food sources (Brown et 
al., 1993). More recently the group of Vetter has performed studies on day to day variations in PA and 
pristanic acid content, and showed that the content is higher in organic than conventional dairy products 
on the German market (Vetter & Schroeder, 2010; Schroder et al., 2011). Their finding that organic dairy 
products, which may be assumed to originate from cattle fed high amounts of green plant material, contain 
more PA than conventional dairy products, correlate with studies on PA content in milk from 72 Nordic 
herds, performed by our self (unpublished data), showing that organic and grazing cattle generally has 
higher PA content in their milk than conventional fed cattle. A frequency distribution of the PA content in 
milk from these herds (plus data from seven Danish butters), can be seen from Figure 5.  
 
 
Figure 5 Frequency distribution of milk phytanic acid content. Frequency distribution of phytanic acid in 
milk fat from Swedish, Norwegian, and Danish farms, shown as mass% of total fat fraction, n=79. 
 
A study from 2005 found that PA in milk from alpine cattle is raised to around 0.5 m% of fat fraction, in the 
grazing period of the year (Leiber et al., 2005), which is just about the same amounts we measured in milk 
from grazing Nordic cattle. In addition a study from 1977, shows that feeding steers grass ensilage leads to 
a raise in their plasma PA content (Lough, 1977). 
Even though not much data are avaible on PA content in various ruminant meat products, it may be 
assumed that both intake of ruminant dairy and meat products, have significant impact on the total PA 
intake of humans. 
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Results and Discussion 
Dairy fat intake and metabolic consequences compared to intake of other fat 
types  
Due to recent indications that dairy fat is more benign in relation to metabolic diseases (German et al., 
2009), than earlier thought, our hypothesis was that one or more of the minor fatty acids found in dairy fat, 
counteract the impairment of metabolic status caused by SFA and tFA, maybe due to synergistic effects. As 
the FA composition in dairy fat is dependent on among others, feeding regime we wanted to compare, 
effects from intake of dairy fat from cattle under different feeding regimes. As we know that the amount of 
green plant material in feed, e.g. grass, is an important factor with regard to the FA composition (Leiber et 
al., 2005), this was one of our focus points. Furthermore it is important to compare intake of dairy fat 
against intake of other major dietary fat types. Therefore we, compared butter intake, in obese mice, with 
intake of oleic acid (MUFA), and linoleic acid (PUFA), as they represent the two major FA types 
recommended to be used as substitutes for SFA in the diet. 
What we saw from the 10 weeks study on fat type in DIO mice, were that oleic acid, compared to butter 
and linoleic acid, had the most detrimental effects on glucose homeostasis and hepatic lipid metabolism. 
We observed increased hepatic ceramide deposition, a tendency to increased hepatic TAG, impaired 
glucose uptake, and up regulation of lipogenic genes, for mice fed a diet with high oleic acid content. Both 
the oleic acid and the linoleic based diets had statistical significant higher hepatic gene expression of FAS, 
than the two butter diets. But, as mentioned it only led to increased hepatic lipid deposition for the oleic 
acid fed group. Butter-based diets had the most detrimental effects on the blood-lipid parameters, 
observed as raised TAG, and total cholesterol, compared to high fat diets based on oleic and linoleic acid, 
and lean reference. 
The results with regard to detrimental effects by intake of oleic acid are controversial, as the general 
assumption is that MUFA is a healthier alternative to SFA-rich products, and the recommendation is to 
replace SFA with MUFA or PUFA. Oleic acid is by far the most abundant MUFA in the human diet. It has 
been proposed that MUFAs protect against metabolic syndrome and CVD, as MUFA should promote 
healthy blood lipid profiles, mediate blood pressure, improve insulin sensitivity and regulate glucose levels 
(Gillingham et al., 2011). This is not equivalent with the results we observed in DIO mice. An expert panel 
has reviewed the literature with regard to prevention of CVD by replacement of SFA with other nutrients. 
They concluded that evidence is strong that risk of coronary heart disease (CHD) is reduced when SFAs are 
replaced with PUFAs. They conclude that replacement of 1 E% SFA from SFA to PUFA, in populations who 
consume a Western diet, lowers LDL cholesterol and is likely to reduce CDH incidence of ≥2-3 %. 
Furthermore, they conclude that there is insufficient evidence to judge whether SFA replacement with 
MUFA, has an effect on CHD risk, and that there are no clear benefit of substituting carbohydrates for SFA. 
They also conclude that no clear association between SFA intake relative to carbohydrates and the risk of 
insulin resistance and diabetes has been shown (Astrup et al., 2011).  
With regard to dairy intake and development of obesity there are generally no indications that these are 
correlated, though factors such as calcium content (Parikh & Yanovski, 2003), and as within the scope of 
current thesis, the content of specific fatty acids such as CLA (Roche et al., 2001), has been proposed to 
have positive effects on the body composition (Ovesen, 2009). 
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Four prospective studies concerning dairy intake and risk of type 2 diabetes has been published. The three 
largest ones (Choi et al., 2005; Liu et al., 2006; van Dam et al., 2006), all distinguish between high and low 
fat dairy intake, and conclude that there is negative correlation between intake of low fat dairy products 
and the risk of type 2 diabetes. The last of the four studies conclude that intake of milk and dairy products 
is associated with a markedly reduced prevalence of MS, but that milk intake showed no significant trend 
with regard to diabetes incident (Elwood et al., 2007). The positive effect on risk of type 2 diabetes, seen 
from low fat dairy product intake in the three studies first mentioned, is not necessarily due to effects from 
dairy fat, but might as well be due to other nutrients in the dairy products. A Swedish study from 2008, has 
shown that increased C15:0 and C17:0 FAs, which is common markers of dairy fat intake, in erythrocyte 
membranes, is accompanied by increased risk of type 2 diabetes (Krachler et al., 2008). Though, our data 
from DIO mice does not indicate that dairy fat is more harmful with regard to glucose homeostasis than 
other fat types. 
From our studies in mice, we do not see clear advantages from intake of the PUFA linoleic acid, on the 
measured parameters, compared to intake of butter. Though, it is very important to remember that there 
are many different PUFAs, and the effects from intake of these might differ a lot, and that other studies has 
shown very clear effects from intake of other PUFAs e.g. fish oils. Important factors are among others n-
3/n-6 distribution, chain lengths, and number of double bonds. Our results that shows raised plasma lipids, 
TAG and total cholesterol for the butter groups compared to the other obese groups, is in line with what 
have been shown in other studies, and has been proposed to be mediated through PGC-β and SREBPs (Lin 
et al., 2005). Another observation from the fat type intervention in DIO mice were substantially higher 
amount of EPA in hepatic phospholipids fraction of the butter groups compared to the other groups. 
Furthermore, the grazing butter group had statistical significant higher amount of EPA than the 
conventional butter group. This is explained by the linoleic acid (LA): α-linolenic acid (ALA) ratio, as seen 
from Figure 6. 
 
 
Figure 6 Hepatic EPA as function depend on LA: ALA ration. EPA content in hepatic posholipids (PL) vs. 
linoleic acid (LA): α-linolenic acid (ALA) ratio in the feed, G: Grazing, C: conventional, the unmarked group is 
lean references. 
35 
 
 
A very important factor to take into account when comparing intake of different fat types, is how it is 
combined with intake of other nutrients, as there might be synergistic effects from intake of different 
macronutrients. It has been shown that sucrose counteracts some of the beneficial effects from fish oil (Ma 
et al., 2011), which indicates that sucrose intake combined with fat intake has aggravating effects no 
matter the type of fat. It is also important not to forget that lack of physical activity and excess energy 
intake in general, is very important factors with regard to development of obesity, and the diseases that 
follow. As, lipids is energy dense compared to other nutritional components, limiting intake of lipids in 
general seems as an apparent way to restrict excess energy intake, hence, it is both lipid quantity and 
quality in the diet that are relevant.  
From our study on T-cell polarization it seems that increased butter intake, has the ability to change the 
expression pattern of IL-4 and IFN-γ, into a higher ratio of IL-4, indicating increased polarization towards 
Th2 as an effect of increased butter intake. It did not seem to be a PA mediated effect as we first 
hypothesized. Hence, we currently do not know the mechanism behind.  
From the combined results, of the butter intervention in mice, and the human interventions, it does not 
seem that the production form or amount of green feed given to cows has clear significant effects on 
metabolic parameters upon intake of dairy fat. Though, we found that plasma insulin and LDL cholesterol 
was raised due to intake of butter from mountain-pasture grazing cattle in the second human intervention, 
which were not the case due to intake of conventional produced butter.  
 
 
Phytanic acid intake and metabolic effects  
From the compiled data on phytanic acid effects, from the studies within this thesis, it does not seem that 
PA deduce the hypothesized effects with regard to metabolic risk factors and T-cell polarization, which 
could have been expected due to its agonist activity towards the nuclear receptors PPARα and RXR. 
Though, we did see effects on glucose homeostasis, as well as interesting effect on hepatic TAG deposition 
due to addition of 0.25% PA to GSO based diet in obese mice, and minor effects on expression of genes 
involved in hepatic lipid metabolism.   
From the study on PA intake in obese mice, the most conspicuous effect was observed in the study with 
addition of 0.25% pa to GSO based high energy diet, as PA addition aggravated the negative effect on 
hepatic TAG deposition from the high fat diet, even though total body and WAT were not affected by 
addition of PA. Both amount of hepatic TAG and total liver mass, were statistical significant higher for the 
group given GSO based diet without PA, compared to lean references, which were not the case when 0.25 
% PA was added. This effect of PA were not observed in the butter based diets, though we do not know if it 
would have been the case, if we had been able to include a butter based diet without any PA.  
So far, we have only gene expression data on hepatic lipid metabolism, from the PA dose response in butter 
based diet. From this we saw statistical significant up regulation of PPARα, and the PPARα dependent 
ACOX1 gene, in the group given 1.0 % PA, compared to the group given 0.2 % PA (P<0.01). This is not 
surprising, due to the agonistic activity of PA towards PPARα, as we also clearly showed that PA is up taken 
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and incorporated into the hepatic PL and TAG fractions. Other PPARα target genes (CD36 and CPT1b) were 
strongly affected by the DIO-diet, but not significantly up regulated by the PA-intake. This shows us that the 
PPARα activation by PA was not as strong as the effects from the high fat diet on these two genes. The 
genes coding for proteins controlling fatty acid synthesis (SREBP1 and FASN) was statistical significant up 
regulated in all the obese groups compared to lean references, without any effect of PA. The transcription 
of the glucose-6-phosphatase (G6Pase) gene was determined as an example of an insulin-regulated gene. 
On average did all three DIO-treatments cause increased expression, although only the increase in the 
group that received 0.6% PA reached statistical significant difference. The relative hepatic gene expression 
of α-methylacyl-CoA racemase (AMCAR) was statistically significant reduced for the 0.2 % and the 0.6 % PA 
groups compared to the lean references (P<0.05 and P<0.01, respectively), while this was not the case for 
the 1.0 % PA group. This indicates that high fat diet might impair the oxidation of PA, but that PA in a 
certain amount can counteract the down regulation of AMCAR gene expression, that seems impaired by 
the high fat diet. Noteworthy, the average expression of the macrophage marker EMR1 (F4/80), was, on 
average, increased in the three DIO-groups, but this did only reach significance in the 1 % PA group. This 
might be interpreted as a tendency to increased hepatic macrophage infiltration due to PA, and thereby a 
negative feature of PA, though it rather seems to be a general effect from high fat diet, that are only 
slightly increased by PA. 
In the first human intervention, dairy fat from two different feeding regimes of cattle from same herd was 
compared upon human intake. The herd was divided into two groups, and fed different amounts of green 
plant material, resulting in among others increased content of PA in dairy fat from cattle given highest 
amount of green plant material. We did not see any effects on markers of the metabolic syndrome, due to 
the intake of cheese and butter from either of the types of dairy fat. Neither, did we see any differences in 
plasma PA concentrations among the two groups. What we did see, and which is important with regard to 
our other studies with PA, was that regardless the feeding regime and the minor differences in PA content, 
there was an increase in plasma PA concentrations after four weeks intervention. This is the main 
contribution from study D, with regard to the understanding of PAs potential as nutritional regulator of 
nuclear receptors.  
An interesting finding from the baseline data for the subjects from the second human intervention, was 
that plasma phytanic acid correlated strongly with both total cholesterol (P<0.0001), and LDL cholesterol 
(P=0.0001). In this intervention, we compared metabolic effects due to intake of butter from grazing cattle 
and conventional fed cattle. The grazing cattle are a low yield production form compared to the 
conventional production. The butter from grazing cattle had among others increased PA content. We 
observed increased insulin levels for the group of subjects given butter from grazing cattle, than for the 
group given conventional butter. This could be interpreted as an indication that PA in physiological 
concentrations might have a negative effect on insulin sensitivity in humans, though it could also be due to 
other factors e.g. other FAs that differ between the two groups. This indication does not seem to be 
confirmed by the results from our mice studies. Though, we found that intake of artificially added high 
amounts in a butter based diet, decreases insulin sensitivity in mice significantly. This might be due to same 
mechanisms, even though we cannot explain how it is conducted. If it is the case that increased intake of 
PA leads to decreased insulin sensitivity in humans, it is of course a negative property, and indicate that 
increased PA concentration is a negative side effects from green feeding of cattle, at least for patients 
suffering from Refsums disease. Though, it is important to remember that the negative effect we observed 
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in obese mice, were with PA concentration almost double than what is observed in dairy fat from grazing 
cattle. However, it does not change the fact, that several studies have shown beneficial correlations of 
dairy fat markers and risk of various metabolic disorders (Gibson et al., 2009; German et al., 2009). Our 
studies does not indicate that PA based nutraceuticals has a bright future as an effective treatment against 
e.g. impaired glucose tolerance, as it has been claimed by patents (Eggersdorfer et al., 2004; Fluehmann et 
al., 2007), though we did see the interesting effects on hepatic TAG deposition from PA addition to PUFA 
high fat GSO diet. 
As no other no other studies has been published, regarding in vivo effects of PA in concentrations similar to 
concentrations found in food products, we cannot compare our findings directly to other studies. Though, 
studies with the PA precursor phytol have been published, however, using phytol concentrations higher 
than what is accessible through food products. In our own lab, addition of 0.2% and 0.5% phytol of total fat 
mass to normal chow diet for four weeks, substantially decreased hepatic TAG in mice (Hellgren, 2010). 
Other groups has shown that addition of 0.5% phytol upregulates gene expression and enzyme activities of 
both peroxisomal and mitochondrial FA oxidation (Gloerich et al., 2005; Hashimoto et al., 2006). A study 
using 0.5 and 1.0% phytol for twelve to eighteen days, showed that phytol induce hepatotoxicity beside 
causing typical PPAR-α mediated effects such as decreased body mass and increased liver mass in mice 
(Mackie et al., 2009). As the amounts of phytol used in these studies is way higher than what is 
physiological possible to get through diet, those results does not seem relevant with regard to a normal 
human diet.  
As mentioned in the discussion of butter effects, we did not see the hypothesized effects on cytokine 
expression in human CD3+ T-cells. Hence, it does not seem that PA has the ability to affect the T-cell 
polarization in direction of Th2, which we hypothesized due to PAs agonist activity towards PPARα and RXR, 
as other ligands of these receptors has such effects(Marx et al., 2002; Lovett-Racke et al., 2004; Du et al., 
2005; Stephensen et al., 2007).  
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Future perspectives 
The results found with regard to intake of high fat oleic acid rich diet, compared to butter end linoleic acid 
based diets, is quite controversial and against the common recommendations. Therefore it seems 
necessary to do further studies in which oleic acid is compared to other fat types, either to confirm or 
decline our findings.  
As we have only compared dairy fat intake towards other fat types in obese mice, we do not know whether 
the effects from dairy fat, oleic acid, and linoleic acid, respectively, compared to each other, would also be 
found in similar human interventions. As we have only compared different types of butter against each 
other, it might be interesting to test whether the differences in between different fat types observed in 
mice, could also be found due to human interventions.  
Due to the effects observed on hepatic TAG deposition and liver weight in the study on PA in GSO based 
diet, it is of course a natural step to measure the gene expression of selected genes from the hepatic lipid 
metabolism. This planned to be done, as we have hepatic tissue stored in appropriate manner. 
Furthermore it would be interesting to test whether the addition of PA to the feed affects the 
thermogenesis, and UCP-1 expression in BAT in vivo, due to the studies by Scluter et al. (Schluter et al., 
2002a; Schluter et al., 2002b).  
With regard to the change we observed in CD3+ T-cell cytokine expression, we observed due to the butter 
intervention, we do at this point not know the mechanisms behind, as PA did not seem to have the 
hypothesized effect compared to palmitic acid. First step could be so check whether the observed changes 
correlates to any other data on the subjects, and depending on these results further steps might be taken 
to find out the mechanism behind. 
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Conclusion 
In the mice feeding study, in which butter intake were compared to diets high in oleic acid and linoleic acid, 
we saw that oleic acid, compared to butter and linoleic acid rich diets, have more detrimental effects with 
regard to glucose homeostasis and hepatic lipid metabolism, as we observed increased hepatic TAG and -
ceramide deposition, impaired glucose uptake and up regulation of lipogenic genes, for the mice fed high 
amounts of oleic acid. Butter-based diets had the most detrimental effects on the blood-lipid parameters, 
observed as raised triacylglycerol (TAG), and total cholesterol (chol). The only significant difference we 
observed between the two butter fed groups, where that, mice given butter from grazing cattle had 
significantly higher hepatic phospholipid EPA levels, than mice given butter from cattle fed lower amounts 
of green plant material. 
 
The PA acid study in mice revealed that PA is incorporated to the hepatic lipid pool. For the phospholipid 
fraction it was in a dose-pendent response, which was not the case with regard to TAG and NEFA. 
Furthermore we saw that animals given grape seed oil based diet, did not have any PA in the hepatic lipid 
fractions.  
 
We observed a change in the polarization of activated human CD3+ T-cells due to 12 weeks intervention 
with intake of 39 g butter/day, measured as raised IL-4: IFN-γ gene expression ratio. No difference in this 
effect was observed between butter form grazing or conventional fed cattle. Neither did we observe any 
effect on expression of fundamental cytokine markers due to phytanic acid incubation.   
From two human dairy fat interventions the most interesting findings were, increased plasma phytanic acid 
concentrations due to four weeks intervention, and tendencies to increased plasma insulin and cholesterol 
in subjects eating butter from grazing cattle for 12 weeks, compared to subjects eating butter from 
conventional fed cattle. Baseline values of plasma phytanic acid correlated strongly to total- and LDL-
cholesterol in the second intervention. 
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Abstract 
Studies have given evidence that intake of saturated fatty acids (SFA) and trans-fatty acids (tFA) 
increase the risk of metabolic disorders. As dairy fat contains considerable amounts of both SFA 
and tFA, intake of dairy has been concerned as unhealthy, though studies now has shown markers 
of dairy fat intake correlates negatively with markers of metabolic disorders. In present study, 
c57bl/6J mice has been fed high fat diets and sucrose in the drinking water, to compare butter diets 
to diets high in either oleic acid or linoleic acid. Furthermore we have compared butter from either 
grazing or conventional fed cattle. This study indicates that intake of dairy fat, with its content of 
SFA and tFA, may not necessarily be detrimental compared to other types of fatty acids such as the 
MUFA oleic acid. We show that oleic acid, compared to butter and linoleic acid rich diets, have 
more detrimental effects with regard to glucose homeostasis and hepatic lipid metabolism, as we 
observed increased hepatic TAG and -ceramide deposition, impaired glucose uptake and up 
regulation of lipogenic genes, for the mice fed high amounts of oleic acid. Butter-based diets had 
the most detrimental effects on the blood-lipid parameters, observed as raised triacylglycerol 
(TAG), and total cholesterol (chol).  
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Introduction 
During the recent decades a still ongoing increase in the incidence of  obesity and metabolic 
diseases,  has been seen throughout the world (Ogden et al., 2006).  Dietary habits are considered to 
be an important factor in modulating the risk of developing these pathologies and dietary fat quality 
has raised particular interest in this context. This is based on the fact that saturated and trans-
unsaturated fatty acids have been shown to reduce, while mono- and polyunsaturated fatty acids of 
the n-6 series improve insulin-sensitivity (Riserus et al., 2009). Due to the considerable amounts of 
saturated (SFA) and trans fatty acids in dairy fat, it has been regarded unfavorable for metabolic 
health and public advice have been to reduce  dairy fat intake (Hu et al., 1999; Hu et al., 2001; 
Riserus et al., 2009). However, a number of studies have now indicated that intake of dairy fat 
might not be as  harmful as earlier thought (Gibson et al., 2009), or even that intake of dairy fat 
might have beneficial impacts in relation to cardiovascular and metabolic disorders (German et al., 
2009). This latter viewpoint is supported by several studies showing a  negative correlations 
between validated biomarkers for milk-fat intake and cardiovascular and metabolic risk markers as 
well as incidence of the first myocardial infarction in case-control studies (Smedman et al., 1999; 
Warensjo et al., 2004; Biong et al., 2006; Hodge et al., 2007; Warensjo et al., 2009; Warensjo et 
al., 2010). Thus, the metabolic effects of dairy fat intake seem to be positively modulated by other 
components than the major saturated fatty acids.   
Although milk-fat is dominated by the saturated FA, it is characterized by a large compositional 
complexity. Thus,  it contain more than 400 different fatty acids, although only 12 different FA 
constitute more than 1% of the total fatty acid mass (Jensen, 2002). Some of these minor fatty acids, 
such as short-chained fatty acids, conjugated linoleic acid (CLA) and phytanic acid, might have 
protective effects that can abolish the negative effects of SFA, either alone or synergistically (Roche 
et al., 2001; Field et al., 2009; Hellgren, 2010; Sleeth et al., 2010). Hence, in the light of the recent 
indications that dairy fat is more benign in relation to metabolic diseases, than earlier thought, it is 
important that the metabolic effects of milk-fat is directly compared with the other major dietary fat 
types, that current public advice recommend milk-fat to be exchanged with, i. e. oleic acid (MUFA) 
and linoleic acid (n-6 PUFA). 
However, the concentrations of several of the potentially bioactive minor fatty acids are highly 
dependent on feeding regimen. Thus, when the cattle are fed green plant material, rather than non-
green feed, such as soy or corn, the concentration of many of the bioactive fatty acids (e. g. CLA, 
phytanic acid, -linolenic acid) are increased. During the last 30-40 year, dairy-cattle farming have 
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gone through a dramatic change, from the use of grass, hay and other feed with origin from green 
plants as the dominating feed-source, to high yield production were corn and soy based feeds 
dominate. Therefore, a significant change in the fatty acid composition of the milk fat has occurred 
in this period, in particular a reduction in the content of potential bioactive fatty acids. Despite that 
this impact on the composition of the dairy fat-fraction is well known, the physiological effects of 
these changes on the consumer, have not been studied thoroughly so far. To clarify these issues, we 
have performed a set of experiments in which the effects on metabolic parameters by intake of 
either butter from high yield conventional production form or butter from low yield grazing cattle 
was compared, as well as we compared the effects of the butter-based diets, with diets were oleic 
acid or linoleic acid was the primary fat source. Our studies revealed that a diet high in oleic acid 
had most detrimental effects on parameters related to glucose homeostasis and hepatic lipid 
metabolism, while the butter based diets had negative effects on blood lipids.  
 
Methods and materials 
Animals care, feed and tissue sampling: Male C57bl/6J mice were purchased from Charles River 
Laboratories International, Inc (Sulzfeld, Germany). They were kept at 21 ⁰C and 50% humidity, 
with a 12-h light cycle (07.00-19.00). The animals were attended daily and weighted weekly. All 
handling and use of animals in this study was approved by The Danish Animal Experiments 
Inspectorate and were carried out according to the guidelines of “The Council of Europe 
Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific 
purposes”. 
From 10 weeks of age, 32 mice were fed an obesity-inducing diet containing 60 E% fat and 15% 
(w/v) sucrose in the drinking-water for 10 weeks, to mimic western cafeteria-type diets high in both 
fat and sucrose. The diets were prepared by adding the experimental fats to “RD12492 px”-powder 
from “Research Diets Inc. (New Brunswick, NJ, USA)”.  Eight mice were used as a lean reference 
group and were given the appropriate control diet recommended by “Research Diets”, diet 
D12450B. The tested fat types was butterfat derived from cows fed under different feeding regimes 
(described below), 75 % grape seed oil: 25 % lard and 75% high oleic sunflower oil : 25% lard  
(High oleic sunflower oil was a generous gift from AAK, Karlshamn, Sweden; lard and grape seed 
oil was from local supermarket). The composition of the diet is given in Table 1, and the FA-
compositions in the different diets can be seen from Table 2. The mice had access to feed and water 
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ad libitum. After 10 weeks on the experimental diets, overnight fasted animals were anaesthetized 
with 0.11 mL pr 25 g animal bodyweight of 44.44 mg/mL ketamin and 2.22 mg/mL 
Narcoxyl(xylazin), before they were sacrificed through cardiac puncture.  Blood was collected in 
heparin-coated tubes and stored on ice, until plasma was isolated. Tissue samples to be used for 
RNA extraction was transferred to RNALater (Applied Biosystems, Carlsbad, California, USA), the 
rest of the tissue was snap-freezed in liquid N2 and stored at -80ºC until it was analyzed. 
 
Table 1 Nutritional composition of diets. Values are given as wt-%. 
Components Lean Butter 
diets 
MUFA 
diet 
PUFA 
diet 
Protein 19,2 23,9 25,7 25,7 
Maltodextrin 10 3,3 14,7 15,8 15,8 
Sucrose 33,2 8,1 8,7 8,7 
Corn startch 29,9 - - - 
Soybean oil 2,4 2,9 3,2 3,2 
Butter
1 
- 37,8 - - 
High oleic acid sunflower oil - - 24,8 - 
Grapeseed oil - - - 24,8 
Lard 1,9 - 8,3 8,3 
Vitamin mix
2 
0,9 1,2 1,3 1,3 
Mineral mix
3 
0,9 1,2 1,3 1,3 
Cellulose, BW200 4,7 5,9 6,3 6,3 
Others
4 
3,5 4,4 4,7 4,4 
1. Amount of butter in diet is adjusted due to watercontent to have the same total fat amount in all high fat diets 
2. Vitamin mix s10026, for further information consult www.researchdiets.com 
3. Mineral mix V10001, for further information consult www.researchdiets.com 
4. Sum of dicalcium phosphate, calcium carbonate, potasium citrate, choline bitartrate, and dye. 
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Table 2 Diet fatty acid compositions. Fatty acid composition in the feed for the four different 
treatments and the lean references, shown as mass% of total fatty acids (nd= non-detectable). 
Fatty acid Lean MUFA PUFA Grazing Conventional 
C4:0 nd nd nd 4,50 4,48 
C6:0 nd nd nd 2,38 2,47 
C8:0 nd nd nd 1,15 1,19 
C10:0 0,08 0,03 0,03 2,01 2,08 
C12:0 0,12 0,04 0,04 2,38 2,35 
C14:0 0,79 0,41 0,41 8,51 8,58 
C14:1 nd nd nd 0,64 0,57 
C15:0 nd 0,03 0,03 0,78 0,76 
C16:0  15,68 9,39 11,78 22,18 20,24 
C16:1 0,85 0,64 0,65 1,00 0,99 
Phytanic acid nd nd nd 0,26 0,18 
C18:0 7,81 5,66 6,39 13,20 13,52 
11tr-Vaccennic acid nd nd nd 2,09 2,46 
C18:1 n-9 cis    28,39 67,42 21,97 23,66 24,15 
C18:2 n-6 cis 36,94 11,58 54,42 5,81 5,89 
C18:3 n-6  0,11 0,26 0,15 0,29 0,35 
C18:3 n-3 4,11 1,01 1,14 1,26 1,11 
9Cis, 11trans-CLA nd 0,04 0,03 0,65 0,66 
Others 5,12 3,49 2,95 7,28 7,95 
ΣSFA 25,1 16,6 19,1 58,0 56,5 
ΣMUFA 31,7 68,7 23,2 28,9 30,7 
ΣPUFA 41,6 13,1 56,0 8,3 8,3 
 
 
Production of test milk/butter 
Milk for the conventional butter was produced by the experimental organic herd at Aarhus 
University by 23 Danish Holstein cows with an average daily milk production of 39 kg with 4.46 % 
fat. The cows were fed a concentrate consisting of 1:1 mixture of oat grain and rapeseed cake with 
11 % fat. This concentrate constituted 40 % of the diet. The remaining 60% of the diet consisted of 
a silage. The silage consisted of a mixture of corn silage, pea-barley whole crop silage with a small 
proportion of white clover grass silage. Feeding of the cows was initiated in November 2008 and 
milk was collected over one week in February. The milk was transported to Thise Dairy (Roslev, 
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Denmark), where it was processed into butter. Total content of green plant material was 19 % of 
total feed. 
Milk for the grazing butter was delivered from cows grazing in Norwegian mountains. Beside the 
grass the cows were given concentrate at the cowshed at night and when milking. While all cattle 
were grazing at daytime, most cows were at fertilized meadows at the farms during night time. 
Cattle were not given hormones, drugs or other that could be perceived as additives in excess of the 
normal or natural. The milk was transported to Tine Dairies (Oslo, Norway), where it was processed 
into butter.  
 
Lipid analysis: Lipids were extracted using the Folch method (Folch et al., 1957), with internal 
standards added, C19:0 NEFA, TAG, PL, long-chain base C17:0 ceramide, for the tissue samples. 
Fat content in feed was analyzed gravimetric. Fatty acids were analyzed as fatty acid methyls esters 
(FAME), preparation of FAME was performed by a method based on the method of  Hamilton & 
Hamilton (Hamilton & Hamilton, 1992), by adding 1.0 mL 0.5 M NaOH in MeOH to the extracted 
lipids, and refluxed for 5 minutes at 80 ⁰C. Mixture was cooled to room temperature, 1 mL 20% 
BF3 in MeOH and 0.5 mL 0.1% hydroquinone i MeOH added, and refluxed for 2 minutes. When 
room temperature was achieved 2mL 0.73 % NaCL (aq) was added. After whirling of mixture 0.5 
mL heptan was added, and the upper phase was transferred to another tube. Heptan extraction was 
repeated on the lower phase, and the new upper phase transferred to the first upper phase. FAMEs 
dissolved in heptan were washed with 1.0 mL of satiated alkaline NaCL (~40 g NaCL and 150 mg 
K2CO3 pr. 100 mL water). For quantification of phytanic acid, C4:0, C6:0 and C8:0, response-
factors were calculated for their methyl-esteres based on the response of palmitic acid methyl ester 
(16:0). The FAME were separated on a 60-m Supelco SP2380 column (Sigma-Aldrich AS, 
Brøndby, Denmark) in a HP 6890 gas chromatograph (GC), in split mode using He as carrier gas. 
Settings for the GC-program were:  Injector temperature 260 ⁰C, split ratio 20 : 1, carrier flow 1.2 
mL/min, detector temperature 300 ⁰C, air flow in detector 300,0  mL/min, hydrogen flow 35 
mL/min. FAME were separated using a temperature program starting at 50 ⁰C and rising to 160 ⁰C 
at 15 ⁰C /min; this temperature was kept for 0 min, hereafter the temperature was raised to 182 ⁰C 
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at 1 ⁰C /min, and directly the temperature was raised to 200 ⁰C at 10 ⁰C /min, and the oven was kept 
at 200 ⁰C for 15 min before the temperature was raised to 225 ⁰C. The final temperature was kept 
for 12 min (total runtime 61.97 min). 
Ceramide was isolated from total lipid extract and quantified as earlier described in (Drachmann et 
al., 2007), with the exception that ceramide with C17 long-chained base was used as internal 
standard.  
 
Analysis of plasma TAG, NEFA, Cholesterol and glucose: Plasma levels of triacylglycerol 
(TAG), non-esterified fatty acids (NEFA), total cholesterol, and glucose, were measured using 
analytical  kits from HORIBA abx; (Montpellier, France) (TAG, glucose, cholesterol),  NEFA was 
analyzed using the appropriate kit from Wako Chemicals Gmbh (Neuss, Germany), on a “Cobas 
Mira Plus” (Roche Diagnostics Systems, Basel, Switzerland). 
Oral Glucose Tolerance Test (OGTT): OGTT was performed after ten weeks on the given diets. 
The animals were fasted for 3 hours prior to gavage feeding the mice with a glucose-solution (1.5 g 
glucose per kg bodyweight). Blood-glucose levels were measured at the time points zero, one, and 
two hours after the glucose load and at the time points zero and two hours after infusion eye-blood 
was taken with 50 µL EDTA-coated capillary tubes to produce plasma for insulin measurements. 
Blood glucose measurements was performed with “On call® Plus Blood Glucose Meter”, by adding 
one drop of eye-blood to the chip.  
Insulin: Plasma insulin was analyzed using “Ultra sensitive mouse insulin ELISA” (Mercodia AB, 
Uppsala, Sweden), following the manufactures guidelines.  
 
Leptin & TNF-α: Plasma levels of leptin and TNF-α was analyzed using the appropriate kits from 
Meso Scale Diagnostics (Gaithersburg, USA) on a Meso Scale Sector Imager 6000 (leptin) and a 
Meso Scale Sector Imager 2400 (TNF-α) following the protocol from the manufacturer, except that 
plates for TNF-α analyses was incubated over night with detection buffer, to increase sensitivity. 
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Gene expression analysis/qRT-PCR: RNA from liver-tissue was extracted on Abi Prism 6100 
Nucleic acid Prepstation from Applied Biosystems (Carlsbad, California, USA), according to the 
manufacturer’s instruction. 
cDNA-synthesis was performed on Unocycler (VWR (Leuven, Belgium), using “High capacity 
cDNA transcription kit” from Applied Biosystems. The quantification was performed on a 7900HT 
Fast Real Time PCRsystem, equipped with 96 wells Fast block, using “Taqman® Environmental 
master mix 2.0” (Applied Biosystems), and with primers and TaqMan-probes were selected from 
Applied Biosystems and Integrated DNA Technologies (Coralville, IA, USA) online catalogue. 
SDS 2.3 and RQ-manager 1.2 software was used for data analyses.   
 
Statistical analysis: Statistical analysis was performed using the software package GraphPad Prism 
(v.5.00). One way ANOVA with “Turkey” post test performed when nothing else noted. In cases of 
inhomogeneous variances between groups in datasets (tested by “Bartlett´s test”) statistical analysis 
is performed on LogY transformed data. In cases where transformation of data did not homogenize 
the variance, data was analyzed using Welch corrected ANOVA using the  R – software package 
(www.r-project.org). Results are given as average ± Standard deviation (SD), (n=8 for all groups, 
except MUFA-control, n=6, and grazing-butter group, n=5, due to loss of animals during the 
feeding period). Statistical outliers were detected using Grubbs test (www.graphpad.com).  
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Results  
Body and organ masses 
All groups given hypercaloric diets were found to have statistically significant higher bodyweight and WAT 
mass, than the lean references (P<0.001). Furthermore, WAT mass of the PUFA group was statistically 
significant higher than for the MUFA group (P<0.05), see  
Table 3. The MUFA and the conventional butter group had statistical significant higher hepatic tissue mass, 
than lean references (P<0.01 for both), see  
Table 3; otherwise was there no other differences in tissue weights between the groups. 
 
Table 3 Body mass, tissue masses, and plasma lipid concentrations. Given as mean±s.d. 
Different letters illustrates statistical significant differences between groups. Statistical analysis 
performed for all parameters are one way ANOVA with Turkey post test. 
  Lean MUFA PUFA Grazing Conventional 
Bodyweight (g) 
27.25±1.28
a
 42.67±2.58
b
 44.75±3,19
b
 43.40±2.61
b
 44.00±2.98
b
 
Hepatic tissue weight 
(g) 
1.05±0.11
a
 1.97±0.56
b
 1.58±0.22
a,b
 1.73±0.43
a,b
 1.91±.76
b
 
WAT (g)
1 
0.40±0.20
a
 5.27±0.48
b
 6.30±0.80
c
 5.64±0.31
b,c
 5.69±0.39
b,c
 
Plasma TAG (mM) 0.64±0.14
a,b
 0.65±0.15
a,b
 0,62±0.11
b
 0.88±0.21
a,c
 0.98±0.14
c
 
Plasma NEFA (mM) 0.85±0.11
a
 0.96±0.14
a
 0.98±0.13
a
 0.94±0.26
a
 1.05±0.18
a
 
Plasma Chol (mM) 2.41± 0.24
a
 3.58±0.50
b
 3.90±0.28
b,c
 4.02±0.55
b,c
 4,60±0.84
c
 
1. WAT is the sum of epididymal-, kidney-, and visceral-white adipose tissue  
 
Glucose homeostasis  
Glucose tolerance was measured by an oral glucose tolerance test (OGTT).  The rate of glucose 
clearance was measured as the difference in blood glucose values between zero to two hours after 
glucose dosage. This, was found to be significantly higher for both the MUFA and the PUFA 
groups compared to the lean references (P<0.01)(Figure 1A), while this was not the case for the two 
butter groups. Furthermore, the MUFA group had significantly slower rate of glucose clearance, 
than the conventional butter group (P<0.05).  
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When Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was calculated from the 
fasting glucose and insulin levels, all obese groups had significantly  higher values than the lean 
references (P<0.001), see Figure 1B.  
Semi-fasting insulin and glucose levels can be seen from Figure 2B&C. Fasting insulin of all obese 
groups, was higher than for the lean reference group (P<0.001). Fasting glucose of the MUFA, 
PUFA and grazing butter group was significantly higher than for the lean references (P<0.05, 
P<0.001, and P<0.01, respectively), and also statistically significant higher for PUFA than for 
MUFA (P<0.01). 
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Figure 1 Glucose homeostasis. A: Delta blood glucose from zero to two hours from oral dosage 
with glucose-solution. B: Homeostatic Model Assessment Insulin Resistance (HOMA-IR) for the 
five different feeding groups given as mean±SD. * vs lean, and ¤ vs. MUFA group. 
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Plasma lipids 
The butter-based diets did generally increase plasma triacylglycerol (TAG) concentration while all 
high-caloric diets caused increases in plasma cholesterol, compared to the lean reference group. 
However, only for the conventional butter group did the level of  plasma TAG reach statistical 
significance to all non-butter fed groups, while the effect of the grazing-butter was slightly less 
pronounced, and did only reach statistically significant against the PUFA-fed and lean reference 
animals (P<0.05 against both).  
We found that plasma cholesterol was significant higher for all treated groups compared to lean 
references (P<0.001for all except against MUFA group: P <0.01), and animals fed the conventional 
butter had on average the highest total cholesterol levels, and it reached statistically significance 
compared to the  MUFA group (P<0.01).  
No statistical significant differences on fasting plasma non-esterified fatty acids (NEFA) were 
observed between any groups, although the animals fed the conventional butter also had highest 
average NEFA-levels.  
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Figure 2 Fasting levels of plasma markers. A: Leptin, B: Glucose, and C: Insulin, given as 
mean±SD. * indicates statistical significant difference vs. lean, and ¤ vs. MUFA group. 
 
A16 
 
Adipokines 
Plasma leptin was statistically significant higher for all obese groups compared to the lean 
references (P<0.001 for all), see Figure 2A, but the different fat sources did not cause any 
differences in leptin level. The inflammatory marker TNF-α, was on the contrary substantially 
affected by the dietary fat source. Thus, in only one out of eighth animals in the PUFA- and 
conventional butter-fed groups did the TNF-α levels reach the detection limits, while it did so in all 
animals in the MUFA-group and 50-60% of the animals in the grazing-based butter and the lean 
reference-group  (Figure 3).  
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Figure 3 Fasting TNFα concentrations. Values below the limit of the standard curve set to zero, and the 
detection limit is marked by a horizontal line. 
 
Hepatic lipid profile 
 As seen in Figure 4A, TAG pr liver mass was shown to be statistically significant for all test 
groups compared to lean reference group (P<0.001). Furthermore there is a tendency that TAG pr. 
liver mass is higher for the MUFA group than other groups given high fat diet (P=0.054 against 
PUFA, P=0.076 against grazing butter, and P=0.18 against conventional butter). Furthermore, the 
MUFA based diet  caused significant increase in the hepatic ceramide levels, compared to the lean 
reference, as well as compared to the other obese groups (P<0.01 against lean references and 
PUFA-group, and P<0.001 against the two butter-groups, Figure 4B). Thus, in the liver from the 
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MUFA fed animals, there were 70% more ceramide, than in the butter-fed groups.  There were no 
significant differences in the concentration of hepatic free fatty acid between the groups. 
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Figure 4 Hepatic lipid deposition A: TAG content showed in mg TAG pr. g hepatic tissue, B: 
Hepatic ceramide content given as as pmol pr.  mg liver tissue, C: Hepatic phospholipid content 
given as mg pr. g tissue. All values given as mean+SD.  * indicate statistical significant difference 
against lean reference and ¤ against MUFA-group. 
 
When we compared the effect of the diets on the phospholipid fatty acid composition in the liver, 
the most pronounced effects was the higher level of the n-3 PUFA´s EPA and DPA in the butter fed 
groups compared to all other groups (P<0.001), and that butter from the grazing cows caused 
significant higher incorporation of eicosapentaenoic acid (EPA, compared to the conventional butter 
group (Figure 5)).  EPA constituted 1.06±0.29 mass% of the total FAs in grazing butter group and 
0.61±0.16 mass% in the conventional butter group (P<0.01), as well as significant higher for 
MUFA and lean than PUFA (P<0.001). DPA were statistically significant higher for the lean 
references compared to MUFA and PUFA-group (P<0.001). As expected, the high linoleic acid 
intake in the PUFA group, reduced the DHA level significantly in this group (P<0.01 against 
MUFA and grazing butter; P<0.001 against conventional butter) and raised the concentration of 
arachidonic acid, compared to the other groups.  DHA was also found to be significant higher in the 
conventional butter group than for lean references (P<0.01). 
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Figure 5 Hepatic phospholipid content of the three long chain poly unsaturated fatty acids; 
eicosapentanoic acid (EPA), docosapentanoic acid (DPA), and docosahexanoic acid (DHA), in the 
five groups given as mean+SD.  
 
Hepatic gene expression 
Since the main effect on hepatic lipids was seen in the MUFA group, we analyzed hepatic gene 
expression of genes related to fatty acid metabolism in this group compared to the two-butter 
groups using the lean-group as reference (Figure 6). All three high caloric diets had statistically 
significant higher expression of Fasn than the lean references (P<0.001 for all three) but it is 
noteworthy, that the MUFA-group has statistical significant higher expression of Fasn in the liver 
than the butter groups (P<0.05). No differences were observed between the four groups with regard 
to Acox1. Cpt1a was statistically significant down regulated in all the obese groups compared to the 
lean references (P<0.001). The relative expression of FA transporter CD36 was highly up regulated 
in all three obese groups compared to lean references (P<0.05 against MUFA, P<0.01 against 
Grazing butter, and P<0.001 against conventional butter).  
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Figure 6 Gene expression of hepatic fatty acid metabolism. A: Sterol regulatory binding protein 
(SREBP1c), B: Fatty acid synthase (FASN), C: CD36, D: Fatty acid transport protein 5 
(slc27a5/FATP5), E: Carnitine acyltransferase 1a (Cpt1a), F: AcylCoenzyme A oxidase1 (Acox1), 
G: Serine palmitoyltransferase, long chain subunit 1 (Sptlc), H: Peroxisome proliferator associated 
receptor-α (PPARα), given as mean+SD. * indicates statistical significant difference against lean 
reference, and ¤ against MUFA-group.  
 
Discussion 
Despite the fact that the only difference between the animals in body-composition was a 
significantly higher WAT mass in the PUFA group compared to the MUFA-group, the compiled 
results of this study point in the direction that the detrimental metabolic effects of high fat diets, is 
higher for diets high in the MUFA oleic acid, compared to  butter and linoleic acid rich diets, in 
regard to systemic parameters describing glucose homeostasis and hepatic lipid metabolism, while 
butter-based diets had most detrimental effects on the analyzed blood-lipid parameters.  Thus, the 
results from the OGTT show that the rate of glucose-clearance (measured as the difference between 
blood glucose levels two hours after oral glucose dosage to the semi-fasted level just before the 
dosage) is substantially aggravated in both the MUFA and n-6 PUFA based diet, compared to the 
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butter-based diets.   Although the glucose clearing abilities of the PUFA group is as reduced as for 
the MUFA group, the PUFA-fed animals did not show the significant increase in HOMA-IR as seen 
in the MUFA group. This is due to the fact that the fasting insulin values of the PUFA group are 
substantially lower. Thus, while both linoleic and oleic acid based diets cause more detrimental 
effects on the animal’s ability to clear glucose in the fed-state, compared with a butter-based diet, 
oleic acid based diets caused most severe disturbances of the glucose homeostasi in the fasted state. 
This could indicate that the MUFA – diet had more detrimental effects on the insulin-based 
regulation of gluconeogenesis than the other two types of fat. However, when we analyzed the 
expression of the insulin-regulated gene for glucose-6-posphatase, there was no difference between 
the groups (data not shown), suggesting that this was not the case. In this context, it is also worth 
noticing that the MUFA-fed group had highest level of systemic sub-clinical inflammation, 
measured as plasma TNF-α level.  
The higher WAT mass of PUFA group compared to MUFA group are worth noticing. This is in 
accordance with previous findings that n-6 PUFA intake increases WAT, in particular when given 
in combination with high-sucrose diets (Ailhaud et al., 2006; Madsen et al., 2008a). The important 
finding in present study is however, that this increase in WAT-mass did not lead to more 
detrimental metabolic effect than what is seen in the leaner MUFA-fed group, neither in regard to 
hepatic lipid accumulation or glucose-tolerance. 
The results for hepatic gene expression, points in the direction that the observed tendency to 
increase in hepatic TAG deposition for the high oleic acid group, is due to increased synthesis, and 
not due to increased uptake or decreased oxidation, as both the fatty acid transporters CD36 and 
FATP5 are up regulated in all obese groups, and ACOX expression seems unchanged. The observed 
expression pattern indicates that lipogenesis might play a role in the increased hepatic lipid 
deposition of the oleic acid group, as SREBP-1c has been coupled to de novo lipogenesis through 
ER stress (Ferre & Foufelle, 2010). The finding that a hyper-caloric diet with a high intake of oleic 
acid, causes a substantial increase in hepatic ceramide content , compared to both LA – and butter 
based diets, is an important finding. Ceramide attenuates signaling from the insulin receptor 
(Chavez et al., 2003),  are involved in the activation of the Nlrp3 inflammasome during  induced 
inflammatory development and have been implicated to play a role in the development of non-
alcoholic hepatic steatosis (Vandanmagsar et al., 2011; Promrat et al., 2011).  Therefore, 
accumulation of excess tissue-ceramide is considered to be major factor, driving the development of 
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metabolic diseases (Lipina & Hundal, 2011). Thus, the reduced glucose tolerance in the MUFA-fed 
animals might be explained by the increased ceramide levels in these animals. Although there was a 
tendency towards higher hepatic TAG levels in the MUFA-group (P=0.054 against PUFA), the 
increased ceramide cannot solely be explained by a general increased fatty acid load in these 
animals, since the relative difference in TAG deposition was substantially smaller than the effect on 
ceramide concentration.  However, in the MUFA group the gene for fatty acid synthase (FAS) was 
significantly upregulated, compared to the other obese groups, and there was a tendency toward 
increased expression of the rate-limiting enzyme in the ceramide synthesis pathway, serine-
palmitoyl transferase (SPT) (Figure 6).  The product of the FASN enzyme, palmitoyl-CoA, is one 
of the substrates for SPT, and the flux through this pathway is partly determined by the enzyme´s 
access to palmitoyl-CoA (Merrill et al., 1988). Thus, enhanced de novo synthesis of ceramide, due 
to an increased de novo synthesis of palmitoyl-CoA can, at least partly, explain the observed 
increased in ceramide levels.  However, the increased concentration of ceramide may also originate 
from hydrolysis of sphingomyelin by the neutral sphingomyelinase (N-SMase), since it recently 
was shown that high fat diets cause increased activity of the N-SMase but not acid 
sphingomyelinase in rat liver (Chocian et al., 2010).      
The up regulation of the gene for the key lipogenic enzyme fatty acid synthase (FASN) in MUFA 
group compared to the other DIO groups, are noteworthy. It has earlier been shown that the 
combination of high sucrose and high fat, cause activation of the FASN-gene (Madsen et al., 
2008b), but that excessive intake of oleic acid further enhance this activation, compared to other 
fatty acids, have not earlier been showed. Since it is generally considered that intake of oleic acid is 
nutritionally advantageous, compared to the saturated fatty acids found in butter (Riserus et al., 
2009), the mechanism behind this effect warrant further studies.  For all the obese groups, we see a 
combined effect of the high fat and high sucrose intake which might be due to activation of 
ChREBP (no data) combined with insulin induced activation of  sterol regulatory element-binding 
protein-1c (SREBP1c) partly via LXR activation. LXR is repressed by PUFA and EPA in particular 
(Yoshikawa et al., 2002), thus the AA – level in the PUFA-group and the high EPA-level in the 
butter group, might repress this effect. Neither of these two factors is present in the MUFA group, 
why the glucose and insulin driven activation of SREBP-1c is unrepressed. 
 The proportion of linoleic acid (LA ) to (ALA) α-linolenic acid in the diet seems to be decisive for 
the EPA content in the hepatic lipid stores, due to desaturation and elongation competition, and 
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recent data indicate that the FA-composition in dairy fat promote the biotransformation of ALA to 
EPA and DPA (Legrand et al., 2010).   
Butter had the most detrimental effects on plasma lipids. TAG and cholesterol tended to be higher 
for the butter groups, most pronounced with regard to TAG, and must be regarded as parameters 
supporting the view that butter-intake increase risk of CVD. It is however noteworthy, that, on 
average, the conventional butter increased all blood lipid parameters more than the butter produced 
from the grazing cows. Although the difference between the butter types did not reach statistical 
significance, this could indicate advantageous effects of the feeding regime based on green-plants. 
It has been suggested that intake of SFAs and trans-FAs raise circulating TAG and cholesterol 
through induction PGC-β and thereby SREBP (Lin et al., 2005), which correlates with what we 
observed for the butter fed animals, but as discussed the raise in plasma lipid levels did not lead to 
raise in hepatic lipid deposition. 
 
Conclusion 
Obese mice fed either one of the butters did not have statistically significantly decreased glucose-
clearance rate, compared to lean, while PUFA and MUFA-fed did have. MUFA fed obese mice had 
significantly higher ceramide concentration in the liver and a tendency to more TAG. The increased 
hepatic ceramide and trend towards higher TAG could be partly explained by a higher expression of 
FASN, and the increased ceramide deposition might be the explanation for the impaired glucose 
homeostasis observed for the group fed high amount of oleic acid. The two butters gave 
substantially higher EPA levels in the liver than the MUFA-diet, despite similar ALA-levels in the 
feed; this is explained by the low LA: ALA ratio. Intake of butter from the grazing cows gave 
significantly higher hepatic EPA levels, than butter from cows fed low levels of green plants.  From 
the compiled results of this study, it seems that the detrimental metabolic effects of high fat diets, is 
higher for diets high in the MUFA oleic acid, compared to  butter and linoleic acid rich diets, in 
regard to systemic parameters describing glucose homeostasis and hepatic lipid metabolism, while 
butter-based diets had most detrimental effects on the analyzed blood-lipid parameters. We 
observed increased hepatic TAG and -ceramide deposition, as well as impaired glucose uptake and 
up regulation of lipogenic genes, for the mice fed high amounts of oleic acid, compared for the mice 
fed either high butter or high linoleic acid diet. From this study it seems, that the content of SFA 
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and tFA in butter not necessarily makes butter fat more detrimental to metabolic health than other 
types of fat, although it has disadvantageous effects on blood lipids.   
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Abstract 
Phytanic acid (PA) and its primary metabolite, pristanic acid have been identified as potent PPAR- 
agonists, as well as being agonists for retinoid-X-receptor (RXR) in vitro. Based on these activities, PA and its 
metabolites are suggested to have preventive effects on metabolic dysfunctions, and several patents claim 
that PA-based nutraceuticals can be applied to improve metabolic health. As there have not so far been 
published studies in which these hypothesized effects of PA has been tested in vivo, we have tested effects 
on metabolic parameters, due to addition of PA in realistic amounts in both butter and grapeseed oil (GSO) 
given to obese mice. We did not find dramatic effects due to PA intake, though addition of 0.25% PA to high 
fat GSO diet attenuated increased hepatic TAG deposition completely, and 1.0% PA in high fat butter diet 
aggravated glucose homeostasis. 
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Introduction 
Considering the global raise in prevalence of obesity and obesity-associated metabolic diseases, identifying 
dietary components that have specific positive effects on metabolic control is highly prioritized in the 
development of health-promoting foodstuff.  One mechanism, through which food components directly 
can affect the metabolic state of the organism, is through agonist activity toward the nuclear receptors in 
the PPAR -family. It is well established that many food products contains molecules, e. g.  fatty acids and 
certain terpenoids,  that have PPAR- and PPAR-agonist activity in vitro (Goto et al., 2010; Varga et al., 
2011), much less is known on whether dietary compounds that in vitro have been  identified as  PPAR-  
agonists, actually are able to modulate lipid and glucose metabolism in vivo, when eaten as parts of a 
normal diet. The branched chain fatty acid,  phytanic acid (PA) (3, 7, 11, 15-tetramethyl hexadecanoic acid) 
and its primary metabolite, pristanic acid have been identified as potent PPAR- agonists (Zomer et al., 
2000; Gloerich et al., 2005; Gloerich et al., 2007), as well as being agonists for retinoid-X-receptor (RXR) in 
vitro (Lemotte et al., 1996). Phytanic acid has also been found to induce uncoupler protein 1 (UCP1) 
expression (Schluter et al., 2002), and thus suggested to induce differentiation of brown adipocytes.  Based 
on these activities, PA and its metabolites are suggested to have preventive effects on metabolic 
dysfunctions (Lemotte et al., 1996; McCarty, 2001; Schluter et al., 2002), and several patents claim that PA-
based nutraceuticals can be applied to improve metabolic health (Eggersdorfer et al., 2004; Fluehmann et 
al., 2007).   
 
 
Figure 1 Structure of Chlorophyll (A), Phytol (B), and Phytanic acid (C).  
 
Phytanic acid is a branched-chain C20 fatty acid, consisting of a C16-long chain with four methyl branches, 
see Figure 1.  The human intake of PA primarily originate from the fat fractions of ruminant products 
(Hansen, 1966; Gloerich et al., 2007). Phytanic acid is derived from phytol (3, 7, 11, 15-tetramethylhexadec-
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2-en-1-ol), an aliphatic alcohol that are part of the chlorophyll molecule, also shown in Figure 1. The phytol 
moiety cannot be released from the chlorophyll-molecule in the human gastro-intestinal (GI) tract, while 
this occurs in the rumen of ruminant animals. In the animals the released phytol is oxidized to phytanic acid 
and incorporated in the ruminant meat and milk-fat  (Hansen, 1966; Gloerich et al., 2007).  Since the 
precursor for its formation is chlorophyll, the concentration found in dairy products is mainly dependent on 
the amount of chlorophyll-containing plant material in the feed of the cattle. The concentration found in 
dairy products varies between 0.15 to around 0.50 percent of the fat fraction, depending on the feeding 
regime of the cows (Leiber et al., 2005; Vetter & Schroeder, 2010).  
Despite the indications from in vitro studies, that PA intake can improve metabolic function, through its 
PPAR- and RXR agonist activity, this have not been tested in vivo, when PA is consumed in concentrations 
similar to the concentrations found in foodstuff.  We have recently shown, that the concentrations of 
circulating PA in humans, are directly modulated by intake of dairy fat (Werner et al., 2011), but to what 
extent dietary PA – consumption also affects fatty acid and glucose homeostasis, is not known. Until now, 
effects of PA in vivo, has been interpolated from studies using phytol in substantially higher dosages than 
what is found in human diets. Even though phytol is processed into PA in the metabolism, the effects of 
phytol-intake might differ from PA, since it has been reported that phytol also function as PPAR- agonist 
(Goto et al., 2005). Furthermore, to evaluate the nutritional/physiological relevance of dietary PPAR-
agonists, it is essential that this is tested using concentration of the active molecule similar to what is found 
in foodstuffs. Therefore,  we have determined the effect of PA intake on glucose-homeostasis, lipid 
accumulation and gene expression of genes related to glucose and lipid metabolism in the liver of diet-
induced obese mice, using concentrations of PA that are similar to the concentrations in dairy fat.  In one 
experiment, butter have been used as background diet for studying the dose-response to increased 
concentrations of PA, in another experiment, we also determined the effect of PA on glucose homeostasis 
and liver lipid levels,  when a  linoleic acid rich grapeseed oil (GSO) was used as background fat.   
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Methods and materials 
Animal care, feed and tissue sampling: Male C57bl/6J mice were purchased from Charles River 
Laboratories International, Inc (Sulzfeld, Germany) and kept at 21 ⁰C and 50% humidity, with a 12-
h light cycle (07.00-19.00). The animals were attended daily and weighted weekly. All handling and 
use of animals in this study was approved by The Danish Animal Experiments Inspectorate and 
were carried out according to the guidelines of “The Council of Europe Convention for the 
Protection of Vertebrate Animals used for Experimental and other Scientific purposes”.  
 
Table 1 Composition of the diets. Values are given as wt-%.  
Components Lean Butter 
diets 
PUFA 
diets 
Protein 19,2 23,9 25,7 
Maltodextrin 10 3,3 14,7 15,8 
Sucrose 33,2 8,1 8,7 
Corn starch 29,9 - - 
Soybean oil 2,4 2,9 3,2 
Butter
1 
- 37,8 - 
High oleic acid sunflower oil - - - 
Grapeseed oil - - 24,8 
Lard 1,9 - 8,3 
Vitamin mix
2 
0,9 1,2 1,3 
Mineral mix
3 
0,9 1,2 1,3 
Cellulose, BW200 4,7 5,9 6,3 
Others
4 
3,5 4,4 4,4 
1. Amount of butter inclusive water content 
2. Vitamin mix s10026, for further information consult www.researchdiets.com 
3. Mineral mix V10001, for further information consult www.researchdiets.com 
4. Sum of dicalcium phosphate, calcium carbonate, potasium citrate, choline bitartrate, and dye. 
 
From 10 weeks of age, the animals in cages randomized to DIO-diets, was given an obesity-
inducing diet containing 60 E% fat in the feed and 15% (w/v) sucrose in the drinking-water for 10 
weeks. The composition was chosen to mimic western cafeteria-type diets, high in both fat and 
sucrose. The diets were prepared by adding the experimental fats to “RD12492 px”-powder from 
“Research Diets Inc. (New Brunswick, NJ, USA)”.  Eight mice, were used as a lean reference group 
for each of the two experiments, and were given the appropriate control diets, as recommended by 
“Research Diets”; diet D12450B (Research Diets, New Brunswick, NJ, USA).  In one experiment, 
animals were given increasing concentrations of PA, on a butter background. Thus, eight animals 
were given butter without added PA ethyl-ester (PA concentration = 0.20% (w/w fat)), eight 
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animals given the same butter, but with the addition of PA-ethyl esters to a final concentration of 
0.6 % PA and finally was eight animals given the same butter with PA ethyl-esters added to a final 
concentration of 1.0 % PA. Production of the test butter (low PA-butter) have been described 
elsewhere (Werner et al., 2011). For the setup with PA in a diet with high amount of linoleic acid, 
we used 75 % grape seed oil: 25 % lard mix (lard and grape-seed oil both from local supermarket) 
(GSO-diet). PA-ethyl ester was added to the concentration of 0.25 % of the fat mass to the feed for 
one group and another group was given identical feed without PA addition.  The composition of the 
diets is given in Table 1, and the FA-compositions in the different diets can be seen from Table 2. 
 
Table 2 Fatty acid composition of the feeds for the two experiments. Shown as mass% of total fatty acids. 
Nd= non-detectable, ta= trace amounts. 
 
Phytanic acid in butter Phytanic acid in PUFA 
Fatty acid 
 
Lean 
0.2 % 
PA 
Butter 
0.6 % 
PA 
Butter 
1.0 % 
PA 
Butter 
 
Lean 
0.25 % 
PA 
PUFA 
0 % 
PA 
PUFA 
C4:0 nd 4.5 4.4 4.6 nd nd nd 
C6:0 nd 2.5 2.4 2.5 nd nd nd 
C8:0 nd 1.2 1.2 1.2 nd nd nd 
C10:0 0.1 2.1 2.1 2.1 0.1 ta ta 
C12:0 0.1 2.4 2.3 2.3 0.1 ta ta 
C14:0 0.8 8.6 8.5 8.5 0.8 ta ta 
C14:1 nd 0.6 0.6 0.6 nd nd nd 
C15:0 nd 0.8 0.8 0.8 nd ta ta 
C16:0  15.7 20.2 20.3 20.2 15.7 12.3 12.2 
C16:1 0.9 1.0 1.0 1.0 0.9 0.6 0.6 
Phytanic acid nd 0.2 0.6 1.0 nd 0.25 nd 
C18:0 7.8 13.5 13.5 13.4 7.8 7.0 7.0 
11tr-Vaccennic acid nd 2.5 2.4 2.4 nd nd Nd 
C18:1 n-9 cis    28.4 24.2 24.0 23.9 28.4 22.6 22.8 
C18:2 n-6 cis 36.9 5.9 6.0 5.8 36.9 52.6 52.8 
C18:3 n-6  0.1 0.4 0.3 0.3 0.1 0.2 0.2 
C18:3 n-3 4.1 1.1 1.1 1.1 4.1 1.0 1.1 
9Cis. 11trans-CLA nd 0.7 0.7 0.7 nd ta ta 
Others 5.1 8.0 7.9 7.8 5.1 2.9 2.9 
ΣSFA 25.1 56.5 56.2 56.3 25.1 20.3 20.1 
ΣMUFA 31.7 30.7 30.5 30.3 31.7 24.9 25.0 
ΣPUFA 41.6 8.3 8.4 8.2 41.6 54.1 54.2 
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The mice had access to feed and water ad libitum. After 10 weeks on the experimental diets, 
overnight fasted animals were anaesthetized with 0.11 mL pr 25 g animal bodyweight of 44.44 
mg/mL ketamin and 2.22 mg/mL Narcoxyl(xylazin), before they were sacrificed through cardiac 
puncture.  Blood was collected in heparin-coated tubes and stored on ice, until plasma was isolated. 
Tissue samples to be used for RNA extraction was transferred to RNALater (Applied Biosystems, 
Carlsbad, California, USA), the rest of the tissue was snap-freezed in liquid N2 and stored at -80ºC 
until it was analyzed. 
 
Synthesis of phytanic acid ethyl esters 
 
Figure 2 Organic synthesis of phytanic acid from phytol. 
 
Phytanic acid (target molecule 4 in Figure 2) was easily prepared on large scale from commercially 
available phytol. The preliminary strategy was based on reduction of the double bond of phytol 
followed by oxidation and esterification. However, hydrogenation over Pd/C resulted in extensive 
deoxygenation of the β-hydroxy group. Instead phytol was first oxidized to the aldehyde via a 
Swern oxidation followed by a Pinnick oxidation to give the carboxylic acid 2 in excellent yield. 
Compound 2 was then converted into the ethyl ester 3 and finally hydrogenated to give the target 
molecule 4 in 81% overall yield. This strategy is advantageous compared to the former syntheses of 
phytanic acid due to their use of expensive reagents for either hydrogenation or oxidation. Detailed 
description of synthesis and purification is given in Supplemental Materials.  
 
Lipid analysis: Lipids were extracted from tissue samples and feed using the Folch method (Folch 
et al., 1957), with internal standards (nonadecanoic acid, C19:0 triacylglyceride (TAG), C19:0 
phosphatidylcholine and ceramide with C17:1 long-chained base) added.  Liver fat content and fatty 
acid composition in TAG, PL and FFA was determined using GC-FID after separation of the lipid 
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classes using preparative TLC and preparation of fatty acid methyl-esters, as earlier described 
(Artmann et al., 2008). 
The FAME were separated on a 60-m Supelco SP2380 column (Sigma-Aldrich AS, Brøndby, 
Denmark) in a HP 6890 gas chromatograph (GC), in split mode using He as carrier gas. 
Settings for the GC-program were:  Injector temperature 260 ⁰C, split ratio 20 : 1, carrier flow 1.2 
mL/min, detector temperature 300 ⁰C, air flow in detector 300,0  mL/min, hydrogen flow 35 
mL/min. FAME were separated using a temperature program starting at 50 ⁰C and rising to 160 ⁰C 
at 15 ⁰C /min; this temperature was kept for 0 min, hereafter the temperature was raised to 182 ⁰C 
at 1 ⁰C /min, and directly the temperature was raised to 200 ⁰C at 10 ⁰C /min, and the oven was kept 
at 200 ⁰C for 15 min before the temperature was raised to 225 ⁰C. The final temperature was kept 
for 12 min (total runtime 61.97 min). Response factors was calculated for methylesters of phytanic 
acid, C4:0, C6:0 and C8:0, based on the response of palmitic acid methyl ester (16:0). Ceramide 
was isolated from total lipid extract and quantified as earlier described in (Drachmann et al., 2007), 
with the exception that ceramide with C17 long-chained base was used as internal standard.  
Fat content in feed was determined by gravitational measurement after Folch extraction. 
Analysis of plasma TAG, NEFA, Cholesterol and glucose: Plasma levels of TAG, non-esterified 
fatty acids (NEFA), total-cholesterol, and glucose, were measured with a “Cobas Mira Plus” (Roche 
Diagnostics Systems, Basel, Switzerland). TAG, total-cholesterol, and glucose kits were from 
HORIBA abx; (Montpellier, France) and NEFA was analyzed using the appropriate kit from Wako 
Chemicals Gmbh (Neuss, Germany). All analyses were performed according to the instruction from 
the manufacturer. 
Oral Glucose Tolerance Test (OGTT): OGTT was performed after ten weeks on the given diets. 
The animals were fasted for 3 hours prior to oral glucose infusion (1.5 g glucose per kg 
bodyweight). Blood-glucose levels were measured to the time points zero, one, and two hours after 
glucose infusion and at the time points zero and two hours after infusion eye-blood was taken with 
50 µL EDTA-coated capillary tubes to produce plasma for insulin measurements. 
Blood glucose measurements was performed with “On call® Plus Blood Glucose Meter” (Acon 
Laboratories, inc., San Diego, USA), by adding one drop of eye-blood to the chip according to the 
manufacturers instruction.  
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Insulin & Leptin: Plasma insulin was analyzed using “Ultra sensitive mouse insulin ELISA” 
(Mercodia AB, Uppsala, Sweden), following the manufactures guidelines. Plasma levels of leptin 
was analyzed using the appropriate kit from from Meso Scale Diagnostics (Gaithersburg, USA) on 
a Meso Scale Sector Imager 6000 (leptin), according to the manufacturers recommendations. 
 
Gene expression analysis/qRT-PCR: RNA from liver-tissue was extracted on Abi Prism 6100 
Nucleic acid Prepstation from Applied Biosystems (Carlsbad, California, USA), according to the 
manufacturer’s instruction. 
cDNA-synthesis was performed on Unocycler (VWR (Leuven, Belgium), using “High capacity 
cDNA transcription kit” from Applied Biosystems. The quantification was performed on a 7900HT 
Fast Real Time PCRsystem, equipped with 96 wells Fast block, using “Taqman® Environmental 
master mix 2.0” (Applied Biosystems), and with primers and TaqMan-probes selected from Applied 
Biosystems and Integrated DNA Technologies (Coralville, IA, USA) online catalogues. SDS 2.3 
and RQ-manager 1.2 software was used for data analyses.  Data was analyzed using the Ct 
method, using glyceraldehydes-6-phosphate expression as reference-gene.  
 
Statistical analysis: Statistical analysis was performed using the software package GraphPad Prism 
(v.5.00). One way ANOVA with “Turkey” post test performed when nothing else noted. In cases of 
unequal variances in between groups in datasets (tested by “Bartlett´s test”) statistical analysis is 
performed on LogY transformed data. Statistical analysis of hepatic tissue mass for the PA dose 
response in butter, is Welch´s ANOVA performed in R. Results are given as average ± Standard 
deviation (SD), (n=8 for all groups). Statistical outliers were detected using Grubbs test 
(www.graphpad.com), data-points identified as outliers (p<0.05) was excluded from statistical 
analyses.  
Results 
Phytanic acid incorporation into hepatic lipid fractions 
Increasing phytanic acid intake from 0.2 to 1.0 % resulted in increased incorporation in both the 
TAG- and PL-lipid pools of the liver (Figure 3), as expected was there no detectable PA in the 
reference group that only was given chow (not shown). From Figure 3A and B it is evident that PA 
is incorporated into PL in a strict dose-dependent response, while this was not the case for TAG, 
were only the highest concentration resulted in significantly higher PA-incorporation. The 
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concentration of PA in FFA was very similar to what was seen in TAG, with significantly higher 
levels of PA in the 1.0 % PA –group, compared to the 0.20%-group.  As expected, the animals given 
the GSO diet had no PA in the hepatic TAG and PL, but that the addition of 0.25% PA to the fat 
fraction of the diet resulted in significant incorporation in both lipid fractions.  
 
0.2% PA 0.6 % PA 1.0 % PA
0.00
0.05
0.10
0.15
0.20
*
P
h
y
ta
n
ic
 a
c
id
 i
n
 T
A
G
(%
 o
f 
to
ta
l 
F
A
)
0.2% PA 0.6 % PA 1.0 % PA 
0.00
0.05
0.10
0.15
** ***
¤
P
h
y
ta
n
ic
 a
c
id
 i
n
 P
L
 (
%
 o
f 
to
ta
l 
F
A
)
0% PA 0.25 % PA
0.00
0.01
0.02
0.03
0.04
0.05
NDP
h
y
ta
n
ic
 a
c
id
 i
n
 T
A
G
(%
 o
f 
to
ta
l 
F
A
)
0% PA 0.25 % PA
0.00
0.01
0.02
0.03
0.04
NDP
h
y
ta
n
ic
 a
c
id
 i
n
 P
L
 (
%
 o
f 
to
ta
l 
F
A
)
A B
C D
 
Figure 3 Phytanic acid incorporation into hepatic lipid pools. A: Phytanic acid incorporation into hepatic 
triacylglycerides after feeding with butter containing varied concentrations of phytanic acid for 10 weeks. B: 
Phytanic acid incorporation in to hepatic phospholipids, otherwise as in A. C: Phytanic acid incorporation in 
to hepatic triacylglycerides after feeding with grapeseed oil containing 0 or 0.25% PA ethyl-esters. D: 
Phytanic acid incorporation in to hepatic phospholipids, otherwise as in C. Data are given as average ± st. 
dev. n= 7-8, * indicates statistical significant difference against 0.2% PA group, and ¤ indicates statistical 
significant difference against 0.6% PA group. ND = Non detectable. 
 
Body and organ masses 
From table 3, it is evident that the DIO-groups have significantly higher body-mass and total WAT 
mass (sum of epididymal-, kidney-, and visceral-WAT), compared to the lean references (P<0.001) 
in both experiments, and that PA addition did not have any effect on these parameters. 
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Interestingly, while hepatic tissue mass was statistical significant higher for all three DIO groups in 
the PA-dose response experiment in butter (P<0.05 for the 0.2 %, and P<0.01 against the two 
other groups) compared to the lean references, 0.25% PA protected against dietary induced 
hepatic weight-gain, when it was given in GSO.  
 
Table 3 Different metabolic parameters for A, phytanic acid dose response in butter high fat feed; and B, 
Phytanic acid in PUFA high fat feed, given as mean ± s.d. * indicates statistical significant difference against 
lean reference. No statistical significant differences observed between high fat groups on these parameters 
within the two setups. 
 A: Phytanic acid dose response in butter B: Phytanic acid in PUFA feed 
 Lean 0.2 % PA 
Butter 
0.6 % PA 
Butter 
1.0 % PA 
Butter 
Lean 0 % PA 
PUFA 
0.25% PA 
PUFA 
Bodyweight (g) 27.3±1.3
 
44.0±3.0
*** 
44.8±4.3
*** 
43.6±4.8
*** 
27.1±1.1
 
42.1±3.2
*** 
41.3±3.2
**
* 
Hepatic tissue 
weight (g) 
1.05±0.11
 
1.91±0.76
* 
1.94±0.58
** 
1.98±0.58
** 
1.09±0.19
 
1.44±0.34
 * 
1.26±0.21
 
WAT mass (g) 0.40±0.20
 
5.69±0.39
*** 
5.72±0.74
*** 
5.49±1.21
*** 
0.47±0.11
 
5.52±0.54
*
** 
5.52±0.68
*
** 
Plasma TAG 
(mM) 
0.64±0.14
 
0.98±0.14
** 
0.82±0.18
 
0.87±0.17
* 
0.90±0.24
 
0.68±0.13
 
0.77±0.17
 
Plasma NEFA 0.85±0.11 1.05±0.18 1.04±0.11 1.08±0.16
* 
1.12±0.30 1.03±0.15 1.19±0.16
 
Plasma Chol 2.41±0.24 4.60±0.84
*** 
4.22±1.05
*** 
4.50±1.06
*** 
2.85±0.95
 
4.54±0.57
*
* 
4.60±0.85
*
* 
Fasting glucose 
(mM) 
11.6±1.3 13.9±3.0 13.4±3.1 12.8±1.9 7.7±1.8
 
14.20±2.6
*
* 
13.9±1.2
** 
Fasting insulin 
(µg/L) 
0.63±0.52 7.82±7.21
***
 13.40±7.22
**
*
 
13.8±6.67
***
 0.52±0.47 3.47±0.75
*
*
 
2.71±1.22
*
 
Leptin (ng/mL) 0.14±0.16 22.56±11.08
***
 
29.26±8.60
**
*
 
30.15±5.23
**
*
 
0.21±0.26 20.72±9.67
***
 
20.45±9.3
6
***
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Plasma lipids, insulin, leptin and glucose homeostasis 
Although the average level of plasma TAG and NEFA was similar, and raised compared to the lean 
reference, in all three DIO-groups in the dose-response experiment, the values for TAG did only 
reach statistical significance at 0.2 and 1.0 % PA (P<0.01 and P<0.05, respectively) and for plasma 
NEFA was it only significant compared to the lean reference at 1.0 % PA (P<0.05). Plasma 
cholesterol was significantly higher in all DIO-groups, without any effect of the PA addition (Table 
3). 
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Figure 4 Glucose homeostasis measurements. A: Difference in blood glucose between the semi-fasted 
value (3.5 h fasting) and the value 2 hours after glucose gavage feeding (Δglucose) at a oral glucose tolerance 
test (OGTT), after feeding with butter containing varied concentrations of phytanic acid for 10 weeks. B: 
Difference in blood glucose between the semi-fasted value (3.5 h fasting) and the value 2 hours after glucose 
gavage feeding (Δglucose) at a oral glucose tolerance test (OGTT), after feeding with grapeseed oil containing 
0 or 0.25% PA ethyl-esters for 10 weeks. C: Homeostatic model assessment of insulin resistance (HOMA-
IR) otherwise as in A. D: Homeostatic model assessment of insulin resistance (HOMA-IR) otherwise as in B. 
n= 7-8, * indicates statistical significant difference against lean reference, and ¤ indicates statistical 
significant difference against 0.2% PA group. 
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In the dosis-response experiment, was there neither any effect of increasing PA concentrations in 
the diet on either hepatic TAG or –ceramide deposition (Figure 5A and C), while 0.25 % PA 
protected against increased TAG accumulation in the liver, when given in GSO (Figure 5B).  The 
level of FFA in the liver was not affected by any dietary treatment (not shown).  
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Figure 5 Effects of dietary phytanic acid on liver lipid accumulation. A: Hepatic TAG in animals given 
varying concentrations of PA-ethyl esters (given as % of total fat) in butter. B: Hepatic ceramide 
concentrations otherwise as in A. C: Hepatic TAG in animals given 0 or 0.25 % (mass % of total fat in diet) 
PA ethyl-esters.  D:  Hepatic ceramide, otherwise as in C.  
 
There were no significant difference in fasting glucose between the DIO-groups and the lean references in 
the dose-response experiment, where butter was used as fat source,  while it was significantly higher for 
both groups given GSO compared to the corresponding lean reference (P<0.01) (not shown).  The results 
from a oral-glucose tolerance test (OGTT) in the dose-response experiment, show that the only statistical 
significant effect on the difference in blood glucose concentration between the fasting value (time 0) and 
2h after glucose gavage (Δglucose), was seen in the 1.0 % PA group, which had higher glucose than the lean 
references and the corresponding 0.6 % PA group (P<0.001, and P<0.05) (Figure 4A). There were no 
statistical significant difference in this value between the three groups in the experiment when PA was 
added to GSO (Figure 4B), although the corresponding value from one to zero hours after oral dosage of 
glucose, was statistically significant higher for the GSO group without PA than for the lean reference 
(P<0.01, data not shown). Fasting insulin was statistically significant higher in the animals from all DIO-
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groups, compared to lean references (P<0.001 for 0.2 and 1.0 % PA in butter, P<0.01 for 0.6% PA in butter 
and GSO without PA, and P<0.05 for 0.25% PA in GSO diet). Likewise, leptin was statistically significant 
higher (P<0.001) for DIO groups compared against the lean references of the respective studies. The results 
of fasting insulin resulted in statistical significant higher values for all DIO groups compared for the lean 
reference of the respective experiments, when homeostatic model assessment for insulin resistance 
(HOMA-IR) was calculated (Figure 4 C and D (P<0.001 for all butter groups, P<0.01 for PUFA without PA, 
and P<0.05 for the PUFA diet with 0.25 % PA). 
 
Hepatic gene expression 
Hepatic gene expression was performed for the PA dose-response in butter. The expression of the 
genes coding for PPARα and the PPARα-regulated ACOX1, was statistically significant (P<0.01), 
although limited, up regulated in the 1.0% PA in butter group compared to the lean references, 
(seen in  
Figure 6), while other PPAR- target genes (CD36 and CPT1a) was strongly affected by the DIO-
diet, but not significantly up-regulated of the PA-intake. The genes coding for proteins controlling 
fatty acid synthesis (SREBP1 and FASN) was statistical significant up regulated in all the obese 
groups compared to lean references, without effect of PA. The transcription of the glucose-6-
phosphatase gene was determined as an example of an insulin-regulated gene. On average did all 
three DIO-treatments cause increased expression, although only the increase in the group that 
had received 0.6% PA reached significance. The average expression of the macrophagal marker 
EMR1 (F4/80), was, on average, also increased in the three DIO-groups, but this did only reach 
significance in the 1 % PA group. The relative hepatic gene expression of -methylacyl-CoA 
racemase (AMACR) was analyzed as a measure of the induction of the phytanic acid catabolic 
pathway. The amount of transcript was significantly reduced in the 0.2 % and the 0.6 % PA groups 
compared to the lean references (P<0.05 and P<0.01, respectively), while this was not the case for 
the 1.0% PA group.  
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Figure 6 Relative hepatic gene expression normalized to the average value for the group given 0.2% 
PA. Values are based on the ΔΔCt-values using GAPDH as reference-gene. Data are given as average ± st. 
dev. n= 7-8, * indicates statistical significant difference against 0.2% PA group, and ¤ indicates statistical 
significant difference against 0.6% PA group.  
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Discussion  
From the compiled data of this study, which is the first in-vivo study in which an intervention with the 
natural PPAR- agonist phytanic acid that have been performed, we did not see any dramatic dose-
dependent effects from physiological realistic PA dosages, when given in the butter diet, although the 
supra-dietary concentrations (1% PA of total fat) caused an impaired glucose tolerance. This indicates that 
PA intake from dairy-products do not have any physiological relevant effects on the control of lipid and 
glucose metabolism, but that intake of products with higher PA-concentrations than around 0.6% of total 
fat, might be detrimental. The lack of effect at lower concentrations than 1.0%, cannot be explained by a 
lack of incorporation into the relevant tissue, as evidenced by the retrieval of PA in the hepatic-lipid pools, 
hereunder the dose-dependent incorporation of phytanic acid into the phospholipid pool (Figure 3). 
However, as evidenced by the expression of the PPAR- controlled genes PPAR- and ACOX, it is also only 
after intake of the 1.0% PA-diets, that dietary PA actually cause a transcriptional activation of these genes, 
and, furthermore, this increase is very small (about 20 – 30 %).  Thus, we can conclude that PA at 
concentrations found in dairy fat, do not induce PPAR- activated gene-expression, but that highly slightly 
higher levels cause a minor increased transcription in some genes. It is also noteworthy that not all assayed 
PPAR- controlled genes were affected by the increased PA-level, even after intake of the 1.0 %-diets. For 
CD 36 and Cpt1a, there was no dose-response to the addition of phytanic acid; expression of both these 
genes was however strongly affected by the DIO-diet. It is likely that the strong effect of the DIO-diet, have 
overruled the very small effect that is seen from PA-activation in PPAR- and ACOX. From the presented 
data, it cannot be excluded that the observed 16-fold induction of CD36 and 50 % reduction in Cpt1a is an 
effect of the phytanic acid levels endogenous in the butter diets. However, we and others have shown that 
upregulation of CD36 and downregulation of Cpt1a are general response to the high fat/high sucrose diets 
in C57bl/6J (Drachmann et al. in preparation)(Koonen et al., 2007).  
The observed effect, that 0.25% PA totally abolishes the increased liver mass and TAG deposition, caused 
by high fat diet, when given in a linoleic acid rich-diet but not in a butter-based diet, is important. It shows 
that the effect of a dietary PPAR-agonist is highly dependent on the fatty acid composition of the diet. The 
effect might be explained by a PA-induced decrease in FA oxidation, increase in FA-synthesis, increased FA 
uptake or a combination of these. It can be hypothesized that this effect is due to synergistic effects 
between PA and the higher levels of PUFAs on PPAR-α on FA oxidation, in the GSO-fed groups. In these 
groups, total PUFA concentration in hepatic PL and TAG was around 52 and 47  %, respectively, while 
corresponding values was only 40 and 9 %, in the butter fed animals (not shown) . Thus, there are 
substantially higher levels of other natural PPAR agonists available in the liver of the GSO-fed animals. 
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However,  others have shown that dietary phytol effects on hepatic FA oxidation is attenuated by both n-3 
and n-6 PUFAs (Hashimoto et al., 2006), which is contra dictionary to this hypothesis.   
The most important finding of this study is the detrimental effect of PA on the glucose clearance rate 
measured as Δglucose values, when PA was given at 1.0 % of total fat in the dose-response study. Although 
the effect did not reach statistical significance, we observed tendencies toward a beneficial effect of PA in 
low amounts (0.6 vs 0.2 % in Figure 4A and 0.25% vs 0% in Figure 4) with regard to glucose clearance after 
an oral glucose-load, which could indicate that the effect of phytanic acid on glucose-tolerance is not linear, 
but that it might improve glucose-tolerance at lower concentrations, and reduce it at higher levels (> 0.6% 
of the dietary fat).  When we consider the PA content in dairy products, the highest amounts of PA 
observed is around 0.55% PA (Leiber et al., 2005), and it therefore seems that PA in dairy products would 
not have harmful effects with regard to glucose tolerance. With regard to insulin resistance, measured as 
HOMA-IR, our data does not show any effects of the addition of PA into high fat diets given to obesity 
prone C57bl/6j mice.  
The observed reduction in expression of AMACR in the obese animals is also noteworthy. Phytanic acid is 
oxidized through a combination of peroxisomal - and -oxidation and AMACR-activity  is essential for this 
to occur (Lloyd et al., 2008). Therefore, reductions in its expression might reduce the efficiency by which 
phytanic acid is oxidized and enhance the tissue accumulation. Since increased tissue accumulation of PA 
have been associated with several serious pathologies, such as hepatotoxicity and  prostate-cancer (Mackie 
et al., 2009), and that the risk of prostate cancer also have been associated with genetic variations in the 
AMACR-gene (FitzGerald et al., 2008), obesity induced reductions in this activity warrants further studies. 
 
  As this is the first time in vivo effects of PA have been tested in concentrations similar to concentrations 
found in food products, we cannot compare our findings directly to other studies. Though, studies with the 
PA precursor phytol have been performed, however, in concentrations higher than what is accessible 
through food products. In our own lab, addition of 0.2% and 0.5% phytol to normal chow diet for four 
weeks, substantially decreased hepatic TAG in balb/c mice (Hellgren, 2010). Other groups has shown that 
0.5% phytol upregulates gene expression and enzyme activities of both peroxisomal and mitochondrial FA 
oxidation (Gloerich et al., 2005; Hashimoto et al., 2006). As the amounts of phytol used in the mentioned 
studies is substantially higher than what it is possible to intake through the diet, those results does not 
seem relevant with regard to a normal human diet. As we have previously shown that it is possible to affect 
the human plasma PA concentration through dairy product intake, it would have been relevant to human 
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nutrition if we had found significant effects from PA intake in the butter based diets. Though, we in this 
study show that relatively low levels of PA protects against hepatic TAG deposition in high fat GSO diet,  it 
can be argued that this does not seem as interesting as PA in the diet primarily comes from dairy and 
ruminant meat products, which are not high in PUFA. However, it indicates that low levels of PA could be 
used as a nutraceutical in PUFA rich products.   
Conclusion 
Intake of PA in concentrations found in dairy-fat, leads to uptake and incorporation into both 
hepatic TAG and PL fractions. When given in a high sugar/high fat-diet, PA have no effect on 
glucose-clearance nor on fasting glucose and insulin, when given in concentrations up to 0.6% of 
total fat, while at 1.0 % PA in total fat, glucose-clearance rate was reduced.  In a PUFA-rich diet, 
low levels of PA (0.25%) protects against obesity induced hepatic lipid-accumulation. 
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Supporting information. 
Synthesis of (7R, 11R)-ethyl 3, 7, 11, 15-tetramethylhexadecanoate 
 
 
(7R, 11R, E)-3, 7, 11, 15-tetramethylhexadec-2-enoic acid 
A mixture of CH2Cl2 (400 mL) and DMSO (9,6 mL; 135 mmol) was cooled to -70°C. To the 
mixture a solution of oxalyl chloride (5.9 mL; 67 mmol) in CH2Cl2 (20 mL) was added drop wise 
while maintaining a temperature below -60°C throughout the addition period. After 15 min a 
solution of phytol (10 g; 34 mmol) in CH2Cl2 (20 mL) was added drop wise, again maintaining a 
temperature below -60°C. After another 15 min Et3N (23.5 mL; 168 mmol) was added and the 
reaction mixture was allowed to reach room temperature. 
The reaction mixture was washed with sat. aq. NH4Cl (300 mL) and H2O (3x150 mL), dried over 
MgSO4 and concentrated to give the aldehyde as a yellow oil. 
The crude product was used in the following step without further purification 
 
The aldehyde (10 g; 34 mmol) was dissolved in 
t
BuOH (680 mL) and THF (340 mL). 2-methyl-2-
butene (180 mL; 1.7 mol) was added followed by a solution of NaClO2 (30.6 g; 0.34 mol) and 
Na2H2PO4 (30.6 g; 0.26 mol) in H2O (340 mL). The reaction mixture was stirred at room 
temperature until full conversion was observed (1 h). 
The reaction mixture was washed with sat. aq. Na2H2PO4 (500 mL) and the aqueous phase was 
extracted with EtOAc (2x500 mL). The combined organic phases were dried over MgSO4 and 
concentrated.  
The product was purified by flash chromatography to give 2 as a colorless oil.  
 
(7R, 11R, E)-ethyl 3, 7, 11, 15-tetramethylhexadec-2-enoate 
2 (10 g; 32.2 mmol) was dissolved in EtOH (65 mL).  Acetyl chloride (0.34 mL; 5 mmol) was 
added and the reaction mixture was stirred at refluxing temperature for 48 hours.  
The reaction mixture was neutralized with Et3N and concentrated. The crude oil was dissolved in 
Et2O (400mL) and washed with sat. aq. NH4Cl (3x300 mL) and H2O (3x300 mL). The organic 
phase was dried over MgSO4 and concentrated. 
The product was purified by flash chromatography to give 2 as a colorless oil.  
 
(7R, 11R)-ethyl 3, 7, 11, 15-tetramethylhexadecanoate 
4 (10 g; 339 mmol) was dissolved in EtOH (75 mL) and THF (25 mL). 10 wt% Pd/C (0.31 g; 0.30 
mmol) was added and and an atmosphere of H2 (1 atm.) was installed. The reaction was stirred until 
TLC indicated full conversion (48 h), filtered through celite, and concentrated to give a colorless 
oil.  
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Abstract 
Scope: To investigate whether dairy fat intake have the ability to alter the type of immune 
response from T-cells. We hypothesized that phytanic acid (PA), which is found in varying 
concentrations in dairy fat, might promote T-cell polarization towards a Th2-type response, due to 
its agonistic activity for the nuclear receptors PPARα and RXR. 
Methods and results: In a double-blinded, randomized, 12-wk, parallel intervention study, 16 
healthy subjects replaced part of their habitual dietary fat intake with 39 g fat from two test 
butters, that contained different amounts of PA. The butters were produced from milk delivered 
from mountain-pastures grazing cows or from cows fed conventional winter feed. Before and after 
the butter intervention, CD3+ T-cells were isolated and activated for 12 hours, followed by 
measurement of IFN-γ, IL-4, and IL-10 gene expression levels. The direct effect of PA on T-cell 
cytokine patterns was further evaluated in in vitro incubation experiments. 
No differences in-between the two butter groups were observed with regard to expression of the 
Th-cell signature genes IFN-γ,IL-4 and IL-10, but a general statistically significant increase in IL-4 
(P=0.0009), IFN-γ (P=0.0106), IL-4/ IFN-γ (P=0.01), and IL-4/IL-10 (P=0.01) upon 12 weeks of butter 
intake was identified.T-cells in vitro incubated with PA versus palmitic acid as a control, showed 
that PA is not likely to contribute to the butter effect on the cytokine levels.  
Conclusion: The 12 weeks butter intervention resulted in greater increases in levels of IL-4, than of 
IFN- γ and IL-10. The Th2 specific butter effect seems not to be caused by increased plasma or 
cellular PA levels, as was hypothesized.  
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1 Introduction 
Studies have indicated that specific dietary components might have an impact on the immune 
response. This might occur through modulation of T-cell polarization, since the balance especially 
between T-helper cell type 1 (Th1), T-helper cell type 2 (Th2) or regulatory T-cell (Treg), determine 
to what extent a certain antigen will induce a cellular or humoral immune response, or whether it 
may be more tolerance promoting towards the antigen.  The branched-chain fatty acid phytanic 
acid (PA, 3, 7, 11, 15-tetramethyl hexadecanoic acid, fig. 1) is an interesting component in this 
regard, since it, as well as its primary metabolite pristanic acid (2,6,10,14- 
tetramethylpentadecanoic acid), has strong agonistic activities on the nuclear receptors RXR and 
PPARα (Kitareewan et al., 1996; Zomer et al., 2000) suggested to specifically affect T-cell function. 
RXRα is highly expressed in T-cells of the Th2 lineage, and overexpression in Jurkat T-cells caused 
increased expression of the Th2-derived cytokine IL-4 but not of IFN-γ, a cardinal cytokine 
produced by Th1 cells. It was therefore previously suggested that RXRα activity play a selective 
role in polarizing Th cells towards a Th2 phenotype (Hwang et al., 2009). RXR-specific agonists as 
well as 9-cis retinoic acid (Dawson et al., 2008) also selectively inhibits IFN-γ production in vitro 
culture systems, though it is not clear whether this is mediated through RXR or retinoic acid 
receptor (RAR). Furthermore, RXR-specific agonists have been shown to mediate differentiation to 
Th2 cells from naïve CD4+ T cells (Stephensen et al., 2002).  
PPARα is also expressed in naive and activated T cells, and several studies have demonstrated 
repression of IFN-γ in activated T cells by PPARα ligands, such as fenofibrate and Wy14643 (Cunard 
et al., 2002; Jones et al., 2002; Lee et al., 2007). The repression of IFN-γ seems to be linked to 
PPARα activity, since it is not observed in splenocytes from PPARα KO mice. Moreover, PPAR -/- - 
C6 
 
mice show an impaired induction of regulatory T cells (Treg) (Dubrac et al., 2011), indicating that 
PPAR- activation also might be involved in differentiation of Treg.  
 
 
Figure 1 Structures of chlorophyll (A), phytol (B), and Phytanic acid(C).  
 
PA is found in dairy and meat products from ruminant animals. The precursor of PA, phytol (3, 7, 
11, 15-tetramethylhexadec-2-en-1-ol, also seen in fig. 1), is released from chlorophyll through 
microbial conversion in the rumen of ruminant animals (Hansen, 1966; Gloerich et al., 2007). Since 
phytol cannot be released from the chlorophyll molecule in the human gastrointestinal (GI) tract, 
the human intake of PA primarily originate from the fat fractions of ruminant meat and dairy 
products. The content of PA in ruminant food products is mainly dependent on the amount of 
green plant material in the feed, although the composition of the ruminal microbiota also might 
be of importance (Lough, 1977; Vlaeminck et al., 2006; Vetter & Schroeder, 2010).  
Based on PA’s possible role as a RXR and PPAR agonist, we hypothesized that increased intake 
of PA-rich dairy products would promote Th2 type propagation. A physiological effect of PA seems 
plausible as we have observed that the serum level of PA is directly correlated to the intake of 
dairy products (Werner et al, 2011), and that the PA concentration in plasma in adults are within 
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the range of the published EC50 value for the binding of PA to RXR (Lemotte et al., 1996; 
Kitareewan et al., 1996; Werner et al., 2011). If PA has the suggested impact on the T-cell 
response it is of importance, as it would indicate that intake of ruminant meat and dairy products 
could promote a Th2 type response.  
To examine the T-cell polarizing effect during natural intake of PA in humans, we performed a 12-
weeks butter fat interventional trial in 16 healthy subjects. The participants received butter 
derived from either grazing or conventionally fed cows. The difference in cattle feeding regimens 
results in varying PA concentrations within the two butter products. The CD3+ T-cell response was 
evaluated before and after the intervention by measurement of the expression of fundamental 
markers of Th1 and Th2 cells upon ex vivo activation. We found no statistically significant changes 
in gene expression of IFNγ, IL-4, or IL-10 that was related to the differences in the cattle feeding 
regimens. However, we observed a general statistically significant enhancement of IL-4 upon 
increased intake butter from both products during the intervention. As average plasma PA levels 
were raised for both butter intervention subgroups, we further tested in an in vitro incubation 
study if PA is able to shift the cytokine profile of activated T-cells. However, despite the overall in 
vivo butter effect, we did not observe any influence of PA on T-cell polarization in vitro, hence 
suggesting that the butter effect on Th2 cell shifting may not be mediated by PA.   
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2 Methods and materials 
Participant information  
The 16 participants in the intervention was a subpopulation from a larger human intervention with 
intake of butter produced from either milk from grazing cattle or from more conventional fed 
cattle. The selection of the sub-population among all participants was blinded and randomized. 
Subjects were mixed male and female, and aged 50 to 70 years. Basic physiological characteristics 
of the 16 subjects who completed the study are given in Table 1.  
 
Table 1 Basic physiological parameters for the 16 healthy participants, and changes in plasma phytanic acid 
concentrations due to 12 weeks butter intervention1. 
 Treatment 
  Conventional butter Grazing butter 
 Before intervention After intervention Before intervention After intervention 
Subjects, (n) 7 9 
Women, (n,%) 28.6 % 66.7 % 
Age, (y) 62.9 ± 4.7 (56-69) 62.0 ± 5.7 (53-68) 
Height, (cm) 178.8 ± 6.23 (170.2-188) 169.1± 6.33 (158-180.5)
**
 
Phytanic acid, (μM) 
 
2.96 ± 0.69  
(2.32-4.10) 
3.39±0.75  
(2.54-4.08) 
2.78 ±0.49 
 (1.98-3.63) 
3.36±0.61  
(2.12-4.03)
¤¤ 
1
 Values are mean ± SD; range in parentheses. BMI, Body mass index. ** indicates statistically significant difference 
(P<0.01) as compared to the conventional group (unpaired t-test). ¤¤ indicates statistically significant difference 
(P<0.01) between the baseline and the after value (paired t-test). 
 
Exclusion criteria were: BMI > 30 kg/m2 (though one person in the conventional butter group had 
BMI>30kg/m2), current or previous chronic disease, regular use of medications, drugs and/or 
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alcohol. All participants were apparently healthy as indicated by a medical and lifestyle 
questionnaire. They all agreed to refrain from taking any dietary supplements, from donating 
blood 2 months before and during the study, and from taking any medication that might interfere 
with study measurements. All subjects were instructed to maintain the same level of physical 
activity throughout the study. The subjects completed a 3-day weighed-food record before the 
intervention and after six weeks of intervention to assess potential differences in dietary intake 
between the groups before and during the intervention. All records were coded before being 
evaluated by a clinical dietician who also calculated energy intake and dietary composition using a 
national database (Dankost; National Food Agency, Søborg, Denmark). The mean habitual energy 
intakes before the intervention were 8.3 MJ/d (range: 5.7-15.8 MJ/d); 31.1 % (24.2-45.9 %) of the 
energy was from fat, 16.3% (11.6-22.8%) was from protein, and 47.3 % (39.1-58.3%) was from 
carbohydrates. The protocol and aims of the study were fully explained (orally and in writing) to 
the participants, who gave written informed consent. The research protocol was approved by The 
Scientific Ethics Committee of the Copenhagen and Frederiksberg (H-B-2009-052). 
Production of test milk 
Milk fat for the human study was delivered from grazing cows from Norway or conventional 
Danish cows. Two different types of milk were produced with different FA composition (Table 1). 
The markedly higher intake of chlorophyll-containing green feed from the grazing cows resulted in 
a 1.7 fold higher PA content compared to the conventional Danish milk. The conventional Danish 
milk was delivered from Arla Food, originated from 47 farms, and was collected in October 2009. 
Cattle feeding routines were traditional and the farmers selected their own ingredients and made 
their own mixtures of feed. A conventional Danish cow feed regime consists of a mixture of corn 
silage (35%), wheat-barley silage (25%), clover silage (20%), soybean meal or rapeseed cake (10%) 
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and a small proportion molasses or beet pellets, straw, vitamins and minerals. The two types of 
milk were transported to Tine Dairies (Oslo, Norway), where it was processed into butter.  
Table 2 Fatty acid compositions for the two butter types used in the intervention trial 
 
  
Conventional  
butter diet 
(wt%) 
Grazing  
butter diet 
(wt%) 
4:0 3.8±0.41 4.4±0.2 
6:0 2.6±0.06 2.5±0.07 
8:0 1.3±0.01 1.2±0.02 
10:0 2.7±0.04 2.2±0.05 
12:0 3.3±0.06 2.6±0.05 
14:0 10.5±0.2 9.4±0.2 
14:1 0.93±0.02 0.70±0.02 
15:0 1.0±0.02 0.86±0.02 
16:0  29.6±0.5 23.7±0.5 
16:1 n-7 1.5±0.03 1.1±0.03 
Phytanic acid 0.18±0.01 0.30±0.01 
17:0  0.48±0.01 0.55±0.01 
17:1 0.20±0.01 ND 
18:0 10.6±0.2 14.4±0.3 
18:1 t-11 1.6±0.03 2.1±0.05 
18:1 n-9     20.5±0.2 24.5±0.6 
18:1 n-7 0.90±0.02 0.74±0.02 
c-9 t-11 CLA 0.58±0.02 0.76±4*10-3 
18:2 n-6  1.7±0.07 1.5±0.07 
18:3 n-3 0.59±0.01 1.01±0.1 
 
Blood sampling, T cell isolation and stimulation 
Blood was collected in EDTA-coated tubes and kept at room temperature until all blood samples 
were collected per day (within maximum one hour). CD3+ T cells were isolated from whole blood 
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using the FlowComp™ Human CD3 isolation kit (Life Technologies, Carlsbad, California, USA) 
according to manufacturer’s recommendations. T cell purity were routinely confirmed to be >98% 
using flow cytometry. T cells were suspended in complete cell culture medium (RPMI 1640 
supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 % heat-
inactivated fetal bovine serum (FBS, all from Lonza)) and activated by adding 3*105/well anti-
CD3⁄CD28-coated expander beads (Life Tech). Stimulation controls were added medium without 
CD3/CD28-coated expander beads. After 12 hours of incubation at 37 oC and 5 % CO2, the T-cell 
activation was terminated by removing 100 µL medium, followed by addition of 100 µL nucleic 
acid purification lysis solution from Applied Biosystems (Carlsbad, California, USA) and immediate 
freezing of the T cell lysate at -80 :C. T cells derived from the butter intervention participants were 
activated just after isolation, whereas T cells used for in vitro incubation with fatty acids (FA) were 
incubated over night at 37 oC and 5 % CO2with the respective FAs before activation. 
In vitro incubation of T cells with BSA-bound fatty acids 
Prior to addition of PA and palmitic acid to T cells, they were bound to FA-free BSA (Sigma-Aldrich, 
Steinheim, Germany) dissolved in complete cell culture medium to a final concentration of 10 µM. 
The ratio of FA to BSA was ~ 1: 0.5 molar-ratios, and the mixture was vortexed for 5 minutes to 
ensure binding of the FA to BSA. T-cells were isolated as described, and dissolved in complete cell 
culture medium to a concentration of 3*106 cells/mL. 3*105 cells were transferred to each well, 
and 100 µL of the medium with FA was added to a final concentration of FA in the incubation 
medium of 5 µM. All samples were made in triplicates. Cells were incubated for 20 hours at 37 oC 
and 5 % CO2 and the following day stimulated for 12 hours, as described above. Five µM of FA was 
selected, since this is close to the concentration we have determined in the subjects after the 
butter intervention (table 2).  
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Fatty acid analysis in lipids and test fats 
Total lipids were extracted and analyzed from blood plasma samples as described by Tholstrup et 
al (Tholstrup et al., 2004) but using TAG C19:0 as internal standard. The butter lipids were 
extracted according to the method of Folch (Folch J. et al., 1957). Preparation of FAME was 
performed based on the method of  Hamilton & Hamilton (Hamilton & Hamilton, 1992); to the 
extracted lipids 0.5 M NaOH in MeOH was added, and refluxed for 5 minutes at 80 :C. The mixture 
was cooled to room temperature. Twenty % BF3 and 0.1 % hydroquinone in MeOH was added to a 
final concentration of 8 and 0.02%, respectively, which was further refluxed for 2 minutes at 80 :C. 
After cooling to room-temperature 0.8 volumes of 0.73 % NaCL (aq) was added and fatty-acid 
methyl esters were extracted twice with 0.2 volumes heptanes. Response factors were calculated 
for methyl esters of PA and short-chained fatty acids (C4-C12), based on the response of palmitic 
acid methyl ester (C16:0). The butter FAME were separated on a 60-m Supelco SP-2380 column 
(Sigma-Aldrich AS, Brøndby, Denmark) in a HP 6890 gas Chromatograph (GC), in split mode using 
He as carrier gas. injector temperature was 260 :C, split ratio 20 : 1, carrier flow 1.2 mL/min, 
detector temperature 300 :C, air flow in detector 300,0  mL/min and  hydrogen flow 35 mL/min. 
FAME from the plasma samples and for identification of c9 t11 CLA in butter the temperature 
program started at 50 :C and raised to 160 :C at 15 :C /min; hereafter the temperature was raised 
to 182 :C at 1 :C /min, and directly to 200 :C at 10 :C /min, the oven was kept at 200 :C for 15 min 
before the temperature was raised to 225 :C. The temperature program used for butter samples 
was starting at 50 :C and rising to 160 :C at 10 :C /min; hereafter the temperature was raised to 
168 :C at 0.5 :C /min and finally the temperature was raised to 225 :C at 30 :C /min and kept at 
this temperature for 10 min. FAME was identified with authentic standards, and PA-concentration 
was determined based on the peak area, compared with the internal standard. 
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qRT-PCR 
RNA was extracted from T cell lysates on an Abi Prism 6100 Nucleic acid Prepstation from Applied 
Biosystems (Carlsbad, California, USA), according to the manufacturer’s instruction. cDNA-
synthesis was performed on Unocycler (VWR (Leuven, Belgium), using the High capacity cDNA 
transcription kit from Applied Biosystems. The quantification was performed on a 7900HT Fast 
Real Time PCRsystem (and each sample measured in duplicate), equipped with 96 wells Fast block, 
using the Taqman® Environmental master mix 2.0 (Applied Biosystems), with primers and 
TaqMan-probes from Applied Biosystems. SDS 2.3 and RQ-manager 1.2 software was used for data 
analyses. WBP4 (Hs00200419_m1) was used as reference gene. Other primers used were IFN-γ 
(Hs0098929_m1), IL-4 (Hs00174122_m1), IL-10 (Hs00174086_m1), and IL-17a (Hs00174383_m1). 
Statistical analysis and methods used for quantification of gene expression 
The levels of gene expression in T-cells from the in vitro incubation with FAs were determined as 2-
ΔCt, where ΔCt is measured as the Ct-value for the respective gene minus the corresponding Ct-
value for WBP4 for each donor individually. Fold changes were measured as 2-ΔΔCt, where ΔΔCt in 
the incubation study is the ΔCt value for PA minus the ΔCt value for palmitic acid (again each 
donor individually), and in the intervention study ΔΔCt is measured as ΔCt value after intervention 
minus the ΔCt value before intervention. Statistical analysis was performed using the software 
package GraphPad Prism (v.5.00). Difference in expression of the individual cytokines, and the 
ratios IL-4/ IFN-γ, IL-4/ IL-10, and IFN-γ/ IL-4, between the groups in the intervention, was tested 
by unpaired t-test and MANOVA (MANOVA was performed using R software package). Statistical 
analysis of cytokine expression before and after intervention was performed as paired t-test. 
Paired t-test was also used to compare cytokine expression after PA and palmitic acid incubation. 
Outlier detection performed with Grubbs test (www.graphpad.com). 
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3 Results 
Changes in PA plasma concentrations upon 12 weeks of butter intake 
A double-blinded, randomized, 12-wk, parallel intervention study in 16 healthy subjects (aged 53 
to 69) was performed in which we replaced part of their habitual dietary fat intake with 39 g fat 
from two test butters (Table 1). The two test butters differed by 70% in their PA concentrations 
(Table 1). Despite the relatively great differences in PA concentration in the two butters, 12 weeks 
of intake of butter fat resulted in a very similar average plasma PA levels in the two butter groups 
(Table 2). A raise by 22 % was seen in the group receiving butter from grazing cattle (P=0.0034, 
Table 2) whereas an 18% increase from the baseline level was observed for the group given 
conventional butter (P=0.22, Table 2).  
Butter intervention and cytokine profiles in activated T-cells 
T-cells from the 12-weeks butter intervention participants were evaluated for their cytokine 
producing abilities before and after the 12 weeks to examine if intake of the two different butters 
may affect the cytokine profile in activated T-cells, and whether this change was correlated to 
changes in plasma PA-level. We activated CD3+ T-cells with anti-CD3/anti-CD28 antibody-
containing beads and compared the gene expression levels of IFNG, IL-4 and IL-10 by qPCR. In 
preliminary experiments, the gene expression levels of IFNG, IL-4, or IL-10 were examined in T-
cells activated for 3, 6 and 12 hours, and based on these pre-studies we settled on 12 hours of 
activation as the optimal time point for detection of all three mRNA-cytokine products in activated 
CD3+ T-cells. Comparisons of the effect of the two types of butter on the gene expression levels in 
activated T-cells (before and after intervention) showed no statistically significant differences in 
IFN-γ, IL-4, or IL-10 levels (Figure 2A).  
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Figure 2. The effect on CD3+ T-cell cytokine profiles of 12-weeks intervention with two butters differing 
in PA content. A; The relative mRNA expression of IFNG, IL-4 and IL-10 in anti-CD3/CD28-activated CD3+ T-
cells after 12-weeks intake of butter from either grazing (n=9) or conventionally fed (n=7) cows. Data are 
presented as the fold change of cytokine expression levels in cells after versus before the intervention, with 
each dot representing data from one individual. B; Ratios of IL-4/IFN-γ, IL-4/IL-10 and IFN-γ/IL-10 in 
activated CD3+ T-cells calculated from data in A. Data were tested for statistically significant differences in 
T-cell responses between the two butter groups by unpaired t-test and MANOVA. 
 
A tendency towards increases in IL-4 levels, lower levels of IFN-γ, and consequently an increase in 
the IL-4/IFN-γ-ratio (P=0.16, Figure 2B) was observed for individuals receiving butter from grazing 
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cows, perhaps due to a marginal greater increase in PA levels during the intervention. This skewing 
of the type of T-cell response could be due to PA, as suggested by our working hypothesis, but as 
only minor changes were seen within the plasma PA levels in the two butter groups, it may be of 
greater relevance to look for an overall butter effect on T-cell cytokine profiles instead of 
subdividing into butter groups. When combining the data from the two butter groups, we 
observed a statistically significant increase in IL-4 (P=0.0009) and IFN-γ (P=0.0106) expression in 
activated T-cells, but not in IL-10 levels, after the 12 weeks butter intervention, compared to the 
expression before the intervention (Figure 3).  
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Figure 3. Overall effects of 12-weeks butter intervention on cytokine expression levels in CD3+ T-cells. 
Gene expression levels of IFNG, IL-4 and IL-10 were measured by qPCR in triplicate cultures of activated 
CD3+ T-cells, at baseline and after 12 weeks butter intervention (n=16). The ratio of IL-4/IFNG was 
calculated based on the qPCR values. * indicates statistically significant difference compared to baseline (*: 
P<0.05, ***: P<0.001), and tested with paired t-test.  
 
Since the fold-increase in IL-4 during the intervention, was higher than both the increase in IFN-γ 
and in IL-10, this resulted in a significant increase in the IL-4/IFN-γ ratio (mean change: 1.6 fold, 
95% CI:1.1-2.0, p for change during intervention = 0.01; Fig 3D) as well as the IL-4/IL-10 ratio (mean 
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change: 2.2 fold, 95%CI: 1.3 – 3.1, p for change during intervention =0.01, not shown) during the 
butter intervention. Thus, based on the overall findings, it seems that daily intake of 39 g butter 
fat from grazing or conventionally fed cows during a 3 month period result in changes in the IL-
4/IFN-γ and the IL-4/IL-10 ratios in ex vivo activated CD3+ T-cells derived from peripheral blood, 
indicating polarization of T-cells towards a Th2 profile due to dairy fat intake.  
Effect of increased extracellular PA levels on T-cell polarization  
As average plasma PA levels were raised for both butter groups during the intervention, we 
hypothesized that the Th2-shift in the activated T-cells might be caused by plasma PA interacting 
with the peripheral blood CD3+ T-cells. Therefore we also studied the influence of PA in an in vitro 
cell culture system based on human-blood derived CD3+ T-cells that were incubated with PA or 
palmitic acid (C16:0), as a control FA. Upon overnight incubation with FAs, the T-cells were 
activated for 12 hours by CD3/CD28-stimulation. In this study, we measured the expression of IFN-
γ (Th1), IL-4 (Th2), IL-10, and also included IL-17 as a marker for Th17 cells. T-cells were incubated 
overnight with 5 µM PA or palmitic acid to ascertain extracellular PA concentrations resembling 
those obtained in the plasma during the butter intervention. The T-cells were then activated for 12 
hours, followed by analysis for gene expression levels of IFN-γ, IL-4, IL-10, and IL-17. We found that 
PA incubation of T-cells did not cause any effects on the cytokine profiles that could be related to 
PA (Figure 4A and 4B). Therefore, based on the data from the in vitro incubation with PA versus 
palmitic acid in physiological relevant concentrations, it seems unlikely that the butter-induced 
increases in plasma PA levels account for the observed shifting in T-cell cytokines upon the butter 
intervention, at least not solely. This inference was further supported by a subsequent correlation 
analysis between changes in plasma PA and gene expression levels in the activated T-cells from 
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the butter intervention. Here, we found no correlations between changes in PA levels and any of 
the measured cytokine levels in activated T-cells (data not shown). 
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Figure 4. Cytokine expression levels in CD3+ T-cells upon in vitro phytanic acid incubation. A; Gene 
expression of IFNγ, IL-4, IL-10, and IL-17a in anti-CD3/CD28-activated CD3+ T-cells after 20 hours incubation 
with 5µM BSA-bound phytanic acid or palmitic acid. Each point represents the mean cytokine level in cells 
from one donor, stimulated in triplicates and measured by qPCR (n=8). Statistical significance was tested by 
paired t-test, with no statistical significance between the two FAs. B; Fold change in individual CD3+ T-cell 
responsiveness upon 20 hours of phytanic acid versus palmitic acid incubation.   
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4 Discussion 
The results from the intervention study show that three month increased intake of dairy fat from 
grazing cows did not enhance neither plasma PA levels nor the cytokine-response from ex vivo 
activated CD3+ T-cells isolated from the study participants, when compared with the effects in the 
control-group consuming dairy fat from conventionally fed cows. However, when analysing the 
entire study-population for effects of the butter intervention, it was very evident that the intake of 
approximately 40g butter/day for 12 weeks had pronounced effects on the cytokine profile in 
CD3+ T-cells in response to CD3/CD28 stimulation. This was in particular manifested as a shift 
towards relatively higher IL-4 induction, compared with both IFN- and IL-10, which is recognized 
as a hallmark of a more Th2-propagated type of response. Concomitant with the shift in T-cell 
response was the increase in circulating levels of PA observed in both butter groups, although this 
only reached significance in the subjects consuming the butter from the grazing group. Thus, the 
results from the butter intervention study do not support the hypothesis that the concentration of 
chlorophyll-containing plant material in the cows diet (i.e. the grazing group) will give rise to 
enhanced plasma PA levels, as compared to conventional butter, that in turn then can affect the 
CD3+ T-cell polarization pattern in the consumers of the dairy-fat. Instead our results confirm our 
earlier results that an overall increase in butter intake, independent of the cows diet, result in 
increased levels of circulating PA in the consumer(Werner et al., 2011), and now furthermore 
suggests that such plasma PA increase is associated with a Th2-skewing of the CD3+ T-cell 
response. However, our further in vitro studies did not substantiate that increased extracellular PA 
levels, as a sole factor, affects the CD3+ T-cell response in a Th2 direction. In these studies we 
selected palmitic acid as a control FA due to the fact that it has identical chain-length as PA, but 
lacks the methyl-branches. Hence, we are controlling for the effect of the methyl-branches that 
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signifies PA compared to the common dietary, un-branched, fatty acids. Furthermore, we 
observed no differences in plasma palmitic acid levels during the butter intervention (data not 
shown), thus excluding an in vivo effect of this FA on the CD3+ T-cell response. The results clearly 
show, that PA in concentrations similar to what is found in plasma, do not have specific effects on 
the cytokine-induction in the activated CD3+ T-cells. Hence, we find it unlikely that the observed 
effect of the butter-intervention is explained by the increase in plasma PA-concentration, rather 
other more complex interactions may play a role for the in vivo-propagated Th2 shifting. 
Alternatively, the manner by which the T-cells are taken up the extracellular PA is different in the 
in vitro incubation system as opposed to in vivo exposure in peripheral blood, thereby giving rise 
to the divergence in T-cell cytokine responses upon rises in extracellular PA.  
Although it is well known that dietary fatty acid composition can modulate the T-cell response, 
this research has primarily focused on the role of n-6 and n-3 polyunsaturated FA (PUFA) (Kim et 
al., 2010), while much less is known on the effect of other fatty acids that are characteristic for 
dairy fat. However, reports on the effects of conjugated linoleic acid (CLA) and its metabolic 
precursor vaccenic acid (C18:1 n-7t), which both are considered to be potentially bioactive fatty 
acids in milk fat, do exist. Specifically, in obese JCR:LA-cp rats the feeding of vaccenic acid for three 
weeks was shown to increase IL-10 production in mitogen-stimulated spleenocytes and 
mesenteric lymph nodes (Blewett et al., 2009), while spleenocytes from obese Zucker-rats fed 
either the dairy-derived CLA isomer t10,c12-CLA or c9,t12-CLA produced less IL-4 than the control 
rats when stimulated with concanavalin A or phorbol-myristate acetat and ionomycin (Ruth et al., 
2008). Thus, the increase in the ratio in IL4/IFN- and IL-4/IL-10 expression we observed in our 
present study, cannot be explained by published effects of these two fatty acids in rodents. During 
our human butter intervention, the participants replaced about 15E% of their habitual fat intake 
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with the intervention fat (Werner et al 2011b, submitted). This change to butter fat is expected to 
reduce their intake of unsaturated FA, while enhancing their intake of saturated FA. To the best of 
our knowledge, there exist no reports on the effect of increased intake of saturated fat on 
polarization of peripheral CD3+ T-cells in humans. In mice models, it has been shown that high fat 
feeding with saturated FA cause a substantial increase in IFN-/IL-4 production in spleenocytes 
compared to feeding with either n-6 or n-3 PUFA (Wallace et al., 2001; Verwaerde et al., 2006). 
Thus, available data from rodent studies indicates another shift in the T-cell cytokine balance upon 
increased intake of saturated fat than the Th2-skewing we observe after increased butter-intake in 
humans. Dairy fat is also characterized by the high content of short-chained FAs (SCFAs). SCFAs 
constitute up to 12 mole% of dairy fat and the specific SCFA receptor GPR43, have been showed to 
be highly expressed on leukocytes and to be important for an appropriately balanced immune 
response (Maslowski et al., 2009; Oh & Lagakos, 2011). However, little is known on the role of 
GPR43 in modulating the cytokine-profile of activated CD3+ T-cells, and of the importance of 
dietary SCFA intake for leukocyte GPR43-regulation, and therefore presently it is not possible to 
estimate if the increased intake of SCFA from butter can partly explain the increased expression-
ratio of IL-4/IFN-in ex vivo-activated T-cells. 
Considering the physiological relevance of the observed skewing in the CD3+ T-cell cytokine-
profile, these are not easily interpreted. Although a Th2-skewing of the T-cell response, relative to 
Th1 or regulatory T-cell type of responses, are considered to increase the risk of developing atopic 
diseases (Jutel & Akdis, 2011), to what extent the observed changes, in a healthy and non-atopic 
population represent an actual risk-factor for development of atopic diseases, will require further 
comprehensive studies.  
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Conclusion 
The feeding regimen of the dairy-cows producing the milk-fat used for butter production did not 
affect expression of fundamental markers of Th1, Th2 and also Treg in ex vivo-activated CD3+ T-
cells derived from subjects eating about 40 g butter/day for 12 weeks. However, compared to the 
response at baseline, the butter-intervention gave rise to upregulation in IL-4 (P<0.001) and IFN-γ 
(P<0.05) expression. Since the upregulation of IL-4 expression was relatively higher than the 
increase in IFN-γ expression, this resulted in a significantly increased activation-induced expression 
ratio of IL-4/ IFN-γ as well as IL-4/IL-10 after the intervention. This indicates that butter intake has 
the ability to enhance polarization of T-cells towards a Th2 phenotype. From the in vitro PA-
incubation study of human peripheral blood CD3+ T-cells, we conclude that PA in physiological 
relevant concentrations are not able to affect the expression of fundamental markers of Th1, Th2 
or Th17 cells, compared to palmitic acid. 
Hence, the observed shift towards increased Th2-propagation in activated T-cells is most likely 
caused by other butter-derived factors than PA.  
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Effect of dairy fat on plasma phytanic acid in
healthy volunteers - a randomized controlled
study
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Tine Tholstrup1
Abstract
Background: Phytanic acid produced in ruminants from chlorophyll may have preventive effects on the metabolic
syndrome, partly due to its reported RXR and PPAR- a agonist activity. Milk from cows fed increased levels of
green plant material, contains increased phytanic acid concentrations, but it is unknown to what extent minor
increases in phytanic acid content in dairy fat leads to higher circulating levels of phytanic acid in plasma of the
consumers.
Objective: To investigate if cow feeding regimes affects concentration of plasma phytanic acid and risk markers of
the metabolic syndrome in human.
Design: In a double-blind, randomized, 4 wk, parallel intervention study 14 healthy young subjects were given 45
g milk fat/d from test butter and cheese with 0.24 wt% phytanic acid or a control diet with 0.13 wt% phytanic
acid. Difference in phytanic acid was obtained by feeding roughage with low or high content of chlorophyll.
Results: There tended to be a difference in plasma phytanic acid (P = 0.0730) concentration after the dietary
intervention. Plasma phytanic acid increased significantly within both groups with the highest increase in control
group (24%) compared to phytanic acid group (15%). There were no significant effects of phytanic acid on risk
markers for the metabolic syndrome.
Conclusions: The results indicate that increased intake of dairy fat modify the plasma phytanic acid concentration,
regardless of cows feeding regime and the minor difference in dietary phytanic acid. Whether the phytanic acid
has potential to affects the risk markers of the metabolic syndrome in human still remain to be elucidated.
Trial Registration: ClinicalTrials.gov: NCT01343576
Keywords: Phytanic acid, cow-feeding regime, absorption, fatty acid, total cholesterol, LDL cholesterol, HDL choles-
terol, C-reactive protein, insulin, glucose
Background
Phytanic acid is a multi branched-chain fatty acid
formed through the metabolism of phytol, which is
released from the chlorophyll molecule in the rumen of
ruminant animals [1]. Hence, dairy-products, ruminant
meat and also some marine fats are the only major diet-
ary sources of phytanic acid or its metabolic precursor,
phytol [2]. Dietary intake of phytanic acid have been
suggested to be involved in both health- and disease
promoting processes, thus some researchers have sug-
gested that it can prevent diabetes and metabolic dis-
eases, while others have suggested that it promotes
development of prostate cancer [3,4].
The potential health-promoting properties is based on
the fact that animal and in vitro studies have shown
that phytanic acid might have preventive effects on
metabolic dysfunctions, since it in animal studies
increase expression of genes involved in fatty acid oxida-
tion, enhance glucose uptake and metabolism in hepato-
cyte and potentially reduce metabolic efficacy through
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increased differentiation of brown adipocyte differentia-
tion and expression of uncoupling protein-1 [5-7].
These effects have partly been explained by the PPAR
and RXR agonist activity of phytanic acid [6,8-10].
Hence, phytanic acid may be an interesting, though so
far overlooked, bioactive FA in dairy products with
potential positive effects on metabolic function. How-
ever, the suggested involvement of phytanic acid in
development of prostate cancer also needs to be taken
into consideration. To be able to evaluate the potential
risks and advantages of a dietary intake of phytanic acid,
we need more data on how intake of phytanic acid con-
taining foodstuffs affects levels of phytanic acid, as well
as data on effects on metabolic markers in humans.
Although earlier observational studies have found a sig-
nificant correlation between dairy fat intake and plasma
levels of phytanic acid [3,11,12] this is to over knowl-
edge, the first controlled human intervention study in
which the relation between dairy fat intake and plasma
phytanic acid are directly established.
It is well known that the FA composition of milk fat is
markedly influenced by the diet, especially by the
amount and FA profile of fat in the cattle fodder
[13-16]. Since phytanic acid is formed from metabolites
of chlorophyll degradation, the content in milk fat is
strongly dependent on the amount of chlorophyll-con-
taining material in the feed [17,18], and will also change
over the year depending on the content of green plant
material in the cows diet. A study has shown that the
phytanic acid concentration in milk fat increased from
0.15 mass% to 0.45 mass%, in cows fed grass only com-
pared to a group fed a mixture of rye grass and maize
silage [18] and it was recently shown that the concentra-
tion of phytanic acid is higher in organic than conven-
tional dairy products [19].
In this study the test fat was made from milk from
one herd divided into two groups that were fed either
“green” silage aiming after a moderate content of phyta-
nic acid (0.24 wt%) and “yellow” silage aiming after a
low content of phytanic acid (0.13 wt%). Thus, we have
investigated how the intake of two different butter and
cheese-types, affect plasma phytanic acid concentration
in humans. In addition, we investigate if intake of milk
fat from the green fed cows, affects the risk markers of
the metabolic syndrome differently from milk fat from
cows fed predominantly non-green feed.
Subjects and Methods
Study design
We conducted a 4 week, double-blind, randomized, par-
allel intervention study. In the intervention period sub-
jects were supplied with diets that differed in FA
composition, especially phytanic acid, by the Depart-
ment of Human Nutrition. Participants were stratified
according to baseline phytanic acid concentration in
plasma and sex into two treatment groups receiving
either a diet with a higher content of phytanic acid, phy-
tanic acid group, than the control diet with a low con-
tent of phytanic acid, control group. We assessed all
outcome variables at the start and end of the interven-
tion period.
Subjects
Male and female subjects, age 20 to 42, were recruited
by advertising in local newspapers. The baseline charac-
teristics of the 14 subjects who completed the study
were not different between the two groups (Table 1).
Exclusion criteria were: BMI > 30 kg/m2, current or pre-
vious chronic disease, regular use of medication, or drug
and alcohol abuse. All participants were apparently
healthy as indicated by a medical and lifestyle question-
naire. They all agreed to refrain from taking any dietary
supplements, from donating blood 2 months before and
during the study, and from taking any medication that
might interfere with study measurements. All subjects
were instructed to maintain the same level of physical
activity throughout the study. The subjects completed a
3-day weighed-food record before the intervention and
after two weeks of intervention, in order to assess
potential differences in dietary intake between the
groups before and during the intervention. All records
were coded before being evaluated by a clinical dietician,
who also calculated energy intake and dietary composi-
tion using a national database (Dankost; National Food
Agenty, Søborg, Denmark). Mean habitual energy
intakes were 10.3 MJ/d (range: 6.7-15 MJ/d); 30.9%
Table 1 Baseline characteristics for the 14 healthy
subjects participating in the 4 week intervention1
Treatment
Control group
(n = 5)
Phytanic acid group
(n = 9)
Women, n 2 6
Age, y 31.6 ± 10.3 (20-42) 28.3 ± 5.2 (21-36)
Height, cm 174.6 ± 12.8 (158-190) 171.5 ± 6.9 (162.5-181.5)
Weight, kg 68.7 ± 10.9 (56.1-80.25) 65.5 ± 9.5 (54.20-82.95)
BMI, kg/m2 22.4 ± 1.7 (20.36-24.5) 22.2 ± 2.1 (19.7-26.2)
Phytanic acid, μM 3.35 ± 1.49 (1.75-5.41) 2.93 ± 0.85 (1.89-4.12)
Glucose, mmol/L 5.53 ± 0.6 (5.11-6.58) 5.29 ± 0.33 (4.81-5.88)
Insulin, pmol/L 22.68 ± 11.88 (7.2-39.1) 29.86 ± 24.58 (7.2-86.6)
TAG, mmol/L 0.76 ± 0.35 (0.44-1.31) 0.88 ± 0.22 (0.63-1.32)
Total CH, mmol/L 4.22 ± 1.01 (3.14-5.38) 4.23 ± 0.83 (2.92-5.87)
LDL CH, mmol/L 2.39 ± 0.72 (1.67-3.24) 2.35 ± 0.54 (1.7-3.55)
HDL CH, mmol/L 1.41 ± 0.3 (1.04-1.83) 1.47 ± 0.3 (0.91-1.91)
CRP, mg/L 0.54 ± 0.96 (0,05-2.26) 1.25 ± 0.86 (0.05-2.62)
1Values are mean ± SD; range in parentheses. CPR, C-reactive protein; CH,
Cholesterol; TAG, Triacylglycerol. There were no significant differences
between baseline values in the 2 groups (ANCOVA).
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(23.7-37.8%) of energy was from fat, 15.1% (11.8-18.1%)
was from protein, and 52.2% (42.6-63.7%) was from car-
bohydrates. There were no significant different between
the 2 groups in habitual dietary intake. The protocol
and aims of the study were fully explained (orally and in
writing) to the participants, who gave written informed
consent. The Scientific-Ethical Committees for Copen-
hagen and Frederiksberg approved the research protocol
(H-B-2009-052).
Production of test milk
Milk for the human study was produced by the experi-
mental organic herd at Aarhus University by 56 Danish
Holstein cows with an average daily milk production of
39 kg with 4.46% fat. The cows were divided into two
groups and fed a concentrate consisting of 1:1 mixture of
oat grain and rapeseed cake with 11% fat. This concen-
trate constituted 40% of the diet. The remaining 60% of
the diet consisted of two types of silage, a “green” silage
aiming after a high content of phytanic acid and a “yel-
low” silage aiming after a low content of phytanic acid.
The green silage consisted of a mixture of white clover
grass and alfalfa silage, while the “yellow” silage consisted
of a mixture of corn silage, pea-barley whole crop silage
with a small proportion of white clover grass silage. Feed-
ing of the cows was initiated in November 2008 and milk
was collected from both groups over one week in Febru-
ary. The milk was transported to Thise Dairy (Roslev,
Denmark), where it was processed into butter and cheese.
The higher intake of chlorophyll-containing “green”
silage resulted in a phytanic acid content of 0.24 wt% in
the butter and cheese used for the phytanic acid group
compared to the control group were the “yellow” silage
resulted in a phytanic acid content of 0.13 wt%.
Diets and test fats
During the intervention period part of the diet of the
subjects was replaced with test foods, butter and cheeses
with differing FA compositions, provided by the Depart-
ment of Human Nutrition (Table 2). The test food was
butter and cheese with different concentration of phyta-
nic acid. The fatty acid (FA) composition of the test fats
in butter are presented in table 2. The FA composition
in the two test fats differed only slightly and phytanic
acid differed with 0.11 wt%. The test butter with the
highest content of phytanic acid, also had the highest
content of a-linolenic acid and a lower n-6:n-3 ratio of
about 1.8. This is in agreement with the higher propor-
tion of clover and grass in the green feeding regime.
The butter and cheese were incorporated into buns and
each day during the intervention the subjects were pro-
vided with 3 buns each day; two buns with butter and
one with cheese. The buns contained 4.1 MJ of energy,
with 10 E % from protein, 51 E % from carbohydrates,
and 39 E % from fat (47.9 g). All buns contained 13 g of
butter each; in addition the cheese bun also contained
32 g of 45+ cheese. This amount of butter and cheese
yielded a fat intake from the test diet of 45 g a day (17.5
MJ), which corresponded to approximately 50% of the
maximum recommended daily intake of fat for a subject
with a daily energy requirement of 10 MJ. To avoid
drop outs we decided to use test fat from both butter
and cheese.
Compliance
We used the concentration of pentadecanoic acid (15:0)
in plasma as an indicator of milk fat intake, and thus of
compliance, because 15:0 in serum is considered as a
valid marker for intake of milk fat in humans [20-22]. In
addition dietary records were used to reinforce the diet-
ary advice and strengthen compliance, and the results of
the last records were used in the calculation of dietary
changes during the study.
Blood sampling and analysis
After a 12-h overnight fast, venous blood was collected
before the intervention period (day 1) and at the end of
the intervention (day 28). Blood for FA analysis was col-
lected into tubes containing EDTA, which were kept on
ice, and the samples were centrifuged at 4°C and 2200 ×
g for 15 min.
Table 2 Fatty acid composition of the two test butter
Butter
Control (wt%) Phytanic acid (wt%)
6:0 1.52 1.51
8:0 1.04 1.2
10:0 2.35 2.31
12:0 2.66 2.60
14:0 9.89 10.07
14:1 0.66 0.62
15:0 0.89 0.91
16:0 22.55 24.80
16:1n-7 1.15 1.16
Phytanic acid 0.13 0.24
17:0 0.47 0.50
17:1 0.20 0.20
18:0 15.39 16.00
18:1n-9 trans 2.59 2.25
18:1n-9 cis 25.67 25.17
18:1n-7 0.92 1.31
18:2 n-6 trans 0.49 0.47
18:2 n-6 cis 1.53 1.48
20:0 0.35 0.27
18:3 n-6 0.00 0.00
18:3 n-3 0.48 0.83
≥20:0 0.69 0.29
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All samples were stored at -80°C until the samples
were analysed. All samples were analyzed at the Depart-
ment of Human Nutrition in Copenhagen, except from
the samples of phytanic acid and FA, which were ana-
lyzed at the Technical University of Denmark (DTU).
Blood lipids
We assessed serum LDL and HDL cholesterol by enzy-
matic colorimetric procedure (ABX Pentra LDL Direct
CP and ABX Pentra HDL Direct CP respectively) on
ABX Pentra 400 Chemistry Analyzer (HORIBA ABX,
Montpellier, France). Total cholesterol was assessed and
analyzed by enzymatic photometric procedure (CHOD-
PAP from ABX Pentra Cholesterol CP) on ABX Pentra
400 Chemistry Analyzer (HORIBA ABX, Montpellier,
France). The concentration of TAG was assessed and
analyzed by enzymatic colorimetric procedure (ABX
Pentra Triglycerides CP) on ABX Pentra 400 Chemistry
Analyzer (HORIBA ABX, Montpellier, France).
Fatty acid analysis in lipids and test fats
Total lipids were extracted and analyzed from blood
plasma samples as described by Tholstrup et al [23]
but using TAG C19:0 as internal standard. The test
fats/butters lipids were extracted according to the
method of Folch [24], while preparation of FAME was
performed as described earlier [23]. Response factor
was calculated for methyl esters of phytanic acid and
short-chained fatty acid, based on the response of pal-
mitic acid methyl ester (C16:0). The butter FAME
were separated on a 60-m Supelco SP-2380 column
(Sigma-Aldrich AS, Brøndby, Denmark) in a HP 6890
gas Chromatograph (GC), in split mode using He as
carrier gas. GC settings were: Injector temperature
260°C, split ratio 20: 1, carrier flow 1.2 ml/min, detec-
tor temperature 300°C, air flow in detector 300,0 ml/
min, hydrogen flow 35 ml/min. FAME were separated
using a temperature program starting at 50°C and ris-
ing to 160°C at 15°C/min; this temperature was kept
for 0 min, hereafter the temperature was raised to 182°
C at 1°C/min, and directly the temperature was raised
to 200°C at 10°C/min, and the oven was kept at 200°C
for 15 min before the temperature was raised to 225°C.
The final temperature was kept for 12 min (total run-
time 61.97 min). FAME was identified with authentic
standards, and FA masses were determined based on
the peak areas, compared with the internal standard.
The commercial standard for phytanic acid was par-
tially separated into two peaks, based on the stereoiso-
meric properties of phytanic acid. Both peaks were
identified in the butter, as well as in the plasma. The
separation was however not good enough to quantify
the distribution between the isomers. The phytanic
acid metabolite pristanic acid, was also separated in
the method, this fatty acid did however not reach
above the detection limit in any sample analyzed.
C-reactive protein
Blood for analysis of C-reactive protein was collected
into dry tubes; after samples were centrifuged at 2200 ×
g for 15 min at 20°C. Serum was stored at -80°C until
the samples were analysed. The CRP concentrations
were measured by using latex immunoturbidimetry
(ABX Pentra CRP CP) on ABX Pentra 400 Chemistry
Analyzer (HORIBA ABX, Montpellier, France).
Glucose and Insulin
Blood for analyses of insulin and glucose concentrations
was collected into dry tubes and fluoride citrate respec-
tively; after coagulation, the samples were centrifuged at
2200 × g for 15 min at 20°C. The samples were stored
at -80°C until the there were analysed. Insulin concen-
trations were measured in serum with a chemilumines-
cent immunometric assay on DPC Immulite 1000
(Siemens Medical Solutions Diagnostics, USA). The
intra-assay CV% for insulin was 4.73%. Glucose concen-
tration was measured in plasma and analyzed by enzy-
matic colorimetric procedure (ABX Pentra Glucose HK
CP) on ABX Pentra 400 Clinical Chemistry Analyzer
(HORIBA ABX, Montpellier, France).
Statistical analysis
We used an analysis of covariance (ANCOVA) to com-
pare effect of the two diets. The respective baseline
values were used as covariates, and the analyses were
thus adjusted for the baseline values of each response
variable. When necessary values were log transformed
to normalize the distribution of residual variance and to
obtain variance homogeneity. Statistical tests were per-
formed on the transformed data. Transformation was
necessary to ascertain the concentrations of HDL cho-
lesterol and CRP. SAS statistical software (version 9.2;
SAS institute Inc, Cary, NC) was used for all statistical
analyses. Data describing the characteristics of the parti-
cipants are summarized as mean ± SD, and data on out-
come variables are expressed as least squares (LS)
means ± SEM, adjusted for baseline values. We tested
baseline, age, BMI, phytanic acid and 15:0 for influence
on the results, but all these parameters were not include
in the statistical model, because no influence on results
were found.
Results
Dietary intake and body weight
No significant changes in body weight and habitual diet-
ary intake were observed during and after the interven-
tion period. We excluded 4 food records (2 from each
group) from wk 2 of the intervention from the statistical
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analysis. The distribution (% energy) of protein (P =
0.7180), carbohydrates (P = 0.7157), and total fat (P =
0.0774) did not differ between the groups.
Compliance
The increase of serum15:0 was highest in the control
group in which an average increase of 31% (p < 0.01 vs.
baseline) was observed compared to an increase of 20%
(p < 0.05 vs. baseline) in the phytanic acid group.
Althoug, there was no difference in 15:0 between the
two groups (p = 0,139), the higher increase could indi-
cate a higher consumption of dairy products during the
intervention in the control group.
Blood samples
There tended to be a slight difference in plasma phyta-
nic acid (P = 0.073) between the two groups (Table 3).
The study was not designed to compare baseline and
treatment, however, due to the explorative approach we
considered important to report that the results showed
a significant increase (P < 0.05) of plasma phytanic acid
within both groups. Noteworthingly, the increase was
highest in the control group where an average increase
of 24% was observed compared to an increase of 15% in
the phytanic acid group. There were no effects of the
two treatments on serum total (P = 0.700), LDL (P =
0.274) and HDL (P = 0.475) cholesterol, the triacylgly-
cerol (P = 0.202), CRP (P = 0.4043), serum insulin (P =
0.450) and serum glucose (P = 0.8126) (Table 3).
Discussion
In the current study we investigated to what extent milk
fat from cows fed either “green” or “yellow” silage affects
the concentration of phytanic acid in plasma in healthy
young men and female. The intake of “green” silage
resulted in a phytanic acid content of 0.24 wt% of total
test fat compared to 0.13 wt% in the control group. The
test fat was produced to mimic the variation we have
seen in dairy fat on the Danish market, with low
concentration of phytanic acid during the winter and
highest concentrations late in the grazing season.
The main finding of this study was a significant
increase of plasma phytanic acid within both groups,
regardless of cows feeding regime and test diet phytanic
acid content. The higher increase in plasma phytanic
acid in the control group compare to the phytanic acid
group is opposed to what we have expected. This could
be due to different compliance and/or random differ-
ences in phytanic acid metabolism between the groups.
Since phytanic acid is not produced endogenously in
human [25], the presence in the human body is of exo-
genous origin and ingested from the diet almost exclu-
sively as preformed phytanic acid [26]. The exogenous
origin of phytanic acid in human makes it reasonable to
assume, that the increased concentration of phytanic
acid found after the intervention, was due to an increase
intake in this period. When the concentrations of phyta-
nic acid in serum from 250 healthy humans were ana-
lyzed, it ranged from 0.04 to 11.5 μM [27]. The large
variation probably may illustrate that dietary habit are
determining the concentration of phytanic acid. How-
ever, genetic factors in regard to the efficacy by which
phytanic acid is metabolized may also play a role
[11,18]. Because the test diet substituted only a part of
the habitual diet the phytanic acid content in the test
diets cannot be regarded as being the sole source of
dietary phytanic acid. The low degree of control of
exposure to additional dietary phytanic acid intake
could potentially also have influenced the plasma phyta-
nic acid concentration in the subjects. Indeed, it may
have contributed to the surprisingly high increase of
plasma phytanic acid within the control group compare
to the phytanic acid group. This is supported by the
higher average increase of 15:0 in the control group
which seems to indicate a higher consumption of dairy
products during the intervention compare to the phyta-
nic acid group. In addition, the control group had a
higher mean phytanic acid and 15:0 concentrations at
baseline (data not shown), indicating a higher habitual
dairy fat intake, which also could explain the higher
concentration of phytanic acid after the intervention. A
second source for phytanic acid is marine food, but the
diet protocols of the subjects did not indicate any differ-
ence in habitual intake or during the intervention.
Although we in this study demonstrate that intake of
dairy products with a low concentration of phytanic
acid increase plasma phytanic acid concentrations, there
was unfortunately no significant difference between the
two groups. This may be related to the small number of
subjects, higher baseline phytanic acid levels in the con-
trol group, higher consuming of dairy fat in the non-test
component of the diet in the control group or a combi-
nation of the above. The modest difference in phytanic
Table 3 Effects of the 4-wk dietary intervention1
Treatment
Control group
(n = 5)
Phytanic acid group
(n = 9)
Phytanic acid, μM 4.16 ± 0.24 3.56 ± 0.18
Glucose, mmol/L 5.37 ± 0.10 5.34 ± 0.08
Insulin, pmol/L 33.05 ± 5.69 28.11 ± 4.22
Triacylglycerol, mmol/L 1.15 ± 0.15 0.9 ± 0.11
Total cholesterol, mmol/L 4.46 ± 0.2 4.56 ± 0.15
LDL cholesterol, mmol/L 2.59 ± 0.14 2.82 ± 0.10
HDL cholesterol, mmol/L 1.28 ± 1.10 1.41 ± 1.07
CRP, mg/L 0.26 ± 2.05 0.58 ± 1.77
1 All values are LSmeans ± SEM. CRP, C-reactive protein. ANCOVA; baseline
values were used as covariates.
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acid concentration in the test diets may not be consid-
ered to be very high but the differences are relevant
since it is similar to the seasonal variation occurring in
Danish dairy products. The current study does not give
indication of any possible effects of plasma phytanic
acid on the metabolic variables and potential risk of
developing the metabolic syndrome.
Although the two test butters also differed in the n-3/
n-6 ratio, due to a higher content of a-linolenic acid in
the phytanic acid rich butter, we do not consider this
differences relevant for the outcome of the intervention,
since intake of linoleic and a-linolenic acid from the
butters only contributed minimally to the test subjects
total intake of these fatty acids. Thus, intake of the con-
trol butter contributed with only about 675 mg linoleic
and 215 mg a-linolenic acid per day and the phytanic
acid rich butter with the same amount of linoleic acid
but with 380 mg a-linolenic acid. Since a typical daily
Danish intake of polyunsaturated fatty acids for men
and women are 14 and 10 g/day, respectively [28], the
contribution from the test-butters have only marginally
affected the total intake.
In the present study population, the plasma phytanic
acid concentration varied between 1.75 and 6.13 μM.
The EC50 for transactivation of all three RXR - isoforms
by phytanic acid have been determined to be between
2.3 and 4 μM [9,10]. This indicate that plasma phytanic
acid concentration in this study population occur in a
concentration in which it has physiological relevance as
a modulator of RXR-activity. Finally, the issue on the
association between prostate cancer risk and phytanic
acid intake needs to be taken into consideration. It has
been hypothesized that phytanic acid could be asso-
ciated with increased risk of prostate cancer [3]. How-
ever, no conclusive adverse effects of phytanic acid
intake and concentrations within the normal range in
healthy humans have been established and there is no
data in the literature indicating that the modest changes
in phytanic acid that are induced in present study,
would have negative impact on human health [29]
The strengths of our study include its controlled and
randomized design, follow-up of dietary compliance dur-
ing the study, the use of validated dietary marker to
monitor the dairy fat intake, the test fat was modified
from milk originating from dairy cattle from the same
herd, and the differences between the two types of test
fat was obtained through natural reproducible cow feed-
ing regimes. Furthermore the controlled cow feeding
procedure is also considered to be an advantage of the
study design. However, since the feeding regimes were
designed to mimic what is possible to perform in Danish
high-yielding herds, it was not possible to keep the cows
on pure green feeding-regime. It would therefore be
interesting to study the effect of dairy fat that are
derived from cows fed pure green material (e. g. grazing
cows), which would result in substantially higher con-
centration of phytanic acid, as well as other bioactive
fatty acids. Among the limitations were the relatively
high intakes of butter during the intervention. However,
the increase in dietary fat during intervention did not
differ between the two groups, and neither did the body
weight after the intervention. It is also possible that dif-
ference in random habitual dietary habits and compli-
ance such as and higher increase in serum 15:0,
indicating higher dairy intake, in the control group after
the intervention may have affected the results.
It would be relevant to use pure phytanic acid, but
this has not yet been possible due to high costs required
to produce purified synthetic phytanic acid products for
human intervention studies. There is a general lack of
evidence to support the results obtained in the study as
research on phytanic acid effect in human is missing.
Further research must elucidate if increase intake of
dietary phytanic acid might play a part in improving the
metabolic syndrome and increase the risk of prostate
cancer in human.
Conclusion
This study indicate that increased intake of dairy fat
modify the plasma phytanic acid concentration, regard-
less of cows feeding regime and the minor difference in
dietary phytanic acid content after 4 weeks. Further
feeding-studies, in which phytanic acid is used in phy-
siological relevant concentration, is essential before it is
possible to conclude whether increased intake of phyta-
nic acid have preventive effect on the metabolic syn-
drome in human.
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Abstract 1 
Background: There is considerable interest in dairy products from low-input system, such as 2 
mountain-pasture grazing cows, because of the belief that they are healthier than those from high-3 
input conventional systems. However, the effects of such products on human health have been poorly 4 
investigated.  5 
Objective: To compare the effect of milk from mountain-pasture grazing cows (green fodder 6 
milk/GFM) on risk markers of the metabolic syndrome and type-2 diabetes with the effect of 7 
conventional Danish milk (control fodder milk/CFM). The study aims to investigate the importance 8 
of phytanic acid content for any apparent effects.  9 
Design: In a double-blind, randomized, 12-week, parallel intervention study, 38 healthy subjects 10 
replaced part of their habitual dietary fat intake with 39 g fat from test butter made from milk from 11 
mountain-pasture grazing cows from Norway or Danish cows fed conventional winter fodder. Insulin 12 
sensitivity was tested by an oral glucose tolerance test before and after the intervention, and blood 13 
was sampled on these occasions. 14 
Results: No difference in blood lipids, lipoproteins, CRP, insulin and glucose were observed. 15 
However, green fodder resulted in a higher LDL cholesterol and insulin concentration compared with 16 
habitual diet. Surprisingly strong correlations between phytanic acid at baseline and total- 17 
(P<0.0001) and LDL-cholesterol (P=0.0001) were observed.  18 
Conclusions: We did not find that butter produced from milk from mountain-pasture grazing cows is 19 
more beneficial for health.  It is possible that phytanic acid may increase total and LDL cholesterol 20 
and have a negative effect on insulin-sensitivity in human.  21 
 22 
 23 
 24 
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Introduction 1 
Increased consumer awareness of the link between diet and health has led to research focused on 2 
altering the fatty acid (FA) composition of cows’ milk to achieve a FA profile consistent with 3 
consumer perceptions of a healthy diet and with public health recommendations. However, 4 
modification of the FA content of milk fat in dairy cows is affected significantly by the extensive 5 
metabolism of lipids that occurs in the rumen and requires an understanding of the interrelationship 6 
between dietary supply of lipids, rumen fermentation, and mammary synthesis of milk fat. Important 7 
targets include reducing the amount of long-chain saturated fatty acids  (SFA´s) such as C12:0-8 
C16:0, enhancing oleic acid to reduce cardiovascular risk, and generally increasing concentrations of 9 
mono- and poly-unsaturated fatty acid (MUFA and PUFA) (1-9).  10 
It is well known that the FA composition of milk fat is markedly influenced by the diet, especially by 11 
the amount and FA profile of fat in the cattle fodder (10-13). The addition of forage, especially of 12 
fresh grass, to  fodder has been found to enhance the proportion of unsaturated FAs in milk fat (14-13 
16), and to elevate the concentration of conjugated linoleic acid (CLA) (16;17). Unlike commercial 14 
CLA, which has proved to be a biologically active fatty acid with beneficial effects on diseases such 15 
as cancer, diabetes, and obesity in animal models (18-20), the major CLA isomer in ruminant fat, c-16 
9, t-11 CLA, appears to be neutral. The majority of human studies of c-9, t-11 CLA isomer general 17 
find no significant effects on CVD risk markers, such as blood lipids (21-25), inflammatory markers 18 
(24;25), and adhesion molecules (24;25). However, the markedly higher intake of chlorophyll-19 
containing green fodder in grazing cows also results in a high phytanic acid content in the milk 20 
(26;27). Phytanic acid may be an interesting, though so far overlooked, bioactive FA with potential 21 
positive effects on metabolic function. Phytanic acid is a multi-branched fatty acid with reported 22 
retinoid X receptor (RXR) and peroxisome proliferatoractivated receptor-α (PPAR-α) agonist 23 
activity (28-33). It has been suggested that phytanic acid, because of due the reported RXR and 24 
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PPAR-α agonist activity (28-30;34) and its ability to induce glucose uptake in hepatocytes, may 1 
prevent metabolic dysfunctions related to the development of metabolic syndrome (19). 2 
In the present study the milk derived from mountain-pasture grazing cows from Norway (GFM) or 3 
from conventionally fed Danish cows (CFM). Fat in the GFM had a lower content of cholesterol-4 
raising SFA´s (C12:0-C16:0) and higher content of c-9, t-11 CLA, alpha-linolenic acid (C18:3 n-3) 5 
phytanic acid, and trans-vaccenic acid (C18:1 t-11) than the CFM and thus tended to produce a more 6 
favourable FA profile. These impacts of feeding are well described and are considered advantageous 7 
from nutritional point of view.  However, the actual effects on human health of milk from pasture 8 
grazing cows have been poorly investigated. The objective of the present study was to investigate the 9 
effects on risk markers of the metabolic syndrome and type-2 diabetes in healthy human of a diet 10 
containing milk delivered from mountain-pasture grazing cows (green fodder milk/GFM) with that 11 
of a diet containing milk fat of typical Danish composition (control fodder milk/CFM). No data 12 
exists on the effects of phytanic acid in a normal diet so we have focussed on this particular fatty 13 
acid. 14 
 15 
Subjects and Methods 16 
Study design  17 
We conducted a 12 week, double-blind, randomized, parallel intervention study.  In the intervention 18 
period subjects were supplied with diets that differed in FA composition by the Department of 19 
Human Nutrition. Participants were stratified according to baseline blood glucose level, gender, and 20 
waist circumference, into two treatment groups receiving either GFM or CFM. Insulin sensitivity 21 
was tested by an oral glucose tolerance test (OGTT) before and after the intervention and blood 22 
samples were taken on these occasions. 23 
 24 
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Subjects 1 
Male and female subjects, age 50 to 70, were recruited by advertising in local newspapers. The 2 
baseline characteristics of the 38 subjects who completed the study are given in Table 1. There 3 
tended to be a significant difference in HDL cholesterol (P=0.056) between the two groups at 4 
baseline. No other differences were observed. Exclusion criteria were: BMI > 30 kg/m2, current or 5 
previous chronic disease, regular use of medication, or drug and alcohol abuse. All participants were 6 
apparently healthy as indicated by a medical and lifestyle questionnaire. They all agreed to refrain 7 
from taking any dietary supplements, from donating blood 2 months before and during the study, and 8 
from taking any medication that might interfere with study measurements. All subjects were 9 
instructed to maintain the same level of physical activity throughout the study. The subjects 10 
completed a 3-day weighed-food record before the intervention and after six weeks of intervention, 11 
in order to assess potential differences in dietary intake between the groups before and during the 12 
intervention. All records were coded before being evaluated by a clinical dietician, who also 13 
calculated energy intake and dietary composition using a national database (Dankost; National Food 14 
Agency, Søborg, Denmark). Mean habitual energy intakes before the intervention were 8.6 MJ/d 15 
(range: 5.6-15.8 MJ/d); 33.5% (24.2-48.2%) of energy was from fat; 16.3% (11.6-22.8%) was from 16 
protein; and 45.7% (30-58.3%) was from carbohydrates. Carbohydrate intake in the GFM group 17 
(43.86 ± 5.47 E%) was reported to be lower than in the CFM group (47.84 ± 5.27 E%) (P=0.029) 18 
when expressed as E%, but not when expressed as g/d. There were no other differences in habitual 19 
dietary intake between the two groups.  The protocol and aims of the study were fully explained 20 
(orally and in writing) to the participants, who gave written informed consent. The Scientific Ethics 21 
Committee of the Copenhagen and Frederiksberg approved the research protocol (H-B-2009-052). 22 
 23 
Production of test milk 24 
 The American Journal of Clinical Nutrition AJCN/2011/021071 Version 1
7 
 
Milk fat for the human study was derived from milk from paster grazing cows in Norway or 1 
conventionally fed Danish cows. The two types of milk produced differed in FA composition. The 2 
markedly higher intake of chlorophyll-containing green fodder in the grazing cows resulted in a high 3 
phytanic acid content in the GFM compared to the conventional Danish milk. The conventional 4 
Danish milk was provided by Arla Food and originated from 47 farms, where all the milk was 5 
collected in October. Cattle feeding routines were traditional and farmers selected fodder ingredients 6 
and made their own mixtures. Conventional Danish milk cattle fodder consists of a mixture of corn 7 
silage (35%), wheat-barley silage (25%), clover grass silage (20%), soybean meal or rapeseed cake 8 
(10%), and a small proportion of molasses or beet pellets, straw, vitamins and minerals. Both types 9 
of milk were transported to Tine Dairies (Oslo, Norway) where the fat was processed into butter.  10 
 11 
Diets and test fats 12 
During the intervention period part of the diet of the subjects was replaced with test foods, butters 13 
with differing FA compositions, provided by the Department of Human Nutrition (Table 2). The FA 14 
composition in the GFM had a 1.3-fold lower content of the cholesterol-raising lauric, myristic and 15 
palmitic acid (C12:0; C14:0 and C:16:0) (36 vs. 45 wt%), a 1.3-fold higher content of stearic acid 16 
(C18:0) (11 vs. 15 wt%), a 1.4-fold higher content of  trans-vacceninc acid  (C18:1 t-11) (1.7 vs. 2.4  17 
wt%), 1.2-fold higher content of oleic acid (C18:1 c-9) (26 vs. 22 wt%), and a 1.5-fold higher 18 
content of  α-linolenic acid (C18:3 n-3) (0.9 vs. 0.6 wt%) compared to CFM butter. Furthermore, the 19 
n-6/n-3 ratio was 1.8 fold lower in the GFM butter (1.6 vs. 2.9). The butter was incorporated into 20 
buns and during the intervention subjects were provided with 3 buns each day.  21 
The buns contained 3.5 MJ of energy, with 7.5 E% from protein, 56 E% from carbohydrates, and 22 
36.4 E% from fat. All buns contained 13 g of butter each, which yielded a fat intake from the test diet 23 
of 39 g a day (15 MJ), corresponding to approximately 15 E% of the subjects daily intake of fat.  24 
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Compliance 1 
We used the concentration of pentadecanoic acid (C15:0) in plasma as an indicator of milk fat intake, 2 
and thus of compliance, because C15:0 in serum is considered as a valid marker for intake of milk fat 3 
in humans (35-37). In addition dietary records were used to reinforce the dietary advice and 4 
strengthen compliance, and the results of the last records were used in the calculation of dietary 5 
changes during the study. 6 
 7 
Blood sampling and analysis 8 
After a 12-h overnight fast, venous blood was collected before the intervention period (day 1) and at 9 
the end of the intervention (day 84). Blood for FA analysis was collected into tubes containing 10 
EDTA, which were kept on ice, and the samples were centrifuged at 4 °C and 2200 × g for 15 min.  11 
All samples were stored at -80 °C until the samples were analysed. All samples were analyzed at the 12 
Department of Human Nutrition in Copenhagen, except the FA-analyses, which were performed at 13 
the Technical University of Denmark. 14 
 15 
Blood lipids  16 
We assessed serum LDL and HDL cholesterol by enzymatic colorimetric procedure (ABX Pentra 17 
LDL Direct CP and ABX Pentra HDL Direct CP respectively) on ABX Pentra 400 Chemistry 18 
Analyzer (HORIBA ABX, Montpellier, France). Total cholesterol was assessed and analyzed by 19 
enzymatic photometric procedure (CHOD-PAP from ABX Pentra Cholesterol CP) on ABX Pentra 20 
400 Chemistry Analyzer (HORIBA ABX, Montpellier, France). The concentration of TAG was 21 
assessed and analyzed by enzymatic colorimetric procedure (ABX Pentra Triglycerides CP) on ABX 22 
Pentra 400 Chemistry Analyzer (HORIBA ABX, Montpellier, France).  23 
 24 
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Fatty acid analysis in lipids and test fats 1 
Total lipids were extracted and analyzed from blood plasma samples as described by Tholstrup et al 2 
(38) but using  TAG C19:0 as internal standard. The test fats/butters lipids were extracted according 3 
to the method of Folch (39), while preparation of FAME was performed as described earlier (38).  4 
Response factor was calculated for methyl esters of phytanic acid and short-chained fatty acid, based 5 
on the response of palmitic acid methyl ester (C16:0). The butter FAME were separated on a 60-m 6 
Supelco SP-2380 column (Sigma-Aldrich AS, Brøndby, Denmark) in a HP 6890 gas Chromatograph 7 
(GC) in split mode using He as carrier gas. GC settings were: Injector temperature 260 ⁰C, split ratio 8 
1:20, carrier flow 1.2 mL/min, detector temperature 300 ⁰C, air flow in detector 300,0  mL/min, 9 
hydrogen flow 35 mL/min. FAME were separated using a temperature program starting at 50 ⁰C and 10 
rising to 160 ⁰C at 15 ⁰C /min; this temperature was kept for 0 min, hereafter the temperature was 11 
raised to 182 ⁰C at 1 ⁰C /min, and directly the temperature was raised to 200 ⁰C at 10 ⁰C /min, and 12 
the oven was kept at 200 ⁰C for 15 min before the temperature was raised to 225 ⁰C. The final 13 
temperature was kept for 12 min (total runtime 61.97 min). FAME was identified with authentic 14 
standards, and FA masses were determined based on the peak areas compared with the internal 15 
standard. 16 
 17 
C-reactive protein  18 
Blood for analysis of C-reactive protein (CRP) was collected into dry tubes; after samples were 19 
centrifuged at 2200 × g for 15 min at 20 °C. Serum was stored at -80 °C until the samples were 20 
analysed. The CRP concentrations were measured by using latex immunoturbidimetry (ABX Pentra 21 
CRP CP) on ABX Pentra 400 Chemistry Analyzer (HORIBA ABX, Montpellier, France).  22 
 23 
Glucose, insulin and C-peptide  24 
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Blood for analysis of glucose, insulin and C-peptide concentrations was collected into respectively 1 
dry tubes and tubes with fluoride citrate; for both serum and plasma preparation the samples were 2 
centrifuged at 2200 × g for 15 min at 20 °C after coagulation. The samples were stored at -80 °C 3 
until analysis. Insulin and C-peptide concentrations were measured in serum with a 4 
chemiluminescent immunometric assay on DPC Immulite 1000 (Siemens Medical Solutions 5 
Diagnostics, USA). Glucose concentration was measured in plasma and analyzed by enzymatic 6 
colorimetric procedure (ABX Pentra Glucose HK CP) on ABX Pentra 400 Clinical Chemistry 7 
Analyzer (HORIBA ABX, Montpellier, France).  8 
 9 
Oral glucose tolerance test  10 
A standard 75-g OGTT was administered at baseline and after 12 weeks of the study, with blood 11 
sampled for glucose and C-peptide at 0, 15, 30, 60, 90, 120 and 180 minutes (40). Three-hour C-12 
peptide and glucose area under the curve (AUC) were calculated from the OGTT data, in millimol 13 
per minute per liter for glucose, and picomol per minute per liter for C-peptide. Glucose and C-14 
peptide AUCs are the sum of the area of each time segment by C-peptide or glucose concentration. 15 
C-peptide AUC is approximate measures of C-peptide secretion in response to a standard oral 16 
glucose load. 17 
 18 
Statistical analysis 19 
We used an analysis of covariance (ANCOVA) to compare the effects of the two diets and used the 20 
respective baseline values as covariates. The analyses were thus adjusted for the baseline values of 21 
each variable. When necessary values were log transformed to normalize the distribution of residual 22 
variance and to obtain variance homogeneity. Statistical tests were performed on the transformed 23 
data. Transformation was necessary to allow parametric statistical analyses of the concentrations of 24 
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glucose, triacylglycerol (TAG), CRP, insulin, C-peptide AUC and glucose AUC. SAS statistical 1 
software (version 9.2; SAS institute Inc, Cary, NC) was used for all statistical analyses. Data 2 
describing the characteristics of the participants are summarized as mean ± SDs, and data on 3 
outcome variables are expressed as least squares (LS) means ± SEM, adjusted for baseline values. 4 
We tested baseline, smoking, age, and BMI for influence on the results, but these parameters were 5 
not included in the statistical model because no effects were found. A minimum level of p < 0.05 was 6 
used to establish significant differences between groups. To analyze data from the OGTT, repeated 7 
measures analysis of variance were used to assess effects over time, differences between the 8 
experimental fats, and interaction between effects of time and type of milk fat during the 3 hours 9 
period of OGTT. If a significant interaction between effects of time and type of fat is found, it means 10 
that the mean difference between the two fats varies with time. Graphs of the time course were used 11 
to illustrate the means difference. In the case of a significant interaction the tests for type of fat and 12 
time effects are not meaningful, and therefore not reported. If, however, there is no significant 13 
interaction, it means that the two time courses can be regarded as parallel, and the effects of time and 14 
type of fat can be tested separately. We used an ANCOVA to compare the AUC for glucose and 15 
AUC for C-peptide. Pearson coefficients (r) and the corresponding probabilities of the statistical 16 
significance of correlations (p) were calculated between baseline values. 17 
 18 
Results 19 
Compliance  20 
There was no difference in plasma C15:0 after the intervention, and the average increase in C15:0 21 
from baseline was around 20% in both groups, which indicates the consumption of a similar amount 22 
of dairy products in both groups during the intervention (data not shown).  23 
 24 
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Dietary intake and bodyweight  1 
Both groups had a minor weight gain during the intervention, (0.93 ± 0.78 and 0.89 ± 1.39 kg for 2 
CFM and GFM respectively), but the weight gain did not differ between the groups when expressed 3 
as kg body weight (P=0.800) or BMI (P=0.547). A dietician evaluated all dietary records. One record 4 
from the GFM group was incomplete and therefore excluded from the statistical analysis. The energy 5 
and macronutrient content in the participants  ´daily diet during the intervention were calculated from 6 
the dietary records (Table 3). The distribution (% energy) of protein (P=0.89), carbohydrates 7 
(P=0.69), and total fat (P=0.40) did not differ between the two groups.  8 
  9 
Blood samples 10 
No significant differences were observed between GFM and CFM in serum total cholesterol 11 
(P=0.44), LDL cholesterol (P=0.49), HDL cholesterol (P=0.45), TAG (P=0.39), CRP (P=0.65), 12 
insulin (P=0.77), C-peptide (P=0.91), plasma glucose (P=0.53) or plasma phytanic acid (P=0.18) 13 
(Table 4). There was no significant difference between the AUCs for either glucose (P=0.89) or C-14 
peptide (P=0.65) after the test diets (Figure 1). There were no significant differences in the time 15 
course of glucose and C-peptide concentrations after the two different test fats, or in the mean 16 
glucose and C-peptide concentrations, according to the repeated-measures analysis of variance 17 
(Figure 1).  18 
The study was not designed to compare baseline and treatment. However, assessment of diet prior to 19 
intervention allowed us to compare the effect of treatment and habitual values. Due to the explorative 20 
approach we consider it relevant to report the results, which show that GFM resulted in a higher 21 
increase in total-, LDL-, HDL-cholesterol and insulin concentrations than CFM. GFM resulted in 22 
5.5% (0.34 mmol/L) higher total cholesterol (P=0.006); 6.5% (0.23 mmol/L) higher LDL cholesterol 23 
(P=0.003); 5.2% (0.08 mmol/L) higher HDL cholesterol (P=0.016); 9.3% (3.15 pmol/L) higher 24 
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insulin (P=0.039); and 18% (0.66 mmol/L) higher phytanic acid (P<0.0001) than habitual diet. No 1 
other significant differences were observed (data not shown). CFM resulted in 4.2% (0.24 mmol/L) 2 
higher total cholesterol (P=0.016); 4.7 % (0.16 mmol/L) higher LDL cholesterol (P=0.053); 3.7% 3 
(0.05 mmol/L) higher HDL cholesterol (P=0.045); and 12% (0.4 mmol/L) higher phytanic acid 4 
(P=0.033) than habitual diet. No other significant differences were observed (data not shown). There 5 
was no difference between the effect of diets on total cholesterol/HDL ratio (GFM compared to 6 
CFM: P=0.923); (CFM compared to habitual diet: P=0.664); (GFM compared to habitual diet: 7 
P=0.711). 8 
There were substantial differences in the FA composition of the two test diets, but this did not lead to 9 
any significant differences between groups in the erythrocyte FA composition (data not shown).  10 
There were strong correlations between plasma phytanic acid at baseline and total cholesterol 11 
(r2=0.42, P<0.0001), LDL cholesterol (r2=0.35, P=0.0001). The correlation between plasma C15:0 12 
and both total cholesterol and LDL cholesterol was weaker (r2=0.14, P=0.02 and r2=0.11, P=0.04, 13 
respectively), although there was a strong correlation between plasma C15:0 and phytanic acid 14 
(r2=0.44, P<0.0001) (Table 5). 15 
 16 
Discussion 17 
This study was designed to compare the effect of butter produced from milk from mountain-pasture 18 
grazing cows with conventional Danish butter on risk markers of the metabolic syndrome and type-2 19 
diabetes in healthy humans. The FA composition of the GFM had a lower content of the cholesterol-20 
raising SFAs, lauric,  myristic and palmitic acid, and a substantially lower n-6/n-3 ratio than CFM, 21 
while the content of stearic- ,oleic- and trans-vaccenic acid was significantly higher in the GFM. 22 
However, despite the differences in FA composition, there were no differences between diets in 23 
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effect on the metabolic parameters or on CRP. However, GFM resulted in a higher increase in total, 1 
LDL, and HDL cholesterol than CFM.  2 
A previous study where 16% of the cholesterol-raising SFA, especially palmitic acid, was replaced 3 
by mainly oleic and stearic acid, did not result in any changes in LDL cholesterol (41), which is in 4 
line with the present findings. However, this is in contrast to the findings of Noakes et al (42), who 5 
concluded that modifying the fat composition of dairy products through the substitution of 6 
cholesterol-raising SFAs with oleic, linoleic and linolenic acids results in a decrease of 0.28 mmol/L 7 
in total plasma cholesterol. The control diets in the study by Noakes et al and in our study were 8 
similar, but the absolute palmitic and myristic acid content was lower, and oleic acid and PUFA 9 
higher (42). Calculated according to the Mensink and Katan equation (5) the change in total serum 10 
cholesterol in our study when changing from the CFM to GFM would be -0.53 mmol/L (the energy 11 
from vaccenic acid was not included in the equation), but we did not find this to be the case. A 12 
reasonable explanation, reported by results from studies by Kris-Etherton s´ group, could be that the 13 
cholesterol-lowering effect of MUFA is obscured when C12:0, C14:0 and C16:0 is high (8). This 14 
may indicate a threshold value for the ratio between cholesterolemic and beneficial FA which has to 15 
be passed to obtain reduction in plasma total cholesterol. This might not have been the case in our 16 
study and in Tholstrup et al (41), in which a substitution of cholesterolemic SFA with oleic and 17 
stearic acid did not result in a decrease in LDL cholesterol. However, a combination of a relative 18 
lower SFA and substantially  higher linoleic and oleic acid in Noakes et al (42) compared to our 19 
study, could be one of the reasons why the hypocholesterolemic effects of oleic and linoleic acid 20 
were successfully “expressed”. 21 
 An increase in ruminant trans FA (rTFA) was a side effect of manipulating the cattle fodder. Two 22 
recent clinical studies found an increase in plasma LDL cholesterol in conjunction with high daily 23 
rTFA intakes: 10-12 g/d, representing 3.6-5% of energy (43;44), but not at 4.2 g/d, representing 1.5% 24 
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of energy intake (43). Another study observed that the consumption of a rTFA-enriched butter (3.6 1 
g/d) lowered total and HDL cholesterol by 6% and 9% respectively, compared to a butter low in 2 
rTFA and high in SFA. The authors concluded that these effects may have been partly attributable to 3 
the higher MUFA and lower SFA content in the rTFA-enriched butter, rather than to the effects of 4 
rTFA alone (45). We also consider it unlikely that rTFA increased LDL cholesterol concentrations in 5 
this study, because no effect of daily rTFA intakes of 4.2 g/d (43) compared with 1g/d and 0.7 g/d 6 
from test food was observed in the current study.  7 
The intake of fresh grass also elevated the concentration of CLA in the milk (16;17). CLA has been 8 
reported to reduce aortic atherosclerosis in animal studies (46;47). One study in which the CLA 9 
content was enriched by rumen technology to provide 1.42 g/d of c-9, t-11 CLA in dairy products 10 
failed to affect LDL cholesterol (25). A similarly produced modified butter that provided substantial 11 
amounts of CLA (4.22g/d) also failed to affect LDL cholesterol (21), which is in line with results 12 
from another study with a daily intake of 5 g of milk CLA. (24). We also consider it unlikely that 13 
CLA could increase LDL cholesterol concentrations in this study. 14 
A focus of the present study was to investigate whether milk fat with a high phytanic acid 15 
concentration affects risk markers of the metabolic syndrome and the risk of type-2 diabetes. We 16 
found a significant increase in plasma phytanic acid in both groups, verifying that an intake of dairy 17 
products with relatively low concentrations of phytanic acid increases circulating phytanic acid 18 
concentration, which is in agreement with results from another recent study conducted by our group 19 
(accepted).  In the present study we found surprisingly strong correlations between phytanic acid at 20 
baseline, total cholesterol (r2=0.42, P<0.0001) and LDL cholesterol (r2=0.35, P=0.0001). The 21 
baseline phytanic acid level probably reflects habitual dairy fat intake, which means that the strong 22 
correlations could be due to the hypercholesterolemic effect of dairy fat. This interpretation is 23 
supported by the fact that plasma phytanic acid and plasma C15:0 corresponds very strongly at 24 
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baseline (r2=0.44, P<0.0001). However, the correlations between plasma C15:0 and both total 1 
cholesterol (r2=0.14, P=0.02) and LDL cholesterol (r2=0.11, P=0.04) are substantially weaker than 2 
those observed for phytanic acid. This suggests that phytanic acid increases LDL-cholesterol beyond 3 
levels that can be explained solely from dairy fat intake. It might therefore also be suggested that the 4 
higher increase in total and LDL cholesterol in the GFM group could be due to the higher phytanic 5 
acid concentration of this diet, giving rise to a higher average increase in plasma phytanic acid in this 6 
group.  7 
We observed no differences in effects on glucose or insulin concentration. However, it is particularly 8 
noteworthy that GFM caused a significant increase in fasting insulin, which was not seen with the 9 
CFM. Prior to the present study, the available literature supported the hypothesis that phytanic acid 10 
might have preventive effects on metabolic dysfunctions related to the development of the metabolic 11 
syndrome (28-30;34). In particular the RXR-activating ability of phytanic acid is of interest, since 12 
RXR is activated by concentrations at the same level as the phytanic acid concentrations reached in 13 
plasma in present study (21). It has been shown that drugs that activate RXR and PPAR-α have a 14 
marked impact on whole body metabolism and act as insulin-sensitizers or as hyperlipidemic agents 15 
(31;32), while it is not clear to what extent dietary changes in natural agonist concentrations are of 16 
physiological importance in humans. The significantly higher increase in insulin and the higher 17 
concentration of phytanic acid in the GFM group could, however, indicate that phytanic acid at 18 
physiological concentrations has a negative effect on insulin sensitivity in humans rather than a 19 
positive effect.  20 
The strengths of our study include its controlled and randomized design, the long intervention period, 21 
follow-up of dietary compliance during the study, and the use of a validated dietary marker to 22 
monitor the dairy fat intake. The study was also designed to investigate dietary changes caused by an 23 
increased intake of dairy products in a realistic setting, and the plasma phytanic acid concentration in 24 
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this study population occurred in a concentration which has physiological relevance as a modulator 1 
of RXR-activity. Among the limitations were the relatively high intakes of butter during the 2 
intervention. Our data cannot determine whether the higher increase in LDL cholesterol and insulin 3 
in the GFM group was causally related to the increased concentration of phytanic acid in the diet or 4 
whether other constituents of the butter may have played a role. Further research is needed to 5 
elucidate whether dietary phytanic acid has a negative or a positive effect in humans. 6 
 In conclusion, we did not find that milk derived from mountain-pasture grazing cows was more 7 
beneficial to human health conventionally produced Danish milk. One possible reason for this may 8 
be that any decrease in LDL cholesterol arising from the substituting of palmitic acid with oleic acid 9 
and stearic acid was obscured by the relatively high content of cholesterolemic SFAs in milk fat. Our 10 
results also suggest that the higher content of phytanic acid might be an additional explanation for 11 
the lack of effect. It could be suggested that phytanic acid increases total and LDL cholesterol and 12 
have a negative effect on insulin sensitivity in human. Additional studies will be necessary to clarify 13 
the effect of phytanic acid on risk markers of the metabolic syndrome.  14 
 15 
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TABLES 1 
Table 1.  Baseline characteristics for the 38 healthy subjects participating in the 12 week 2 
intervention1 3 
  CFM GFM 
Subjects, (n) 18 20 
Women, (n,%) 55.6 % 65 % 
Age, (y) 60.7 ± 5.9 (50-69) 61.9 ± 4.9 (52-69) 
Height, (cm) 173.2 ± 7.5 (159.8-188) 170.5 ± 8.4 (158-187) 
Weight, (kg) 79.9 ± 15.5 (61.35-122.6) 73.6 ± 8.4 (56.3-93) 
BMI, (kg/m2) 26.5 ± 3.6 (21.22-34.69) 25.4 ± 2.7 (20.81- 30.55) 
Glucose, (mmol/L) 5.7 ± 0.47 (5.14-6.57) 5.6 ± 0.51 (5.02-7.14) 
Insulin, (pmol/L) 41.39 ± 35.04 (7.2-127) 30.59 ± 20.05 (7.2-90.75) 
C-peptide, (pmol/L)  611.78 ± 287.82 (298-1299.5) 566.23 ± 224.03 (349.5-1065.5) 
TAG, (mmol/L) 1.27 ±0.59 (0.73-2.74) 1.17 ± 0.46 (0.76-2.62) 
Total-cholesterol, (mmol/L) 5.51 ± 0.86 (3.98-7) 5.82 ±  1.15 (3.95-7.53) 
LDL-cholesterol, (mmol/L) 3.25 ± 0.59 (2.45-4.21) 3.29 ± 0.83 (1.46-4.53) 
HDL-cholesterol, (mmol/L) 1.29 ± 0.31 (0.75-1.73) 1.46 ± 0.29 (1.02-2.06) 
CRP, (mg/L) 1.02 ± 0.93 (0.05-3.11) 1.18 ± 1.46 (0.05-5.42) 
Phytanic acid, (μM) 3.01 ± 0.61 (2.3-4.28) 3.02 ± 0.69 (1,98-4,76) 
Total:HDL-cholesterol  4.27 ± 2.77 (5.31-4.05) 3.99 ± 3.97 (3.87-3.65) 
1
 Values are mean ± SD; range in parentheses. CPR, C-reactive protein; TAG, Triacylglycerol. There 4 
were no significant differences between baseline values in the interventions groups (mixed model 5 
analysis of covariance. ANCOVA).  6 
 7 
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Table 2. Fatty acid composition of the two test butter. 1 
 % wt 
Control fodder 
milk 
Green fodder 
milk 
C4:0 0.80 1.04 
C6:0 1.36 1.32 
C8:0 1.08 0.96 
C10:0 2.79 2.17 
C12:0 3.43 2.58 
C14:0 11.0 9.43 
C14:1 0.98 0.71 
C15:0 1.08 0.88 
C16:0  31 24.4 
C16:1 n-7 1.58 1.15 
Phytanic acid  0.17 0.37 
C17:0  0.51 0.60 
C17:1 0.21 0.24 
C18:0 11.1 15.1 
C18:1 t-11 1.71 2.45 
C18:1 n-9     21.5 25.8 
C18:1 n-7 0.94 0.39 
c-9, t-11 CLA 0.58 0.73 
C18:2 n-6  1.79 1.52 
C18:3 n-3 0.61 0.93 
 2 
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Table 3.  Macronutrient intake after 6 weeks of the intervention diets1 1 
% of energy CFM GFM 
Protein 14.3 ± 0.4 14.3 ± 0.4 
Carbohydrates 46.7 ± 1.3 47.5 ± 1.3 
Total Fat 35.1 ± 0.9 34.0 ± 0.9 
Saturated FAs 15.8 ± 0.7 16.0 ± 0.7 
Monounsaturated FAs 10.6 ± 0.4 10.2 ± 0.4 
Polyunsaturated FAs 3.6 ± 0.2 4.0 ± 0.2 
1
 All values are means ± SEM. FAs: Fatty acids.  Values were obtained from 3-day weighed food 2 
records. One dietary record was incomplete and therefore excluded from the statistical analysis.  3 
No significant differences between the two groups were found (mixed model analysis of covariance. 4 
ANCOVA; mean values adjusted for baseline values which were used as covariates). 5 
 6 
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Table 4. Effects of the 12-wk dietary intervention1 1 
 CFM                                               GFM 
Glucose, (mmol/L) 5.7 ± 1.01  5.6 ± 1.01  
Insulin, (pmol/L) 31.7 ± 1.09  32.9 ± 1.08  
C-peptide, (pmol/L) 581.3 ± 1.04  577.7 ± 1.04  
TAG, (mmol/L)  1.1  ± 1.06  1.2  ± 1.06  
Total-cholesterol, (mmol/L)  5.9 ± 0.09   6.0 ± 0.08  
LDL-cholesterol, (mmol/L)  3.4  ± 0.21  3.5  ± 0.2  
HDL-cholesterol, (mmol/L) 1.4 ± 0.03   1.5 ± 0.03  
CRP, (mg/L) 0.6  ± 1.28  0.8  ± 1.26  
Phytanic acid, (μM) 3.4 ± 0.14 3.7 ± 0.13 
Total:HDL-cholesterol  4.3  ± 4.48 4  ± 4.3 
1
 All values are LSmeans ± SEM. TAG, Triacylglycerol;  CRP, C-reactive protein. (mixed model 2 
analysis of covariance. ANCOVA; baseline values were used as covariates). 3 
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Table 5. Pearson s´ correlations coefficients between baseline variables1   1 
  Phyt HDL  LDL  Total CH Glucose Insulin CRP TAG C15:0 
Phyt 1.0 0.248 0.5952 0.6453 0.163 0.013 0.283 0.292 0.6664 
HDL   1.0 0.250 0.5398 -0.3618 -0.4488 -0.266 -0.4628 0.113 
LDL    1.0 0.9267 -0.142 -0.110 0.156 0.213 0.3355 
Total CH    1.0 -0.163 -0.195 0.065 0.152 0.3796 
Glucose     1.0 0.4028 0.4858 0.5947 0.4068 
Insulin      1.0 0.122 0.4608 -0.025 
CRP       1.0 0.4628 0.3598 
TAG        1.0 0.3318 
C15:0                 1.0 
1
 CRP, C-reactive protein; TAG, Triacylglycerol;  CH, cholesterol; Phyt, Phytanic acid; C15:0, 2 
Plasma pentadecanoic acid. n = 38. 3 
2 Significantly correlated P=0.0001 4 
 3
 Significantly correlated P<0.0001 5 
 
4
 Significantly correlated P<0.0001 6 
5
 Significantly correlated P=0.04 7 
6
 Significantly correlated P=0.02 8 
7
 Significantly correlated P<0.0001 9 
8
 Significantly correlated P<0.05 10 
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FIGURE LEGENDS 1 
Figure 1. Oral glucose tolerance test (OGTT) measurements performed after 12 weeks. All values 2 
are mean ± SEM. Glucose tolerance was measured using a standard 75 g oral glucose-tolerance test.  3 
There was no significant difference in the time course of glucose and C-peptide concentration after 4 
the two different test fats or in the mean glucose and C-peptide concentration according to the 5 
repeated-measures analysis of variance. There was no significant difference between AUCs. 6 
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